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ABSTRACT
Although HAART has introduced great improvements in the clinical outcome of RIV -1-
infected individuals, the current protocols often fail in completely restoring the CD4+ T-cell
lymphopenia. Therefore, innovative approaches based on the use of immune adjuvants to
HAART, including cytokines like IL-2, IL-15 and IL-7, are being explored. The present
thesis aims at investigating the immunomodulatory effects of IL- 7 in HIV ISIV infection,
focusing on its pro-survival properties.
The first part of this work describes the results of a study in vitro to evaluate the effects of
IL-7 on T cells from RIV -I-infected individuals, and shows that this cytokine strongly
protects both CD4+ and CD8+ T cells from spontaneous apoptosis. IL-7-mediated apoptosis
reduction ex vivo inversely correlated with the CD4+ T-cell count of the patient in vivo,
suggesting that IL-7 treatment could be useful also for patients at with advanced disease.
Moreover, the protective effect of IL-7 was not associated with the induction of cellular
proliferation or viral replication.
The second part of this work describes the results of a study in vivo of IL- 7 administration
during the acute phase of SIV infection in rhesus macaques, the pathogenic animal model
for AIDS. IL-7 treatment prevented the depletion of circulating naive and memory CD4+ T
cells that typically occurs within the very first weeks of infection, primarily by reducing the
levels of apoptosis. Moreover, IL-7 treatment also induced sustained increases in all subsets
of circulating CD8+ T cells. Of note, treatment with IL-7 did not have any effect on SIV
plasma viral load nor on the content of SIV DNA provirus. Finally, IL-7-treated animals
developed earlier and stronger CD8+ and CD4+ T-cell responses as compared to untreated
animals, although overall no protective effects on disease progression were observed.
Taken together, these data further support the use of IL-7 as an immunomodulatory adjuvant
to HAART in RIV-I-infected individuals, and suggest that this cytokine may be a useful
tool to preserve or restore the CD4+ T-cell pool during both the acute and chronic phases of
the infection.
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1.0 HIV-l/AIDS
1.0.1 HIV-1 Pandemics
Since in 1983 a retrovirus (later named the human immunodeficiency virus, HIV)
was first isolated from a patient with acquired immunodeficiency syndrome (AIDS), more
than 65 million persons have been infected by the HIV type 1 (RIV -1), and more than 25
million have died of AIDS, making it the most destructive disease in the recorded history.
According to the "UNAIDS REPORT ON THE GLOBAL AIDS EPIDEMIC 12010" by the
Joint United Nations Programme on HIV/AIDS (UNAIDS), in 2009 over 33 million people
were living with AIDS (2.5 million of which were children under 15 years old), 2.6 million
people got infected by HIV-l (370000 children under 15 yo) and 1.8 million died of AIDS
(260000 children under 15 yo). The proportion of women living with HIV is slightly less
than 52% of the global total.
The pandemic is not homogeneously distributed around the world, some Countries
being more affected than others, and it appears to have established in most regions, although
prevalence continues to increase in Easter Europe and Central Asia and in other parts of
Asia due to a high rate of new HIV-l infections (Figure 1.1). Sub-Saharan Africa remains
the worst region, accounting for 68% of the people living with HIV worldwide (1.3 million
below 15 years of age) and for 72% of the world's AIDS related death in 2009. Globally,
34% of people living with HIV in 2009 resided in the 10 countries in southern Africa; 31%
of new HIV infections occurred in these 10 countries, as did 34% of all AIDS-related deaths.
About 40% of all adult women with HIV live in southern' Africa (Figure 1.1).
The scaling up of treatment is profoundly affecting sub-Saharan Africa. At the end of
2009,37% of adults and children eligible for antiretroviral therapy were receiving it in the
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region overall, compared with only 2% seven years earlier (1). AIDS-related deaths
decreased by 18% in southern Africa (1). Besides this, South Africa is one of the few
countries in the world where child and maternal mortality has risen since the I990s. AIDS is
the largest cause of maternal mortality in South Africa and also accounts for 35% of deaths
in children younger than five years (2). The second region of prevalence is Asia, where 4.9
million of people were living with HIV in 2009, and where the AIDS picture is dominated
by India epidemic.
AIDS continues to be a major global health priority: the number of people living
with AIDS continues to increase and AIDS-related illnesses remain one of the leading
causes of death globally.
However, there is growing evidence of success in HIV prevention in diverse settings,
particularly thanks to an effective prevention of mother-to-child transmission, through
strategies aimed at the reduction in overall HIV among reproductive-age women and men,
the reduction of unwanted pregnancies among HIV -l-infected women, the provision of
antiretroviral drugs to reduce the chance of infection during pregnancy and delivery and
appropriate treatment and care and support to mothers living with HIV (including infant
feeding). Ideally, the provision of antiretroviral prophylaxis and replacement feeding could
reduce transmission from and estimated 30-35% to around 1-2%. Most countries have not
yet reached all pregnant women with these services, but the data are encouraging. Indeed,
exclusively examining the provision of antiretroviral prophylaxis to HIV-positive pregnant
women, UNAIDS estimates that 200000 cumulative new HIV infections have been avoided
in the past 12 years.
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Moreover, there is increased evidence that improved access to treatment is having an
impact.
In high-income countries, where antiretroviral drugs have long been widely
available, access to treatment has had an extraordinary impact on HIV-related mortality (3),
and a 10-fold rise in access to treatment between 2003 and 2008 in low- and middle-income
countries is also starting to provide similar reassuring evidences from recent studies in
different regions (4-7).
Although current estimates of coverage of antiretroviral treatment for children are
close to those of adults (World Health Organization, United Nations Children's Fund,
UNAIDS, 2009), the provision of therapy to children has specific challenges, including the
faster progression to.AIDS, the difficulty of diagnosing HIV, and the higher costs for
developing appropriate antiretroviral drugs for children, that are now starting to be
addressed by some controlled studies (8-10). However, even with the impressive medical
outcomes achieved through diagnosis and treatment, mortality within the first months of
therapy still remains high in HIV-l-infected children in sub-Saharan Africa (11, 12).
One of the main problems that still characterize the fight against AIDS is the failure
to match national AIDS strategies to the documented national needs. While high HIV
prevalence has been well documented in sex workers for a long time, recent studies
conducted have shown elevated levels of infection in other risk populations, including
injecting drug users and men who have sex with men, in many countries worldwide. Thus,
prevention strategies targeted towards different risk populations according to the national
needs seem to be necessary, whereas gaps are still evident in basic prevention approaches.
For instance, even though most of new infections in Sub-Saharan African regions occur
14
among old heterosexual couples, few prevention programmes have been specifically
targeted towards them.
1.0.2 HIV History
HIV, the causing agent of AIDS, belongs to the lentivirus family of retroviruses. Of
the two types of HIV that infect humans, HIV -1 and HIV -2, HIV -1 is the more virulent and
the more easily transmitted and it is the cause of the vast majority of HIV infections
globally; by contrast, mv-2 appears to be less easily transmittable and is associated with
significantly slower progression to immune deficiency (13, 14). The two types of HIV have
a different geographic localization, with HIV-I being found globally, and HIV-2 confined
primarily to West Africa and India (13, 15). Research conducted using molecular
phylogenetics, which compares viral genomic sequences to determine relatedness, revealed
that HIV evolved at some point from the closely related Simian immunodeficiency virus
(SIV), which was transferred from non-human primates to humans in the recent past (as a
type of zoonosis) (16). HIV-2 seems to be closely related to a virus of the sooty mangabey
(Cercocebus atys atys), an Old World monkey inhabiting southern Senegal, Guinea-Bissau,
Guinea, Sierra Leone, Liberia, and western Ivory Coast (13). Conversely, the known strains
of HIV -1 are more closely related to the simian immunodeficiency viruses endemic in West
Central African forests and each of the known HIV -1 strains is either closely related to the
SIV that infects the chimpanzee subspecies Pan troglodytes troglodytes (SIVcpz), or to the
SIV that infects Western lowland gorillas (Gorilla gorilla gorilla), called SIVgor (17). The
pandemic HIV-I group M (main) is most closely related to the SIVcpz collected from the
southeastern rain forests of Cameroon (18). Thus, this region is presumably where the virus
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was first transmitted from chimpanzees to humans. However, reviews of the epidemiological
evidence of early HIV -1 infection in stored blood samples, and of old cases of AIDS in
Central Africa have led many scientists to believe that HIV -1 group M early human
epicenter was probably not in Cameroon, but rather farther south in the Democratic
Republic of the Congo, more probably in its capital city, Kinshasa (17-20).
Using HIV -1 sequences preserved in human biological samples along with estimates
of viral mutation rates, scientists calculate that the jump from chimpanzee to human
probably happened during the late 19th or early 20th century. Some molecular datation
studies suggest that HIV-l group M had its most recent common ancestor (MRCA) in the
early 20th century, probably between 1915 and 1941 (21,22), while another study published
in 2008 suggested a common ancestor between 1873 and 1933 (with central estimates
varying between 1902 and 1921) (23).
According to the 'Natural Transfer' theory (also called 'Hunter Theory' or 'Bushmeat
Theory'), the "simplest and most plausible explanation for the cross-species transmission" of
SIV or HIV (post mutation), the virus was transmitted from an ape or monkey to a human
when a hunter or bushmeat vendor/handler was bitten or cut while hunting or butchering the
animal (24). The resulting exposure to blood or other bodily fluids of the animal can result
in SIV infection (25). How the SIV virus would have transformed into HIV after infection of
the hunter or bushmeat handler from the ape/monkey is still a matter of debate, although
natural selection would favor any virions capable of adjusting so that they could live, infect
and reproduce in the T cells of a human host.
Up to the 1980s, it is not known how many people had developed AIDS. "The
dominant feature of this first period was silence, for the human immunodeficiency virus
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(HIV) was unknown and transmission was not accompanied by signs or symptoms salient
enough to be noticed. While rare, sporadic case reports of AIDS and sero-archaeological
studies have documented human infections with HIV prior to 1970, available data suggest
that the current pandemic started in the mid- to late 1970s. By 1980, HIV had spread to at
least five continents (North America, South America, Europe, Africa and Australia). During
this period of silence, spread was unchecked by awareness or any preventive action and
approximately 100,000-300,000 persons may have been infected." Jonathan Mann (26).
The first cases of AIDS appeared in the USA in the early 1980s, when a number of
gay men in New York and California started to develop rare opportunistic infections and
cancers resistant to treatment. It soon became clear that all these were manifestation of a
common syndrome, which was for the first time defined as AIDS (Acquired Immune
Deficiency Syndrome) in September 1982 by the Center for Disease Control (CDC) (27). By
the end of the year the number of AIDS cases in the USA had risen to 3,064 and of these
1,292 had died (28). In May 1983, doctors in the group ofLuc Montagnier at the Institute
Pasteur in France reported that they had isolated a new virus, which they suggested might be
the cause of AIDS (29). One year later, on May 4, 1984, Robert C. Gallo and his
collaborators published a series of four papers in Science demonstrating that a retrovirus
they had isolated, called HTLV-III in the belief that the virus was related to the leukemia
viruses of Gallo's earlier work, was the cause of AIDS (30-33).
1.0.3 DIY-l Groups and Subtypes
The strains of HIV-I can be classified into four groups: the "major" group M, the
"outlier" group 0 and two new groups, Nand P, which may represent four separate
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introductions of simian immunodeficiency virus into humans. More than 90% of HIV-l
infections belong to HIV -1 group M. Group 0 appears to be restricted to west-central Africa
and group N - a strain discovered in 1998 in Cameroon - is extremely rare. In 2009 a new
strain closely related to gorilla simian immunodeficiency virus was discovered in a
Cameroonian woman. It was designated HIV-l group P (34).
Within group M there are at least nine genetically distinct subtypes (or clades) of HIV -
1, named A, B, C, D, F, G, H, J and K. Occasionally, two viruses of different subtypes can
meet in the cell of an infected person and mix together their genetic material to create a new
hybrid virus (35). Many of these new strains do not survive for long, but those that infect
more than one person are known as "circulating recombinant forms" or CRFs (36). The
classification ofHIV strains into subtypes and CRFs is a complex issue and the definitions
are subject to change as new discoveries are made. So far 48 CRFs have been identified
(37). Within the A and F subtypes, separate sub-clusters have been given the designations
AI, A2, A3 and A4, and Fl and F2 (38).
The HIV -1 subtypes and CRFs are typically associated with certain geographical
regions, with the most widespread being subtypes A (sub-subtype Al and the A/G
recombinant, CRF02_AG) and C (39) (Figure 1.2). Subtype A and CRF A/G predominate
in West and Central Africa, with subtype A possibly also causing much of the Russian
epidemic, whereas Subtype C is predominant in Southern and East Africa, India and Nepal.
Subtype B, historically the first recognized and most studied variant of HIV -1, continues to
predominate in North America, Western and Central Europe, and Australia. This subtype
accounts for only a small fraction of the worldwide pandemic «15%) (39) and is the
predominant sub-type found among MSM infected in Europe (40). Subtype D is generally
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limited to East and Central Africa with sporadic cases being detected in Southern and
Western Africa (41). CID recombinants are common in Tanzania, and BIC recombinants are
prevalent among injecting drug users in China (42). One of the CRFs is called AlE because
it is thought to have resulted from hybridization between subtype A and some other "parent"
subtype E. However, no one has ever found a pure form of subtype E (37). CRF AlE is
prevalent in South-East Asia, but originated in Central Africa. Subtype F has been found in
Central Africa, South America and Eastern Europe. Subtype G and CRF AlG have been
observed in West and East Africa and Central Europe. Subtype H has only been found in
Central Africa; J only in Central America; and K only in the Democratic Republic of Congo
and Cameroon. At present, >40% of all new infections in Europe are of the non- B African
and Asian subtypes (39, 43) (Figure 1.2). Although this is the nowadays picture, it is
continuously evolving, with new HIV genetic subtypes and CRFs being discovered, as virus
recombination and mutation continue to occur, and the current subtypes and CRFs continue
to spread to new areas, as the global epidemic continues.
1.0.4 Genetic VarlabiHty of DIY and Functional Implications
Genetic variability of HIV is high, both within an HIV -1 subtype (15 to 20%,) and
between subtypes (25 to 35%) (38) and is primarily due to the high error rates of the viral
reverse transcriptase, which results in approximately 10 genomic base changes per
replication cycle. The most common errors are substitutions, even if deletions and insertions
also occur, although their frequency is more difficult to estimate. The envelope gene (env)
seems to be subject to the most extensive genetic variation, although alterations can also
occur in other genes (44-46). HIV -1 undergoes continuous genetic variability within
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individual patients, who usually harbor a considerable number of highly related but
individually distinguishable viral variants, which are referred to as quasispecies, with a
heterogeneity usually not exceeding 2-5% in the env gene (47, 48).
A broad range of viral genetic variability (in the range of20-30% in the env gene) has
been documented for isolates from distinct geographical locations, largely attributable to
differential geographic distribution of the multiple genetic subtypes of HIV -1. Within a
single geographic region, the range of genetic variability in the env gene is estimated to be
6-19%, although differences higher than 30% have been documented (49-51). The extent of
genetic variability in a given geographical location increases over time after the introduction
of a particular subtype in a population. Initially, the heterogeneity in the env gene can be as
low as 3-5%, which is comparable with the range of intra-patient variability, with further
diversification at an estimated rate of approximately 1% per year. In addition, recent data
have provided evidence that genomic recombination between two different HIV-l
populations frequently occurs in vivo, resulting in biologically viable viruses with mosaic
genomes, a phenomenon which may result in additional HIV genetic variability and viral
genetic shifts (52-54).
The differential characteristics of viral subtypes and their interactions with the human
host may influence HIV transmission and disease progression. HIV -1 viruses can be defined
for their capacity to use the chemokine receptors CCR5 (R5 viruses) and/or CXCR4 (X4
viruses) as a co-receptor, and, generally speaking, R5 viruses are more frequently
transmitted than X4 viruses that emerge later in infected patients and are associated with
more rapid disease progression (55). All HIV-l subtypes can use both coreceptors, but
subtype Dmay be dual-tropic (i.e., an R5X4 virus) most frequently (56). The percentage of
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X4 virus appears to be lower in subtype C than in subtype B, even when the viruses are
obtained from patients with advanced AIDS (57). There are suggestions in the published
literature that HIV-l subtype or CRF may affect efficiency of transmission (58-61).
Whether subtype differences result in variable rates of disease progression has been
investigated in several prospective, observational studies of the course of HIV -related
disease in cohorts infected with various subtypes and the results reported are discordant (62-
65). Several studies suggest that subtype D appears to be associated with a more rapid rate
of disease progression than other HIV -1 subtypes (66, 67), and the propensity of subtype D
to exhibit a greater degree of dual-tropism than other subtypes (56) may help to explain this
observation. The notable caveat relevant to all these studies of disease progression is that
confounders such as access to medical care, nutritional status, host genetic factors, and mode
of viral transmission (e.g., sexual, injection-drug, or vertical) may contribute to the divergent
results.
Another crucial point is if HIV subtype diversity may also influence the response to
antiretroviral treatment, and this issue is particularly relevant considering that subtype B is
the one with more clinical data available, but it is not the most diffused (50% of prevalent
HIV infections and 47% of all new HIV-l infections are with subtype C (38». Indeed, as
documented by several studies, the data on baseline antiretroviral susceptibility derived from
studies of subtype B may not be applicable to non-B subtypes (68-70). Moreover, certain
HIV -1 subtypes might spread or progress more rapidly than others, making treatment
decisions more challenging (66).
Another factor that could be influenced by genetic variability is the effectiveness of
treatment. However, even if there are potential problems with comparing responses to
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therapy among persons infected with group M, non-B-subtype strains - who frequently
live in settings with limited resources - and those infected with subtype B, the data
available thus far are encouraging. Indeed, it appears that HIV -1 subtypes do not affect
major differences in the response to antiretroviral therapy (71-74).
Of course, the most important implication of HIV -1 subtype diversity regards vaccine
. development (75). Hosts infected with HIV-l have cellular and humoral immune responses
to their infecting strains, but there is evidence of mutational escape by viruses from
responses by CD8+ cytotoxic T cells and neutralizing antibodies over time (76, 77).
Although cross-reactive responses to other viral subtypes have been shown (78, 79), the
strength and breadth of these responses are typically limited (80). Critical to the
development of a successful HIV -1 vaccine will be our ability to decipher the genetic
diversity of the virus, elicit broadly neutralizing antibodies, and generate strong CD4+ and
CD8+ T-cell responses (81,82). The induction of both neutralizing antibody and strong
cellular responses remains a big challenge that is influenced by the high degree of variability
of the virus. Several approaches are currently under investigation to try to obtain broader
immunological responses that can counteract different isolates simultaneously. This issue is
even of greater importance if we consider that even within a single individual, the virus
continuously evolves with time, to try to escape from the host immune response.
1.0.5 HIV-l structure and genome
HIV -1 belongs to the lentiviral family of retroviruses, and, like the other members of
the family, this virus has an RNA genome that is transcribed into a DNA molecule by the
enzyme reverse transcriptase and then integrated in the genome of the host cell. Lentiviruses
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are typically characterized by prolonged periods of disease progression, have high mutations
rates, are transmitted exclusively by the exchange of body fluids and, most importantly,
cannot be easily eradicated from infected cells, thus making it very difficult to completely
solve the infection. They also differ from other viruses in their ability to infect non-dividing
cells (83).
The HIV -1 virion is a roughly spherical particle with a diameter of about 120 nm,
quite large for a virus. It's genome is composed of two copies of positive single-stranded
RNA that encodes for the nine genes of the virus, held together by RNA-binding proteins
and enclosed by a conical capsid composed of2,000 copies of the viral protein p24 (83).
The viral enzymes (reverse transcriptase, RNaseR and integrase), tRNA and the accessory
proteins required for viral infectivity, cDNA synthesis and virion assembly during budding
from the cell surface are also contained within the capsidic core (83). A matrix composed of
the viral protein p17 surrounds the capsid ensuring the integrity of the virion particle. The
virion is in turns surrounded by the envelope, a double phospholipids layer that originates
from the membrane of the cell where the virus buds from, which contains about 70 copies of
the HIV -1 envelope glycoprotein, Env. Each Env glycoprotein is a heterodymer composed
of the trans-membrane protein gp41 and the surface protein gp120, non-covalently bound
(84) and env glycoproteins associate together to form trimeric envelope spikes on the
surface of the virus (85).
Like all retroviruses, HIV -1 genome encodes three major genes: gag, pol and env. The
gag gene encodes the Gag polyprotein, which is processed during maturation to MA (matrix
protein, pI7), CA (capsid protein, p24), SP1 (spacer peptide 1,p2), NC (nucleocapsid
protein, p7), SP2 (spacer peptide 2, pl) and p6 (83). The pol gene encodes the PrI6OSag-pol,a
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polyprotein derived by ribosomal frame-shifting, that forms the viral enzymes reverse
transcriptase, integrase, and HIV protease and the env gene encodes the glycoprotein gp160,
that is then cleaved in gp 120 and gp41 by a cellular protease during trafficking towards the
cellular surface (83). In addition to gag, pol and env, HIV-l genome encodes for six other
genes (tat, rev, vif, vpr, ne/and vpu or vpx in HIV-2), which have regulatory (tat and rev)
and accessory functions (vi/, vpr, ne/and vpu). Tat is a transactivator of the LTR region,
whereas rev allows fragments ofHIV mRNA that contain a Rev Response Element (RRE)
to be exported from the nucleus to the cytoplasm (86). Vif counteracts the antiviral activity
of the human enzyme APOBEC by targeting it to cellular degradation (87). Vpr regulates
nuclear import of the HIV -1 pre-integration complex, and is required for virus replication in
non-dividing cells such as macrophages (88). Nef is expressed early in the viral life cycle
and ensures T cell activation and the establishment of a persistent state of infection;
moreover, it also promotes the survival of infected cells by downmodulating the expression
of several surface molecules important in host immune function, including major
histocompatibility complex-I (MHC I) and MHC II,C04 and C028 (89). Finally, vpu is
involved in viral budding and it seems to counteract the action of the cellular protein BST-2
(C0317, tetherin) (90).
1.0.6 HIV-l Life Cycle
The HIV -1 life cycle can be overall divided into six phases (Figure 1.3):
1) binding and fusion
2) uncoating and reverse transcription
3) integration
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4) transcription
5) assembly
6) budding and maturation.
Phase 1: binding and fusion
HlV-l selectively infects human CD4+ T cells and other cell types that express CD4,
including macrophages and dendritic cells. The very first step of HlV binding to the target
cell is the interaction ofHlV gp120 with the cellular receptor CD4 (91, 92). This interaction
triggers a conformational change in HlV gp120 that induces the exposure of the so-called
co-receptor binding site, so that the env glycoprotein becomes then capable to interact with
the co-receptor, usually CCR5 or CXCR4 (93). This in turns leads to a second
conformational change, mainly involving the gp41 moiety of the env glycoprotein, which
brings it in close proximity with the cellular membrane (94). Gp4l then experiences a
structural rearrangement that leads to the formation of a six-helix bundle structure, a process
that gives the protein the free energy state necessary for fusion, pore formation and entry of
the viral capsid into the target cell (95).
Co-receptor usage
Several seven transmembrane (7TM) receptors have been identified as potential co-
receptors for HlV and SlV by their capacity to support infection ofCD4+ cell lines in vitro,
and they are all members of (or closely related to) the chemokine receptor family. CCR5 and
CXCR4 are the major co-receptors and all mv-1 isolates can use one or both, with CCR5
being used by the majority of isolates worldwide. Basing on their co-receptor usage, HIV-l
isolates are called X4 or R5, depending on the usage of CXCR4 or CCR5 to enter cells.
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Isolates capable of using both molecules as co-receptors are called dual tropic (R5X4).
Whereas the interaction between CD4 and gp 120 is conserved among all primate
lentiviruses and some of the amino acids that form the CD4 binding site on gp 120 are
already variable on the surface of the protein, the co-receptor binding site is not usually fully
exposed until CD4 is bound, being covered, in the CD4-unbound state, by the VIN2loop of
gpI20 (93). The co-receptor binding site is formed by the so-called "bridging sheet" that lies
between the VIN2loop and the V3loop, and by some aminoacids of the V3loop itself
(93). The determinants of co-receptor usage are likely to be complex and involve parameters
of viral replication, host genetics and immune activation, in addition to genetic changes in
the HIV -1 envelope gene. The major determinant of co-receptor usage is the V3 region of
gpI20: positively charged amino acids in this region (particularly at positions 11 and/or 25)
have been shown to correlate with CXCR4 use (96-98), whereas R5 isolates have a low
number of positively charged residues and R5X4 isolates have a V3 charge pattern that is
similar to X4 envelopes, even though their dual tropic properties apparently involve multiple
discontinuous regions of Env (99-102).
Initially, primary HIV isolates were classified in two distinct groups, defined as
rapid/high or syncytium-inducing (SI), T-cell line tropic, and slow/low or non-syncytium-
inducing (NSI) isolates, monocyte-derived macrophage tropic. Subsequently, M-tropic/NSI
variants were shown to predominantly use CCR5 for entry into macrophages and were
designated R5 viruses and T-tropic/SI variants were shown to use CXCR4 and were
designated as X4 viruses (102). However, this distinction is not absolute, as CD4+ T cells
can be infected by R5 viruses (103), and macrophages can be infected by some primary X4
isolates (104). Dualtropic R5X4 viruses can infect both macrophages and T cells.
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After exposure, R5 M-tropic viruses typically predominate in the early stages of
infection, even when the donor is infected by both R5 and X4 viruses (105-107). This may
be explained as a consequence of the fact that tissue-resident macrophages, monocytes and
dendritic cells may provide the initial cell target during the transmission event. However, it
remains unclear ifR5 viruses are the only ones transmitted or rather X4 viruses are less fit,
even if the mutations responsible for RSIX4 switch have been shown to confer a replication-
fitness disadvantage to the resulting viruses (108, 109). Indeed, relatively few mutations
seem to be required for the co-receptor switch, and this occurs several years after the first
infection (110, 111). Even if the major determinant for co-receptor usage is the V3 loop of
gp120, mutations in the VIN2 region may also playa role (112, 113); interestingly, these
mutation seem to compensate for the loss-of-fitness mutations in the V3 region, thus
allowing phenotype switch to occur (114). X4 viruses have also been reported as more
susceptible to cytotoxic T-Iymphocyte (CTL) activity as compared to RS viruses (115), and
this may explain both the prevalence ofRS variants in the early stages of the infection and
the appearance ofX4 variants at more advanced stages of the disease, when the immune
system is more compromised.
X4 variants emerge later, when the virus is trafficked from the site of infection to
lymphatic tissues, where replication was shown to occur robustly in T cells; however, this
happens only in 50% of cases, demonstrating that X4 viruses are not necessary for
progression to AIDS (116-118), although evidences suggest that the switch from RS (NSI)
variants to X4 (SI) variants may increase the rate of disease progression (119, 120). The
reasons for the enhanced cytopathic effect ofX4 viruses are not fully understood, but this
may be due to altered replication kinetics and/or the ability ofX4 strains to infect naive
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CD4+ T-cells in addition ofCD4+ memory T-cells (121, 122).
Phase 2: uncoating and reverse transcription
Following entry of the virus into the target cell, the capsid (CA) partially disassembles
(uncoats) to release the ribonucleoprotein complex (RNC) (123, 124). A correct regulation
of core uncoating is essential for completion of the early steps of the HN -1 replication cycle
that include reverse transcription of the HN-l RNA, synthesis of the double-stranded viral
DNA intermediate and formation of a functional pre-integration complex (PIC). In the PIC,
CA appears to be lost, while MA, NC, RT, IN and the accessory protein Vpr remain
associated (125, 126). Retroviruses have the ability to convert their RNA genome into
double-stranded DNA early post-infection, and this reaction is catalyzed by the RT enzyme
(127). In HIV-l, RT is a heterodimer of two subunits, p66 and pSI, both derived from the
Pr1600agPoiprecursor. Reverse transcription proceeds in the series of steps described below
(128):
- DNA synthesis proceeds to the 5' end of the RNA molecule starting from a tRNA
bound to the primer binding site (Pbs)
- the RNA strand of the DNAIRNA hybrid is degraded by the RNaseH activity of the
RTenzyme
- first strand transfer: the remaining minus-strand strong-stop DNA "jumps" from 5' to
3' end by using short regions of homology ("R" regions)
- the minus-strand fragment is completely synthesized
- the plus-strand is synthesized using RNA fragments remaining from step 2 as primers
- the tRNA is removed from the pbs by RNaseH
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- plus-strand is synthesized until the end of the minus-strand.
Considering that reverse transcription involves "jumps" from one template to the
other, novel recombinant DNA genomes can arise when the two RNA molecules are not
genetically identical (129). This phenomenon, together with the high mutation rate of the RT
enzyme (3xl0s per replication cycle (130», results in HIV-l being very heterogeneous in
sequence and rapidly capable of evading the host immune responses.
During the reverse transcription process, HIV -1 genome remains associated with the
RTC, and the viral DNA is transported to the nucleus as part of the PIC, even though this
process has not been fully elucidated yet and more studies are required to fully understand
the role of viral and cellular factors in the translocation of the PIC into the nucleus.
Phase 3: integration
Following nuclear import of the viral PIC, HIV-IIN catalyzes the insertion of the
double stranded DNA genome into the genome of the target cells (83). mV-IIN is a protein
that functions as a multimer, even if it is unknown how many molecules make the functional
holoenzyme (131). The integration process can be divided in several steps:
- 3' -end processing: IN cuts off some nucleotides from the 3' end of both strands of the
viral DNA
- strand transfer: IN cleaves the cellular target DNA and joins the 3' -recessed ends from
step with the cleaved cellular DNA
- cellular enzymes fill in the gap between the integrated viral DNA and the host DNA.
In the PIC, the ends of viral DNA are organized into a multi-component complex, the
so-called "intasomes", in which both viral and cellular proteins coexist (131, 132).
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Phase 4: transcription
The integrated provirus serves as a template for the synthesis of viral RNAs that
ultimately are required for the encoding of the full complement of structural, regulatory and
accessory proteins used to direct virus replication.
Transcription ofRN-l proviral DNA is regulated by interactions between cellular
transcription factors and the RN-l s'-long terminal repeat (LTR) (133). A number of the
sequences present in the viral LTR closely resemble the promoter regions present in the
human genome, thus RN -1 is able to utilize the transcription machinery of the host for viral
gene expression and replication. The RIV -1 promoter is divided into 3 distinct regions (134,
135). The modulatory enhancer and core promoter regions are located upstream of the
transcription start site, whereas the Trans-Activation Response region (TAR) lies
downstream of the start point.
The site of initiation of the RNA synthesis is RN-l LTR, which is composed of three
regions: U3 (unique 3'end), R (repeated) and US (unique s'end). The U3 contains several
elements that drive the binding of RNA polymerase II (pol II) to the DNA template,
including a TATA box (for transcription factor lID), and three Spl and two NF-kB binding
sites, plus a "modulatory region" upstream of the NF-kB binding sites (136).
RNA synthesis is greatly increased when the transcriptional transactivator protein Tat,
a 101 aminoacid protein that transactivates LTR-driven gene expression through the Trans-
Activation Response region (TAR), is present (137-139). In particular, Tat interacts with the
cyclin Tl (cycTl) (140), which forms a heterodimer with the cyclin-dependent kinase 9
(CDK9), and together they are part of a large protein complex called positive-transcriptional
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elongation factor b (P-TEF -b). Tat recruits the human P-TEF -b compels to TAR, resulting in
the phosphorylation of the C-terminal domain of RNA Pol II and in a dramatic stimulation
of transcriptional processivity .
.Transcription from HIV-I LTR leads to a large numbers of RNA transcripts of three
different types: 1) long unspliced RNAs that encode for Gag and GagPol precursors and
constitute the genomic RNA, 2) partially spliced mRNAs, around 5 kb, encoding for Env,
Vif, Vpu and Vpr and 3) small multiply spliced mRNAs, translated into Rev, Tat and Nef
(141). In this context the role of Rev is crucial to shuttle the unspliced and partially sliced
RNAs from the nucleus to the cytoplasm. Rev is a 116-aminoacid protein that interacts with
the Rev Responsive element (RRE) located in the Env gene and in all unspliced and partially
sliced RNAs with a stoichiometry of eight Rev proteins each RRE forming a complex
capable of interacting with the nuclear cellular export machinery (142). As a consequence,
RNA molecules are transported into the cytoplasm.
Phase 5: assembly
A major role in the virus assembly process is played by the Gag precursor polyprotein
PrSSGag, which contains domains that target it to the plasma membrane and bind the
membrane itself (MA), promote Gag-Gag interactions (CA), encapsidate viral RNA genome
(NC), associate with Env glycoprotein and promotes budding from the cell (P6) (126, 143-
147).
The Env glycoprotein is synthesized in the rough ER to generate the precursor gp160,
where oligomerization also occurs (148). Gp160 is transported to the cell surface via the
secretory pathway and in the Golgi it is cleaved by a host protease (furin or furin-like
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enzyme) to generate SU glycoprotein, gp 120 and TM glycoprotein, gp41. After cleavage,
gp41 anchors the complex to the membrane and associates non-covalently with gp120t
which results in a high amount of gp120 shedding from Env-expressing cells and virions.
Env glycoprotein complexes that reach the cellular membrane are either rapidly internalized
or incorporated in new virus particles though a process that still remains almost completely
. understood (126). Some studies have reported that HN-l assembly occurs at the plasma
membrane (149-151) whereas others have suggested that virus assembly may take place in
an endosomal compartment and that release of the viral particles follows an exosomal
pathway in which virus- containing endosomes fuse with the plasma membrane releasing
their contents (152-154).
Part 6: budding and maturation
The final step in the process of virus assembly is the budding of the virus particle from
the cellular membrane, and this occurs though specific sequences encoded by the virus itself,
the so-called "late" or "L" domains. In HN -1 t the L domain is present in p6 and most likely
it interacts with host factors. During or shortly after virus release from the plasma
membrane, the viral protein PR cleaves the Gag and GagPol polyproteins, setting in motion
a series of structural rearrangements that ultimately leads to virus maturation (155). In
immature virions, Gag monomers are aligned projecting inward from the membrane
associated MA domain at the N-terminus to NC at the C-terminus (156). Following
cleavage, CA forms a conical shell around the RNA/protein complex within the core. The
failure of the virus to mature properly is associated with a complete loss of infectivity and
core condensation is essential for the very early post-entry steps of the replication cycle.
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1.1 HIV-l Immunopathogenesis
1.1.1 Typical course ofHIV-l infection
The typical course of HIV-I infection is illustrated in Figure 1.4. It begins with an
acute symptomatic illness that lasts a few weeks, associated with high levels of plasma HIV-
1 viremia, a sharp decline in the peripheral CD4+ T cell count (157-165), establishment of a
. reservoir of latently infected cells (166), and development of an HIY -l-specific immune
response (167-170). After this very first phase, there is a 100- to lOOO-folddrop in the levels
of plasma viral load, a partial restoration of the peripheral blood CD4+ T cell count, and the
beginning of an asymptomatic phase that can last up to 10 years, characterized by a slow
decline in peripheral blood CD4+ T cells and a slow rise in HIY -1 plasma viremia. This sort
of "silent" phase continues until peripheral blood CD4+ T cells fall below 200 cells/ul and
the total CD4 +T cells in the body decrease by at least half (171) and at this point
opportunistic infections and tumors start to occur, thus stating the beginning of the so-called
full-blown AIDS phase.
Acute phase of HIV-l infection
Exposure to HIV -1 occurs primarily through the mucosal route, either gastrointestinal
or reproductive, which is thought to be the initial site for viral replication within the target
cells of the mucosal tissue. In this context, CCR5 is usually the main target coreceptor for
naturally transmitted viruses (107, 110, 121, 172-174).
Even though little is still known about the primary pathophyisiological events for
lymphocyte and viral dynamics in acute HIV -l-infection, recently some light has been shed
by studies conducted in the animal model for HIV -1 infection, SlY infection in Rhesus
macaques, in which the fundamental pattern of infection is highly similar to that observed in
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HIV -l-infected individuals (175, 176). After both intravenous and intravaginal inoculation
ofSIV, the majority of infected cells are CD4+ T cells in the lamina propria of the mucosal
tissues (159, 177-183). By contrast, dendritic cells do not seem to be a major target for viral
replication, but they can facilitate the infection in trans of CD4+ T cells through binding of
intact virions to DC-SIGN (184-186), with the exception of Langerhans cells in the vaginal
epithelium that can become productively infected by the virus by 18 hours post-inoculation
and migrate afterwards to the local lymph nodes where they propagate the virus to CD4+ T
cells (187, 188). After the establishment of the infection, both SIV and HIV -1 infect other
secondary lymphoid organs, including lymph node, thymus, spleen and mucosal tracts, and
this may result in the formation of a pool oflatently infected cells (159, 180, 189-191).
Virus transmission seems to be a local cell-to-cell phenomenon that depends upon the status
of the target cell rather than on the total number of target cells in the body. Indeed, the initial
target for HIV-I infection are CD4+ T cell that express the coreceptor CCR5, memory T
cells that typically resides in the mucosal surfaces of the intestinal, respiratory and
repr:oductive tracts, and is less common in blood, lymph node and spleen (179, 192-197).
Mucosal CCR5 positive cells are usually also activated cells, expressing activation markers
such as CD69 and HLA-DR (179, 181, 195), and this further qualifies them as ideal targets
for the virus. Moreover, the mucosal environment is rich in inflammatory cytokines that can
activate T cells thus promoting the infection and propagation ofHIV-l in resting CD4+ T
cells (198, 199). Finally, the gastrointestinal tract is the largest lymphoid compartment in the
body, accounting for, at steady state, at least 60% of the total body T cells (200). As a
consequence, SIV and HIV -1 infections in the very first phase result in a profound damage
of the immune system, with a rapid depletion of CCRS+ CD4+ T cells that is much greater
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and earlier in the intestinal mucosa than in peripheral blood, lymph nodes and spleen (178-
180). In the macaque model this happens within the first three weeks of infection (177, 178,
180, 182). The loss ofCD4+ T cells seems to be biphasic, with a dramatic depletion of
preexistent T cell targets during the acute phase of the infection and subsequently a slow
progressive decline of the remaining cells that characterizes the chronic phase (Figure 1.4).
Interestingly, most of the cells that are lost within the acute phase seem to be Ki67+
proliferating cells, and this may constantly generate new CCRS+ CD4+ memory T cells that
can become target for viral replication in the post-acute phase. CD4+ memory T cells
presumably die of direct and indirect virus cytopathic mechanisms (201-206) and of CD8+ T
cell-mediated destruction (207). Considering that, in this context of T-cell activation, both
generalized and mediated by the virus, T-cell homing and trafficking between blood and
lymphoid organs are dramatically altered (208, 209), the CD4+ T-cell depletion observed in
the peripheral blood may only approximately reflect, and likely underestimate, the total loss
of CD4+ T cells.
Besides the immune system seems to have the capacity of reconstituting itself after a
profound depletion, this does not happen completely in SIV or RIV -1 infection, at least not
in the CD4+ T-cell pool, even following treatment (210-212).
After the brief period of acute infection, the immune system has to face a double
problem: the reconstitution of the profoundly depleted CD4+ T-cell pool and the ongoing
viral replication that keeps on inducing T-cell activation, impairing thymic output,
disrupting lymph node architecture, and inducing CD4+T-cell apoptosis (213), thus
contributing to the propagation of the virus itself and further compromising the homeostatic
balance and maintenance capacity of the resting narve and memory CD4+ T-cell pool.'
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The chronic phase of HIV-l infection
Viral and T-cell dynamics during the chronic phase of the infection are markedly
different from those observed in the acute phase: plasma viral loads are lower and tend to
increase slowly, and CD4+ T cells in the peripheral blood recover partially after the
resolution of the acute phase, but then decrease, slowly as well, before the onset of AIDS,
over a variable period of on average ten years (214). This overall picture is accompanied by
high levels of immune activation, to the point that chronic RIV -1 infection is actually a
condition of chronic immune activation (215) and the level of chronic activation can be
itself a better predictor of disease progression than plasma viral load (216-219). Chronic
immune activation, either virus-specific or non-specific "bystander", in turns determines a
state of "high turnover" of both CD4+ and CD8+ T cells (220-224). Besides chronic
activation may explain the high death rates of T cells, this per se does not account for the
profound CD4+ T-cell depletion observed. Indeed, it has been proposed that CD4+ T-cell
death may occur as a result of various mechanisms on the various compartments of the
resting T cell pools, including both memory and naive CD4+ T cells (225). These
mechanisms involve direct effects of the virus as well as non-destructive effects and act on
both memory CD4+ and CD8+ T cells; however, being CD4+ T cells more vulnerable than
CD8+ T cells and CD8+ T cells capable of higher levels of proliferation in response to
antigens, this phenomenon is more dramatic for CD4+ T cells, and their reconstitution
depends greatly on naive CD4+ T-cell output from the thymus (211, 226-233).
Besides the direct and indirect effects on the T-cell pool, RIV -1 infection also exerts
negative effects on the thymus, bone marrow and lymph nodes. Abnormal thymic
morphological changes including thymocyte depletion and advanced involution (234-238)
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have been documented in both children and adults (234, 239, 240). Thymic dysfunction has
been associated with early progression to the disease in perinatally infected infants (241-
243) and SN infection causes similar changes (244, 245). HN-l infection also inhibits the
production of hematopoietic lineages other than CD4+ T cells (246) and HIV-l-infected
individuals are often pancytopenic. Bone marrow and lymph node architecture is also
abnormal (247-249) and stromal auxiliary cells from the bone marrow are infected and
dysfunctional (250, 251).
The major features of T-cell dynamics during the chronic phase of the infection are
shown in Figure 1.5 and include: a) pathological changes in thymus, bone marrow and
lymph nodes, and decrease in thymic output, b) depleted memory CD4+ T-cell pool from the
acute phase, c) chronic activation ofCD4+ and CD8+ T cells, d) increased t-cell death due to
increased immune activation, e) expansion of the activated CD8+ T-cell pool, f) more.
activated CDS+ T cells than CD4+ T cells re-entering the resting memory pool, g) death of
the vast majority of activated T cells, h) activated CD4+ T cells being the major source of
virus, i) activated CD4+ T cells destined to die independently of infection and j) infected
activated CD4+ T cells failing to re-enter the memory T-cell pool.
The chronic phase of HN -1 infection is a quasi-stable state in equilibrium between T
cell activation, death, and renewal and production and removal of virus. As immune
degradation progresses this equilibrium eventually breaks down resulting in clinical
immunodeficiency and full-blown AIDS (214). Despite the rapid decrease in viral load
observed at the end of the acute phase, it usually takes several months to reach this steady
state, and this often occurs after a period of strong fluctuations in the viral load. Several
factors may contribute to this initial control of viral replication, including the diminishing
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availability of the CD4+ target T cells (252), and the development of an effective immune
response. Evidences suggest a temporal correlation between the drop in viremia and the
appearance of HIV -l-specific CD8+ T-cell responses, but not with neutralizing antibodies,
which seem to have a lower impact on the control of viral replication (253-257). In SN
infection the emergence of SIV-specific CD8+ T-cell responses c~incides with viral
clearance (189, 258) and changes in viral sequences allowing escape from CD8+ T-cell
responses develop rapidly during the acute phase in both monkeys (259-261) and humans
(262). Loss of specific immunity may playa role in accelerating viral replication and
promoting progression toward the disease (263, 264). The frequency of HIV-I-specific T
cells, particularly albeit not exclusively CD8+, is consistently high throughout the infection
before the onset of AIDS (265-269), but these cells fail to suppress viral replication, and the
reasons for this may be multiple. First, the recruitment of'narve CD4+ T cells together with
HN -l-specific CD8+ T cells into infected lymphoid sites may on one hand increase the rate
of viral clearance (270), but on the other hand, it may also provide new targets for viral
replication (271), which will in turns increase T cell activation and induce the recruitment of
more HIV -l-responding cells, leading to further activation, in a sort of positive feedback
loop (272). Second, continuous cycles of activation and infection result in a sort of post-
activation state of the remaining HIV-I-specific CD4+ T cells, that may not be capable of
proliferating in response to additional stimuli and activation signals (273). Third, HIV-I-
specific CD8+ T cells are also defective (high sensitivity to Fas-induced apoptosis (264), low
expression of perf orin (274), lack of cytokine production (275), TCR with low functional
avidity (276), inappropriate signaling (276), skewed maturation profiles (277) and
diminished proliferation in response to antigens (278)), as a consequence of chronic antigen
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stimulation.
In conclusion, CD4+ and CD8+ HIV-l-specific T-cell responses make a partially
successful attempt to control the infection; however, this specific response, by driving CD4+
and CD8+ T cell activation, providing new targets for viral replication and being itself target
for preferential infection, may become part of the problem as well.
Finally, another important factor to take into account is the high mutability and genetic
flexibility of HIV -1 and SIV that allow them, in response to immunologic pressure, to adapt
to the host and evolve into variants capable of using a broader range of target cells and with
increased pathogenicity or decreased susceptibility to the immune response (107, 110, 117,
121,207,279,280).
1.1.2 New insights: structure and function of the gut
The mucosa-associated lymphoid tissue (MALT), of which the gastrointestinal (GI)
immune system (also referred to as gut-associated lymphoid tissue, GALT) is the largest
component, plays a critical role in the interaction between primate lentiviruses and the host
immune system. Indeed, (i) most of the HIV transmissions occur through the mucosal route,
either vaginal or rectal, (ii) a significant amount of viral replication occurs at the level of
MALT in all stages of the disease and (iii) a progressive depletion and dysfunction of the
mucosal immune system is a key feature of HIV /SIV associated immunodeficiencies (281).
Moreover, the typical depletion ofCD4+ T cells that characterizes the progression to AIDS
is more rapid and severe at the level of MALT than in the peripheral blood or in secondary
lymphoid organs (282).
The GI tract, being by far the largest surface of the body in contact with the external
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environment, is the entry route for many human pathogens that enter the body through the
GI mucosal surface. On the other hand, the intestinal microbial flora plays an essential role
in the digestive function of the GI tract, and its integrity is crucial. Thus, the body has
evolved several strategies to maintain the equilibrium between the need to preserve
commensal microbes and to protect against enteroinvasive pathogens (283-290): first, a
continuous layer of epithelial cells kept together by tight junctions separating the lumen
from the intestinal lamina propria that constitutes a physical barrier; second, mucus and
glycocalyx lining the apical side of the epithelial cells; third, antimicrobial molecules
produced and released in the mucosal environment (291-295). Besides this physical barrier
function, the GI mucosa is also actively involved in the innate and adaptive immune
response to antigens, by the GALT, which represents the most abundant lymphoid tissue in
the body, containing the vast majority (more than 40%) of the lymphocytes of the body
(296).
Functionally, the GALT can be divided in two compartments: the inductive and the
effective compartments (297) (Figure 1.6). In the inductive compartment, composed of
mesenteric lymph nodes, Peyer's patches and isolated lymphoid follicles, overlaid by an
epithelial membrane containing M cells, antigens are collected from the lumen and immune
response is first induced. These cells transcytose particulate antigens to antigen-presenting
macrophages located at the basal surface of the epithelium (298), which constitute the first
phagocytic cells to interact with microorganisms that have entered the intestinal mucosa.
Intestinal macrophages have avid phagocytic and bactericidal activities that protect the host
from pathogens and they regulate the immune response to commensal bacteria (299).
Antigen-presenting dendritic cells (DC) sample both commensal and pathogenic microbes
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for subsequent transport and presentation to B and T lymphocytes (300). In the effector
compartment (epithelial cells and lamina propria), the adaptive immune cells differentiate
and exert their immune effector functions, either cellular- or humoral-mediated. The
intraepitheliallymphocytes are mainly CDS+ T cells or Ty~cells, whereas the lamina propria
contains CD4+ T cells, as well as CD8+ T cells, natural killer (NK) cells and B cells (301-
307).
This complex defense system under normal homeostatic conditions can effectively
prevent or restrict the entry and propagation of commensal and pathogenic organisms,
including HIV -1 (299). It has been suggested that the anti-inflammatory responses induced
by commensal flora protect the intestinal epithelium from pathogenic insults (308). This
relationship, however, appears to extremely delicate and anything that perturbs either
immune or epithelial homeostasis can lead to inflammation and life-long inflammatory
conditions such as Crohn's disease and ulcerative colitis.
1.1.3 HIV-l infection and the gut
HIV and SIV can be considered as mucosal pathogens, since natural transmission
occurs mainly though the mucosal surfaces (309). Even if epithelial cells cannot be
productively infected by these lentiviruses, however, they can capture virions and transfer
them to dendritic cells, macrophages and CD4+ T cells of the sub epithelial layers (310-312).
Dendritic cells then in turns can facilitate infection ofCD4+ T cells by HIV and SIV via
"infectious synapse", a dendritic cell/T cell conjugate that also promotes the spread of the
virus to adjacent cells (313-315). As a consequence, as suggested by several studies
conducted in macaques, the OJ mucosa is the first and predominant site of SIV infection,
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where SIV -infected lymphocytes accumulate and the virus highly replicates (158, 159, 182).
The first description of the early events that occur following SIV infection at the level
of the gut was by Veazey and Lackner that in 1998 documented a 70-95% loss ofCD4+ T
cells in the jejunum, ileum and colon by day 21 post-infection in SIVmac239-infected
macaques (182). Subsequent studies confumed this observation and elucidated the
mechanisms underlying SIV -associated mucosal CD4+ T-cell depletion (316-318). The main
conclusion from these studies is that the early phase of SIV infection is associated with a
rapid dramatic loss of mucosal CD4+ T cells, particularly with a memory phenotype and
expressing the HIV -SIV coreceptor CCR5. Indeed, the large population of
memory/activated CCR5+ CD4+ T cells residing in the gut represents the ideal target for
viral infection and replication (182, 316-322), also considering that the majority of newly
transmitted HIV and SIV strains are CCR5-tropic, and activated cells are preferentially
infected and killed by lentiviruses (159, 173,323,324). Interestingly, in a study conducted
in SIVmac251-infected macaques, up to 60% ofCD4+ T cells were found to harbor SIV
DNA by day 10 post-infection, thus postulating a relevant role of direct virus-mediated T-
cell killing during the very early acute phase of the infection (317), even though additional
mechanisms have also been proposed, including CD95-mediated T-cell apoptosis (318).
Investigating the early events occurring at mucosal level during the acute primary
phase if HIV infection in humans is a challenge for obvious practical and ethical reasons.
However, a few studies were performed, by three research groups separately (Dandekar,
Markovitz and Douek), on samples obtained from jejunal, colon and terminal ileum biopsies
of acutely HIV-l-infected individuals, showing an early, severe and mostly irreversible
depletion of CD4+ CCR5+ memory T cells, albeit to a lesser extent as compared to SIV
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infections (316-318, 320-322, 325). Thus, the model for HIV pathogenesis involves the
selective depletion of memory CD4+ T cells from mucosal tissues during the early acute
phase of the infection, inducing a significant impairment of mucosal immunity that may
result in a series of pathogenic events mostly apparent during the chronic phase.
Whereas the CD4+ T-cell depletion in the acute phase is mainly due to direct
cytopathic effects of an uncontrolled viral replication primarily on memory/activated
CD4+CCR5+ T cells, during the chronic phase, in which the immune system is to some
extent capable of controlling viral replication, a key role is also played by host-specific
factors, such as a chronic, generalized immune activation state (326). Indeed, in addition to
the loss of CD4+ T cells, gene expression profiling studies in GI tract biopsies reveal that
several genes associated with cell cycle regulation, lipid metabolism, and epithelial cell
barrier and digestive functions are dysregulated in HIV -l-infected individuals (327). The
enteropathy is characterized by diarrhea, increased inflammation, increased permeability and
malabsorption (328) and, histologically, infiltrates of lymphocytes and epithelial damages
including villous atrophy and blunting and crypt hyperplasia (329). Recent studies have
documented the preferential GI depletion of a subset of CD4+ T cells defined by their
secretion oflL-17, the so called Thl7 cells, that are critical against bacteria and fungi at
mucosal surfaces and contribute to the homeostasis of enterocytes (330).
Taken together, these data indicate that the GI mucosal barrier suffers a serious
immunological and structural insult in HIV-I and pathogenic SIV infections and that this
damage may adversely affect the barrier function of the gut. The idea is that the loss of
mucosal immune function favors a breakdown of the physical and biological mucosal barrier
that results in the translocation of microbial products from the gut to the systemic circulation
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(Figure 1.7). Indeed, chronically HIV-l-infected individuals have significantly increased
levels of plasma lipopolysaccharide (LPS), an indicator of microbial translocation, as
compared to uninfected individuals (331). Microbial products would in turn cause a broad
activation of the immune system through their binding to certain toll-like receptors (TLR-4)
and consequent bystander activation of non HV -specific lymphocytes (331). These findings
point to microbial translocation as a cause of immune activation in chronic HIV / SIV
infections, thus providing a link between damage to the GI tract and progression to AIDS.
CD4+ T-cell depletion alone does not seem to be sufficient to result in mucosal
translocation and inflammation, as indicated by studies in non-pathogenic SIV infections in
African green monkeys and sooty mangabeys (332), natural hosts for SIV, which show
CD4+ T-cell depletion associated with immune activation and microbial translocation during
the acute phase, but do not progress to AIDS, as both phenomena resolve as the animal
enters the chronic phase, even in a context of viral replication (Figure 1.7).
Thus, it seems that CD4+ T-cell depletion during the acute phase of the infection, is
necessary, but not sufficient nor predictive of progression to AIDS, which seems to be a
more complex phenomenon, initially triggered by the virus, but ultimately related to the
nature of the host, and resulting from multiple immunologic abnormalities, including but not
limited to, CD4+ T-cell depletion and immune activation, that exacerbate proliferation and
apoptosis (225, 333-337).
1.1.4 Mechanisms for CD4+ T-cell Depletion
As outlined above, the mechanisms contributing to CD4+ T-cell depletion during the
acute and chronic phases of HIV -1 and SIV infection seem to follow different dynamics and
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to be mediated by different processes. During the acute phase a key role is played by viral
replication and cytolysis. Indeed, HIV -1 can directly induce cell death in the cells it infects
by several mechanisms: i) syncytia formation in CXCR4+ cells (338), ii) disruption of the
plasma membrane due to continuous virus budding (339) or to viral proteins such as Vpu
that can alter membrane permeability (340), iii) cellular toxicity mediated by un-integrated
linear viral DNA (341), iv) HIV-l protease that inactivates the anti-apoptotic protein Bcl-2
and activates procaspase 8, making the cell more susceptible to apoptotic stimuli (342, 343)
and v) interference with the apoptotic pathways, through direct action of the virus with
cellular pro- and anti-apoptotic proteins.
By contrast, during the chronic phase ofHIV/SIV infection, additional mechanisms,
including defective T-cell regeneration, limited regenerative capacity, anergy and
programmed cell death (PCD) or apoptosis, become increasingly relevant (339).
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1.2Apoptosis
1.2.1 General Overview
Three distinct but overlapping PCD pathways have been described based on
differences in the stimuli, cytokine environment and death-inducing signaling cascades. The
first two pathways, apoptosis and autophagy, do not affect the integrity of the plasma
membrane and thus, do not induce an inflammatory response (344). The third pathway,
necrosis, involves mechanical rupture of the membrane, release of cellular organelles and
induction of a phagocytic inflammatory response (344). Autophagy and necrosis have been
studied in vitro, while apoptosis has been extensively investigated both in vitro and in vivo
in HIV-l-infected patients (344), where a positive correlation with lymphocyte activation
and disease progression has been documented (345). Apoptosis, also called programmed cell
death, is an important mechanism that plays a central role in the development and
homeostasis of multicellular organisms, and can be dysregulated in several pathological
processes including tumors and viral infections. During this process, a cascade of
biochemical events leads to characteristic morphologic changes of the cell and ultimately to
death. These changes include blebbing, cell shrinkage, nuclear fragmentation, chromatin
condensation, and chromosomal DNA fragmentation. Unlike necrosis, which is a form of
traumatic cell death that results from acute cellular injury, apoptosis produces cell fragments
called apoptotic bodies that are quickly engulfed by phagocytic cells and removed from the
extracellular environment before the contents can spill out and cause damage, thus
preventing inflammation (346).
Apoptosis can follow mainly two distinct pathways: the extrinsic pathway, which is
initiated outside the cell by the so-called "death molecules" or by other stress factors, and
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the intrinsic pathway, which begins when the stress or damage occurs within the cell itself.
In both pathways, signaling results in the activation of a family of Cys (Cysteine) proteases,
named caspases that act in a proteolytic cascade to disrupt the cell (347) (Figure 1.8).
The more classical "extrinsic" cascade is triggered by the binding of the "death
molecules" to their specific "death receptors" (DRs) on the surface of the cell, and activates
caspases within seconds of ligand binding, causing apoptotic damage within hours.
Although there are differences in the signaling pathways activated by the different DRs, it is
possible to outline a general apoptotic signaling pathway. These receptors belong to the
superfamily ofTNFR (Tumor Necrosis Factor Receptor) and are characterized by a Cys-rich
extracellular domain that binds the ligand and a homologous intracellular domain known as
the Death Domain (DD). Binding of the ligand to its receptor can lead to the release of
cerami de, which is thought to promote lipid raft fusion, resulting in a large scale clustering
of the receptors, thus amplifying the apoptotic signaling. Following ligand binding a
conformational change in the intracellular domains of the receptors reveals the DDs that
recruit various apoptotic proteins, including FADD (Fas-Associated via Death Domain),
TRADD (Tumor Necrosis Factor Receptor-l-Associated Death Domain) or Daxx containing
DDs, to the receptor. This protein complex is called the DISC, or Death Inducing Signaling
Complex. The final step in this process is the recruitment of caspase-8, to the DISC, and the
initiation of apoptosis. The best-characterized DRs are Fas and TNFRI (Tumor Necrosis
Factor Receptor-I), which bind Fas-Ligand (FasL) and TNF-a (Tumor Necrosis Factor-
alpha), respectively (348). Other DRs include the TNF-related apoptosis inducing ligand
(TRAIL) receptors DR4 and DRS.
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Apoptosis can also be activated by various forms of cellular stress, including
gamma- and UV radiation, treatment with cytotoxic drugs and removal of cytokines. Stress
induced apoptosis involves altering mitochondrial permeability and formation of a channel,
the mitochondrial apoptosis-induced channel (MAC), in the outer mitochondrial membrane,
with subsequent release of cytochrome C (cytC), with regulatory functions (349). Released
cytC binds to Apoptotic protease activating factor - 1 (Apaf-I) and ATP, and subsequently
to pro-caspase-9 to create the apoptosome. In this complex, the pro-caspase is cleaved to its
active form of caspase-9, which in turn activates the effector caspase-3. The MAC can be
regulated by several proteins, including those encoded by the mammalian Bcl-2 family of
anti-apoptotic genes, the homo logs of the ced-9 gene found in C. elegans (350). Bax and/or
Bak form the pore, while Bcl-2, Bcl-xL and Mel-I inhibit its formation. Bax, Bid and Bim
are initially inactive and require translocation to mitochondria to induce apoptosis. The Bel-
2-associated death promoter (Bad) protein is a pro-apoptotic member of the Bcl-2 family
that, after dephosphorylation, is able to form heterodimers with anti-apoptotic proteins (Bcl-
2 and Bcl-xL) and prevents them from inhibiting apoptosis (351, 352). When a stress injury,
such as oncogenes, direct DNA damage, hypoxia, and survival factor deprivation, occurs
within the cell the apoptotic pathway that is triggered is called "intrinsic" pathway. The p53
is a sensor of cellular stress and is a critical activator of the intrinsic pathway. This protein
initiates apoptosis by inducing transcriptional activation of pro-apoptotic and repressing
anti-apoptotic Bcl2 family members. Additional p53 targets include Bax, Noxa, Puma (p53-
Upregulated Modulator of Apoptosis) and Bid. The p53 also trans activates other genes that
may contribute to apoptosis including PTEN (phosphatase and Tensin Homolog Deleted On
Chromosome-IO), APAFI, Perp, p53AIPI (p53-regulated Apoptosis-Inducing Protein-I),
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and genes that lead to increases in ROS (Reactive Oxygen Species). These ROS lead to a
generalized oxidative damage to all mitochondrial components (353).
Other proteins released from mitochondria, SMAC (Second Mitochondria-Derived
Activator of Caspase)/ Diablo, Arts and OmiIHTRA2 (High Temperature Requirement
Protein-A2), counteract the effect oflAPs (Inhibitor of Apoptosis Proteins), which normally
bind and prevent activation of caspase-3 (354). The interaction between Bel family
members, lAPs, SMAC and OmiIHTRA2 is central to the intrinsic apoptosis pathway.
Recent studies demonstrated that another nuclease, Endonucelase G, mitochondrion-
specific, trans locates to the nucleus and cleaves chromatin DNA during apoptosis (355).
Another protein, AIF (Apoptosis Inducing Factor) was also shown to have a role in
apoptosis, becoming active upon translocation from mitochondria to nuclei, where it initiates
chromatin condensation and large-scale DNA fragmentation (356).
1.2.2 Apoptosis in HIV/SIV Infection
Several studies have documented abnormal levels of apoptosis both in vitro (357-
367) and in vivo (368, 369) in CD4+ and CD8+ T cells from Hl'V-l-infected individuals. Of
note, the vast majority of T cells undergoing apoptosis in RIV -l-infected patients are not
infected by the virus (368). This observation led to the definition of 'bystander' apoptosis,
referring to apoptosis when it is not occurring as a direct cytopathic effect of the virus in an
infected cell. RIV -1 and RIV -2 differ in their natural course of infection: RIV -2 is
characterized by higher CD4 counts, low level of viremia; low transmission rate (370), as
well as by lower immune activation and CD4 T'-cell apoptosis (371). The level ofCD4+T-
cell apoptosis in HIV -l-infected individuals has been shown to correlate with the stage of
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the disease (372-377) and changes in the levels ofT-cell apoptosis following highly active
antiretroviral therapy (HAART) were shown to predict the immunological response to
therapy (378-380). Taken together, these observations indicate that the increased
susceptibility to apoptosis of T lymphocytes from HN -l-infected individuals can be
considered as a marker of disease progression and support the hypothesis that the chronic
immune system activation that follows HIV -1 infection could be one of the mechanism
responsible for this cell death process (368, 381, 382).
Apoptosis seems to be a relevant mechanism contributing to CD4+ T-cell depletion
during both the acute and chronic phases of HIV /SIV infections. Indeed, the level of
apoptosis during primary SIV infection was shown to be predictive of the rapid or slow
progression towards AIDS (383) and to be greater in primates infected with a pathogenic
SIV strain (384). Moreover, studies performed in pathogenic and nonpathogenic primate
models of HIV or SN infection during the chronic asymptomatic phase identified a
correlation between the induction of T-cell apoptosis in vitro and the pathogenic nature of
the infection in vivo (367, 381, 385-392).
Enhanced levels ofapoptosis in CD4+ T cells were observed in Hl'V-l-Infected
human individuals, and in rhesus macaques and chimpanzees infected with pathogenic
strains of SIV leading to AIDS (386), while enhanced CD8+ T-cell apoptosis was observed
in both pathogenic and nonpathogenic primate models. By contrast, no increased propensity
of either CD4+ or CD8+ T-cell in vitro apoptosis and normal levels ofT-cell apoptosis in the
T-cell-dependent areas of the lymph nodes were observed in either naturally or
experimentally SlY-infected sooty mangabeys (381).
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Taken together, all these reports underscore the relevance of apoptosis inAIDS
pathogenesis, and suggest that the capacity to induce apoptosis during primary SIV
infection, which seems to be directly correlated with the pathogenicity of the infection itself,
is a feature that does not depend solely on the virus, but is also related to specific host-virus
interactions that playa key role in determining the potential to induce AIDS.
1.2.3 Mechanisms of Apoptosis in HIV/SIV Infection
Various mechanisms have been proposed to contribute to the spontaneous apoptosis
observed during the course of HIV -1 infection. Among them sustained immune activation
associated with dysregulated cytokine production (345,393), loss of extracellular survival
signals ("death-by-neglect") (394), inappropriate signaling mediated by HIV-l envelope
binding to CD4 (395-397) or coreceptors (398), direct effect of accessory viral proteins,
including Tat and Nef (399-403), defective antigen presentation (404) and activation of
death receptors (366, 405-410), seem to play an important role.
Sustained immune activation, "death by neglect" and dysregulated cytokine production
Since many of the molecular steps required for apoptosis (such as chromatin
condensation or caspase activation) are in common with pathways of cellular activation
(411), the two phenomena are closely related and strictly linked in the so called activation-
induced cell death (AICD). Priming of a cell can occur in different ways, including repeated
stimulation through CD3/TCR (412), via CD4 (395) or activation without co-stimulation
(413), and these stimuli upregulate Fas and FasL expression on the surface of the cell (414).
Several studies have documented increased immune activation and accelerated T-cell
regeneration rates in the chronic phases ofHIV/SIV infection (222, 223, 345, 393), and
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elevated T-cell turnover is know to lead to the exhaustion of the immune system. Moreover,
this excessive immune activation has been suggested to induce apoptosis through FaslFasL
(376,415,416). Activated lymphocytes, at the end of an immune response, when antigens
and inflammatory cytokines are cleared, can undergo death-by-neglect in the absence of
further stimuli. In this case, cell death is preceded by the loss of a positive extrinsic signal
rather than the presence of a negative signal, as a consequence of which cells undergo
atrophy, characterized by a decrease in cell size and protein content and loss of cellular
ATP, and die (417-419).
Another factor that may contribute to apoptosis in HN-1 infection is cytokine
dysregulation, which is likely to occur as a consequence of the death ofTh lymphocytes
(420). It has been hypothesized that as HIV-l disease progresses there is a shift in the
cytokine response from a predominantly type-I cellular immune response (IFN-y, TNF-a,
IL-12), to a type-2 humoral response (lL-4, IL-5, IL-lO, IL-13), and type-I cytokine
responses decrease as the disease progresses (421). Considering that resistance to apoptosis
in vitro seems to be associated with a predominant type-I response (360, 362), and that IL-2
and Ifn-y exert anti-apoptotic activities, whereas IL-4 and IL-l 0 increase susceptibility to
apoptosis (364, 422), this type-l/type-2 shift of the immune response could have drastic
effects on apoptotic events. Although, gene expression data demonstrated that IFN-a is
capable of strongly inducing a number of pro-a pop totic genes in the TNF superfamily (423),
suggesting that susceptibility to apoptosis may not strictly fit the type-1I-2 paradigm, it is
however clear that cytokine dysregulation plays an important role in HIV -induced apoptosis,
regardless of the assignation of these cytokines to a type-lor type-2 phenotype.
The role of other cytokines, such as TNF-a and other TNF-family members, and the
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growth factors IL-2 and IL-15, is still a matter of debate. Indeed, although TNF is one of the
strongest pro-apoptotic signals and its serum levels were shown to be increased, as well as
its modulation being dysregulated, in HIV-1-infected individuals (424), there is only limited
evidence for TNF -mediated apoptosis in either infected and bystander lymphocytes and
clinical trials of anti- TNF therapies failed to show improvement in either immunological or
clinical outcome (425). The role of the T cell growth factors IL-2 and IL-15 in HIV-induced
apoptosis is also unclear: treatment with recombinant IL-2 or IL-15 was shown to increase
or decrease T-cell apoptosis susceptibility, depending on the activation status of the cell;
moreover, IL-2 and IL-15 were shown to increase susceptibility to C095-mediated
apoptosis (426), while protecting against spontaneous apoptosis (427); finally, treatment
with IL-2 in vivo was shown to decrease overall the levels ofapoptosis in HIV-I-infected
individuals (428).
Direct effect mediated byHIV-l envelope and other viral proteins
Inactivated mv-1 virions (429) and HIV -1 proteins released into the extracellular
environment can have dramatic effects on lymphocytes. HIV-1 proteins such as gp120, Tat,
Nef and Vpu have been shown to induce cell death in both infected and uninfected cells.
Soluble gp 120 has been shown to promote the cross-linking ofC04 molecules on the
surface of the cells (395), and this, in the absence of TCR stimulation, triggers apoptosis
(430). Moreover, binding of soluble gp120 to its receptors, C04 and the coreceptors CCR5
and CXCR4, triggers both Fas-dependent and -independent apoptotic cascades (398, 431,
432). Finally, cell surface presentation of gp120 can induce cell death mediated by close
cell-to-cell in both infected and bystander cells (396, 397,433).
HIV-l proteins Tat and Nefhave also been implicated in directly inducing apoptosis in
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both infected and bystander uninfected cells (399-403). HN-l Tat protein, secreted from
infected cells (434), has been suggested to upregulate caspase 8, Fas-ligand (FasL) and
TNF-related apoptosis-inducing ligand (TRAIL) (402, 435-437) in bystander cells.
However, the role of Tat is not solely pro-apoptotic, as this protein was also shown to
protect against TRAIL-mediated apoptosis (438), though upregulation of Bcl-2 (439). HN-
1- Nefprotein was shown to induce cell death in neuronal cells as well as in a wide range of
blood cells via a Fas-dependent mechanism (440-442).
In HIV -l-infected cells, the virus has evolved strategies for both inducing and
preventing apoptosis at the same time, to try to preserve its "source" of new virions. In this
context, the role of the same HN-l proteins, Tat and Nef, seems to be peculiar in that both
proteins were shown to promote apoptosis (see above) or to reduce apoptosis, for instance
by decreasing the expression of MHC I molecules that serve for the presentation of non-self
viral epitopes on the surface of an infected cell to promote cell-killing by CTLs (443).
Similarly to Tat (439), HN-l Vpr protein was reported to induce the expression of Bcl-2
and decrease the expression ofBax (444), while at the same time prolonging the G2 cell
cycle delay (445) and trans activating the viral promoter at the LTR (446), to boost viral
replication. However, despite these strategies, infected cells have a shortened half-life and
therefore are more prone to die, thus contributing to the overall decrease in the CD4+ T-cell
pool.
Defective antigen presentation
Several studies have reported reduced myeloid and/or plasmacytoid dendritic cells
(mDC and pDC) numbers in the blood ofHIV-l-infected individuals (447,448). In addition,
loss of Langerhans cells has also been reported (449). DCs are susceptible to HIV-l
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infection. However, although they are considered to be an early target ofHIV in sexual
transmission (158), there may not be an absolute requirement for the productive infection of
these cells. Indeed, it has been proposed that HIV -1 binds to DC-SIGN on DCs in the genital
tract and is internalized into non-lysosomal compartments where it retains infectivity (186),
to be then transported by DCs to the draining lymph node, where it is transmitted to
permissive T lymphocytes during antigen presentation (185). The virus can also be kept in a
silent form in DCs that are thus considered as a potential HIV reservoir. On Langerhans
cells this "transfer" process may be mediated by langerin, another C-type lectin expressed
on these cells that was shown to bind HIV-I (313). Several reports suggest a functional
impairment in the DC compartment in the course of HIV -1 infection, both in the capacity to
induce allogeneic T-cell proliferation (450-453) and in the capability to produce IFN-a
following antigen stimulation (454). DC dysfunction could contribute to the observed
increase in T-cell apoptosis, as a consequence of the lack of appropriate co-stimulatory
signals, that may result in T-cell anergy followed by T-cell deletion (455).
Activation of death receptors
Extensive death-receptors mediated apoptosis is thought to occur in many infectious
diseases, including HIV /SIV infection. As outlined above, several HIV -1 proteins may
interact directly with the death receptor apoptotic pathway, altering the expression of various
death receptors, including Fas and TRAIL-receptors. Indeed, peripheral blood mononuclear
cells (PBMC) from HIV-I-infected individuals express higher levels of FasL and Fas (407),
and this upregulation further increases with disease progression (365, 405, 456). Augmented
levels of soluble Fas were also documented in the plasma of HIV-I-infected individuals, and
this can be used as a marker for the prognosis of AIDS (457). An increased susceptibility to
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TNF-mediated apoptosis was observed in both CD4+ and CD8+ T cells from HIV-I-infected
individuals (410), accompanied by an upregulation ofTNF-R2 expression (458). High levels
ofTNF and soluble TNF-R2 were also observed, and were found to be predictive of disease
progression (424). TRAIL-dependent AICD was detected in CD4+ T cells isolated from
HIV -I-infected individuals in vitro, particularly in infected cells, and the addition of
antagonistic TRAIL-specific antibodies reduced apoptosis (459). HIV-I Tat protein seems to
upregulate TRAIL expression, thus triggering apoptosis in bystander uninfected cells (437,
460). Thus, TRAIL seems to be one of the most significant molecules for apoptosis in HIV-
1 infection, and was also shown to induce apoptosis in neurons both in vitro and in vivo, thus
potentially explaining neuronal death in Hl'V-l-associated encephalopathy (461-463).
Finally, in HIV-I infected individuals, the expression level of other co-stimulatory and
death molecules, including CD28, CD40 and CD40-ligand, is also altered (464-466).
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1.3 Non-Human Primate (NHP) Models for HIV-l Infection and AIDS
The challenge in establishing animal models for HIV -1 is that the virus does not
replicate in most of the animal species tested (467), with the exceptions of chimpanzee and
gibbon apes (468). However, HIV -1 infection of chimpanzees is typically non-pathogenic,
with only rare animals developing AIDS-like symptoms after prolonged incubation period
(386,469,470) and these species are endangered and costly to maintain, limiting their use
for research purpose (471).
The family ofCD4+ T-Iymphotropic primate lentiviruses comprises two human
viruses (HIV -1 and HIV -2) and at least 40 simian immunodeficiency viruses (SIV) that can
be found naturally in non-human primates (NHPs). The similarities between SIV and HIV
with respect to genomic structure and biological features renders infection of various
macaque species with SIVs, or with chimeric viruses containing both SIV and HIV
sequences (SHIVs), the most reliable animal models to study HIV-I infection and AIDS.
Natural hosts for SIV (sooty mangabeys and African green monkeys) generally do not show
any signs of AIDS, despite chronic sustained levels of viral replication. Actually, few
reports have demonstrated that SIV infection in natural hosts can eventually lead to the
development of immunodeficiency. However, clinical disease seems to occur in the minority
of cases, and only when animals have been infected over long periods of time. Indeed: (i)
AIDS cases were reported for mandrils infected with SIVmnd-l and SIVmnd-2 after 17
years of infection (472); (ii) a sooty mangabey (SM) naturally infected with SIVsmm
progressed to AIDS after an incubation period of 18 years (473) and (iii) an African green
monkeys (AGM) coinfected with SIVagm and simian T-cell leukemia virus (STLV) was
also reported to progress to AIDS (474). Transmission ofSIV from natural hosts (SMs and
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AGMs) to Asian non-natural NHP host species (pigtailed and rhesus macaques) has been
shown to lead to AIDS (475). Similar to humans and macaques, naturally or experimentally
infected SMs, AGMs and mandrills show viremia levels which are persistently as high or
even higher than those known with progression in humans (381, 472, 476-478). Studies of
naturally SN-infected AGMs during the chronic phase of the infection show signs of viral
replication in the same tissues as during pathogenic infections, including gut and thymus
(479-481) and both T CD4+ lymphocytes and macrophages are infected (479). Among the
existing primate lentiviruses, infection of macaques with these SIV s most closely
approximates HIV-l infection in humans. Similarities include CD4+ T-cell and macrophage
tropism, CD4+ T-cell depletion, serologic and immunologic responses and pathology,
including neuropathology and opportunistic infections. However, the incubation and disease
time are usually shorter and there are no lesions similar to Kaposi's sarcoma, which may
occur in HN-l-infected individuals (482). Considerable efforts have been made to
understand the similarities and differences between pathogenic and non-pathogenic SIV
infections, with the hope of uncovering new host defenses that will guide conventional
AIDS vaccine development. Several mechanisms, such as effective host control of viral
replication, effective host control of viral pathogenicity, and failure of the virus to induce
immunodeficiency, despite successful persistent infection, have been proposed to contribute
to the nonpathogenic nature of SIV infection in natural hosts, and it is likely that more than
one concur.
For Hlv-l-infected patients and SIV-infected macaques plasma viral load is the best
predictor of disease progression (483-486). In captive NHPs naturally infected with SIVs
(SIVsmm, SNagm, SIVmnd-l, and SIVmnd-2), viral loads during the chronic phase of the
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infection are higher than in chronically HIV-1-infected asymptomatic patients (472, 476-
480, 487, 488), and longitudinal analyses of the dynamics of plasma viremia in naturally
SlY-infected animals suggest that the level of viral replication is relatively constant over
time (472, 473, 489). Thus, it does not appear that the lack of disease in naturally infected
animals is associated with effective host containment of viral replication in these species.
Studies of SIV -infected SMs and AGMs showed that, despite a significant CD4 +T-cell
depletion, the regenerative capacity of the CD4+ T-cell compartment is fully preserved (332,
381), and this may playa key role in determining the lack of disease progression in naturally
SIV -infected monkeys.
Both HIV -I and SIVmac infections induce immune responses characterized by robust
neutralizing and cellular immune responses (490), but a continuous immune escape occurs
(491). Conversely, for natural infections ofNHPs, the general consensus is that the immune
responses are lower compared to those documented inpathogenic models (492) and this has
led to the hypothesis that it is the low level of immune activation that protects natural SIV
hosts from CD4+ T-cell depletion and AIDS (493). Lower levels of immune activation may
in fact favor the preservation of the number and/or function ofCD4+ T cells as well as of
other immune cell types (including CD8+ T cells, 'YO T cells, NK cells, macrophages, etc.),
whose functional integrity may contribute to the preservation of the CD4+ T-cell pool. This
theory is consistent with the observation that, during pathogenic HIV /SIV infections,
generalized immune activation is an important driver and predictor of disease progression
(335). An explanation for this lower immune activation could be related to the observation
of increased numbers of Tregs, paralleled by an increase in TGF-p and IL-IO levels, in the
plasma of SIVagm-infected AGMs, during the acute phase of infection (494). Alternative
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mechanisms may involve dendritic cell- T cell interface, pro inflammatory cytokine response,
regulation of T cell homing to inflamed tissues, and maintenance of the balance of distinct
CD4+ T cell subsets (Thl, Th2, Thl7) (333).
As described above, a series of studies showed that pathogenic HIV ISIV infections
are characterized by an early, severe, and largely irreversible depletion of mucosal
CD4+CCR5+ memory T cells. Thereby, a model of AIDS pathogenesis has been formulated
in which the selective depletion of memory CD4+T cells from mucosal tissues during acute
HN infection is a key determinant of disease progression. However, an early, severe, and
persistent depletion of mucosal CD4+ T cells was also observed during nonpathogenic SN
infection in natural hosts, with a kinetics that closely resembles that observed in pathogenic
infections (495). Of note, the early mucosal CD4+ T cell depletion of natural hosts either
does not progress further after reaching a stable plateau (in SMs) or is followed by a
significant recovery of these cells (in AGMs) (495), thus implying that the severe loss of
MALT CD4+ T cells during the acute phase of the infection may not be sufficient for the
development of AIDS and that other factors, maybe related to the nature of the host, are
required to induce mucosal and systemic immune dysfunction. Indeed, albeit for the very
early acute phase of the infection, the majority of naturally SIV-infected SMs generally
maintain normal CD4+ T cell counts in the peripheral blood throughout the infection (496).
One possible explanation could be that natural SIV hosts have evolved to be less dependent
on CD4+ T cells to maintain the overall function of the mucosal immune system (497).
Alternatively, additional factors, such as the lack of local immune activation, would
contribute to protect the CD4+ T cell-depleted mucosae of natural SIV hosts from losing
their barrier function (495).
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Another striking immunologic difference between natural non-natural SIV hosts is
the lower level of CCR5 expression on CD4+ T cells in the blood, lymph nodes, and
mucosal tissues of natural SN hosts (498). Although this is not sufficient to confer
protection against infection of CCR5-tropic viruses, it is possible that the restricted CCR5
expression only to a limited group of CD4+ T cells, likely those that have already
encountered an antigen and are therefore at a more advanced stage of activation, may
contribute, in synergy to the overall lower level of immune activation, to preserve the
homeostasis of the "resting" CD4+ T-cell pool (333) (Figure 1.9).
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1.4 Treatment ofHIV-l infection
1.4.1 Antiretroviral therapy (ART)
Nowadays, the treatment options for clinicians working with HIV -l-infected individuals
include several classes of drugs:
Entry inhibitors (or fusion inhibitors) interfere with binding, fusion and entry of
HIV -1 to the host cell by blocking one of several targets (maraviroc and enfuvirtide)
CCR5 receptor antagonists target CCR5 receptor on the surface of the T-Cell and
block viral attachment to the cell
- , Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs) inhibit reverse
transcription by being incorporated into the newly synthesized viral DNA strand as a
faulty nucleotide
- Non-nucleoside reverse transcriptase inhibitors (NNRTls) inhibit reverse
transcriptase directly by binding to the enzyme and interfering with its function
Protease inhibitors (PIs) target viral assembly by inhibiting the activity of protease,
an enzyme used by HIV to cleave nascent proteins for the final assembly of new
virions
Integrase inhibitors inhibit the enzyme integrase, which is responsible for integration
of viral DNA into the DNA of the infected cell (raltegravir, 2007)
Maturation inhibitors inhibit the last step in gag processing in which the viral capsid
polyprotein is cleaved, thereby blocking the conversion of the polyprotein into the
mature capsid protein (P24) (Ifn-o).
Historically, the very first antiretroviral drug discovered for the treatment of HIV-I
infection was zidovudine (ZDV), which was approved by the U.S. Food and Drug
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Administration (FDA) in 1987. This drug belongs to the class ofNRTIs and inhibits the
enzyme reverse transcriptase (RT) by inducing chain termination and an interruption of
HIV -1 cDNA synthesis (499). The second FDA approved drug was didanosine (ddI), an
analog of adenosine, introduced in 1991 in the United States (500). Unfortunately, scientists
soon discovered the limitations of monotherapy regimen, mainly related to the appearance of
HIV-1-variants that were resistant to the inhibitory effect of this molecule (501-503). It
became increasingly clear that a combination of drugs would probably have been more
effective and most likely required in order to counteract the emergence of resistant variants
and to try to achieve a more profound and hopefully sustained suppression of viral
replication. In 1995, David Ho promoted a "hit hard, hit early" approach with aggressive
treatment with multiple antiretroviral drugs early in the course of the infection (504), but the
associated risks of increasing side effects and developing multidrug resistance were shortly
emphasized (505). As the understanding and clarification of the HIV-l replication cycle
progressed, additional viral proteins started to be identified as potential new targets for
antiretroviral drugs. This led to the discovery and development of the protease inhibitors
(PI), the second class ofanti-HIV-l compounds to be employed for the treatment ofHIV-1
infected individuals. This class of compounds acts though directly binding to the active site
ofHIV-1 protease, thus blocking virus maturation and the generation of new infectious viral
particles (506). Shortly after, triple combination therapy consisting of a PI and two
nucleoside RT inhibitors (NRTIs), ultimately referred to as highly active anti-retroviral
therapy (HAAR T), was introduced as the standard of care for HIV -1+ patients in the
developed world (507-511). Subsequently, a third class ofanti-HIV-1 agents, the non-
nucleoside RT inhibitors (NNRTIs) became available. NNRTIs are a structurally distinct
64
group of drugs that bind to the HIV -1 RT at a position other from the active site, causing
conformational changes in the active site itself (512). Like PIs, NNRTIs have a synergistic
effect when used in combination with two different NRTIs (506). Integrase inhibitors act by
blocking the action of viral integrase and, since they target a distinct step in the retroviral
life cycle, they may be taken in combination with other types of drugs to minimize
adaptation by the virus. They are also useful in salvage therapy for patients whose virus has
mutated and acquired resistance to other drugs. The first integrase inhibitor approved by the
FDA was raltegravir, approved on October 12,2007, which was shown to increase the
efficacy of optimized background therapy (513).
Other treatment options that were recently introduced for the treatment of HIV-l
infection include two promising entry inhibitors, Enfuvirtide and Maraviroc. Enfuvirtide, or
T20, is a fusion inhibitor that has been approved for use in treatment-experienced patients
(514). It is a synthetic peptide that mimics amino acids 127-162 of HIV-I gp41, a key
domain involved in viral fusion with the cell membrane. Maraviroc, which was approved by
the FDA in 2007, binds to CCR5 preventing interaction with HIV and CCR5-mediated
signaling events (SIS).
The final class of antiretroviral drugs under development for the treatment of HIV -1-
infected individuals are maturation inhibitors, whose prototype is bevirimat that targets the
internal HIV -l-structural precursor Gag and its function in the final assembly of the mature
infectious virus (516). Besides bevirimat, HIV-l assembly and budding is currently being
exploited as a new potential target for antiretroviral therapy. For instance, it is known that
HIV-l Vpu acts by restricting the antiviral activity oftetherin, an integral membrane protein
that binds to fully formed virions thus retaining them on the surface of infected cells (517);
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therefore, targeting Vpu-tetherin interaction may represent a new therapeutic target. Another
interaction that it might be worth to try targeting is that ofHIV-1 Vifwith APOBEC3G, a
DNA editing enzyme that exerts its antiviral activity by introducing C-to-U changes in the
newly synthesized viral single stranded cDNA, thus promoting its degradation (518). Small
inhibitors aimed at blocking this interaction may provide a novel therapeutic option.
1.4.2 Immune-reconstitution agents
As describer above, multiple classes of antiretroviral drugs are now available and
HAART regimens are effective in suppressing HIV-l replication in the majority of patients.
However, some patients still have a discordant response to HAART, in that viral load is
suppressed, but CD4+ T-cell counts remain low and HAART alone may not be sufficient to
completely restore the immune system. In these patients the use of immunomodulatory
agents in addition to antiretroviral drugs could help to try to restore the CD4+ T-cell
lymphopenia and therefore the immune functions. Current strategies have focused on
immunomodulatory cytokines, such as interleukin-2 (IL-2), interleukin-7 (IL-7) and
interleukin-15 (IL-15), in virtue of their central role in regulating T-cell proliferation and
survival, to try maintain T-cell homeostasis (519). IL-2, IL-15 and IL-7 belong to the y-
chain family and their receptors share a common y-chain, CD 132, which is responsible for
the signal transduction via activation of the JAK-STAT and PI3K pathways. Activation of
the JAK-STAT pathway is associated with the induction of the anti-apoptotic protein Bcl-2,
~".
whereas activation of the PI3K pathway induces cellular proliferation (519). In addition to
the common y-chain, each of these receptors has one or two specific chains responsible for
the binding with the cytokine and/or additional signaling pathways. Indeed, IL-2R is a
66
heterotrimer composed ofCD132, a specific a-chain that binds IL-2 (CDI25) and the IL-
2IIL-I5R (3 chain (CDI22); IL-I5R is composed oflL-I5Ra, CDI22 and CD132 and IL-7R
is a heterodimer composed oflL-7Ra (CDI27) and CD132 (519). Even if these cytokines
share signaling pathways, however they have distinct effects, due to 1) unique signaling
events, 2) different receptor expression on different T-cell subsets (Figure 1.10) and 3)
variable levels of the cytokines in different compartments.
IL-2
IL-2 is secreted by activated CD4+ T cells and, although it can support the expansion
of antigen-stimulated CD4+ and CD8+ T cells, its primary role is related to the regulation of
regulatory T cells (Tregs) and to the maintenance of peripheral tolerance (520).
IL-2 has been used in RIV -I-infected individuals in several types of clinical trials:
the earliest based on frequent high doses intravenous administrations and the more recent
consisting of infrequent low doses subcutaneous administrations (521-530). Phase I studies
of exogenous IL-2 in RIV-I infection were initiated as early as 1983, before the availability
of cART and since then, there have been at least 15 phase II studies employing various
formulations of recombinant IL-2 (rIL-2). These trials demonstrated that treatment with IL-2
induces an increase in the absolute number of circulating CD4+ T cells, particularly in
patients with pre-treatment CD4+ T-cell counts above 200 cells/ill in the absence of
HAART, or below 200 cells/ill but in the presence ofHAART, with no increases in CD8+ T-
cell counts (521, 522, 525-528, 531-535). IL-2-driven CD4+ T-cell expansion seems to
involve mainly narve CD4+ T cells, and a population of CD4+ CD25+ T cells expressing
intermediate levels ofCD45RA and CD45RO (526, 527). Of note, this expansion was
shown to be polyclonal (521). Moreover, in these studies, treatment with IL-2 was not
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associated with any increase in CD8+ T-cell activation (525, 527, 530,). Albeit this positive
immune-reconstitution effect, IL-2 administration was also associated with transient
increases in the plasma viral loads, both in the absence and presence ofHAART (521, 525,
526), as well as with severe side effects. Besides the consistent increase in CD4+ T-cell
count observed in these studies, none of them were powerful enough in determining whether
the increase in CD4+ T-cell count could be translated into a clinical benefit, although a trend
towards a reduction in opportunistic infection resulted from a pooled analysis (536) and in a
study in patients with advanced HIV (530). As a consequence of these non-conclusive
results, it became clear that clinical endpoint studies were required in order to clarify
whether CD4+ T-cell increase could be considered a reliable marker of a successful therapy,
and to investigate the antiviral effects. Two phase III clinical studies of recombinant IL-2
administration in HIV-l-infected individuals, named SILCAAT and ESPRIT, were started
back in 1999, with enrollment completed at 1695 and 4111 patients in 2002 and 2003,
respectively (537). Both studies, besides documenting sustained increases in CD4+ T-cell
counts of 19% (SILCAAT) and 26% (ESPRIT) in IL-2 and ART treated individuals, as
compared to individuals treated with ART alone, failed to show any kind of clinical benefit.
One explanation could be that the CD4+ T cells expanded by IL-2 do not have the same
functionality as those depleted during the course of HIV -1 infection or those restored with
ART (538). Alternatively, the predominant expansion of naive and central memory cells,
without expansion of effector memory cells, could be the explanation for the lack of defense
against OD pathogens, or it is possible that this expansion does not specifically fill in the
deficits in the T-cell receptor repertoire. Finally, the CD4+ T cells expanded by IL-2,
expressing intermediate levels ofCD25 and the transcriptional regulator FoxP3, remind of
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Tregs cells (527), and therefore they could have suppressor activity, even if additional data
are needed to confirm this hypothesis. Despite the uncertainty regarding clinical efficacy of
rIL-2, the French Government did allow access to IL-2 for the treatment of patients with
CD4+ T-cell counts < 200 cells/ul on combined ART, an access scheme that, however,
ceased in 2007. In a very recent study, intermittent IL-2 treatment was also shown not to
have any effect on CD4+ T-cell depletion in the gut ofHIV-l-infected individuals (539). In
light of this "failure" concerning the use ofIL-2 to try to improve the clinical outcome of
HIV -l-infected individuals, alternative settings in which this cytokine could be useful are
currently under investigation. The first is the potential use ofIL-2 (with ART) to induce the
re-activation and eventually the eradication of HIV from latently infected CD4+ T cells, in
order to reduce the pool of viral reservoir (540-542), and studies showing reactivation of
latent integrated virus in vitro with IL-2, together with clinical trials demonstrating lower
changes from baseline plasma HIV-l RNA in patients treated with IL-2 plus ART as
compared to ART alone, may provide a rationale for this approach (536). However,
preliminary studies designed to explore this theory so far failed to give definitive results
(542). The second setting in which IL-2 treatment is being investigated is the role that this
cytokine may have in delaying the start of continuous combination ART, and this strategy is
based on the idea of avoiding ART for as long as the CD4+T-cell compartment can be
preserved. Two examples are the ANRS 119 study and the STALWART study (543,544).
The third potential use ofIL-2 is the treatment with combined ART in order to delay the
time for re-initiation of ART, an option explored in the TILT and in the ICARUS study
(545, 546). Besides the therapeutic described so far, another field in which IL-2, as well as
other v-chain cytokines like IL-IS (see below), could find a place is therapeutic vaccination.
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Indeed, these cytokines could be useful to increase T-cell levels and/or their function to
boost HIV-I-specific T-cel1 responses to the vaccine (547). Overal1, the main barrier to
moving forward with this strategy seems to be, at least for now, the poor performance of
these vaccines in controlling the viremia, even when T-cell responses are boosted (548).
IL-15
IL-I5 exerts its function mainly in a membrane-bound isoform (549) expressed on a
variety of cell types, including monocytes/macrophages, dermal fibroblasts, keratinocytes,
epithelial cel1s neuronal cells, dendritic cells and T cells (550-555). It is primarily implicated
in the expansion of CD4+ and CD8+ EM T cells, even if it was also shown to promote the
survival and growth ofNK and NK-T cells (556-558). Moreover, in T cells, IL-I5 induces
both a proliferative and differentiation signal, so that CM T cells not only proliferate, but
also differentiate into EM T cells (559). Finally, IL-I5 was shown to induce the homeostatic
proliferation ofCD4+ and CD8+ EM T cells in the periphery (560). The complexity of the
IL-I5IIL-I5R system is further increased by the fact that IL-I5Ralpha is often shed from the
cells, and its soluble form can bind and sequester the active cytokine (558).
The immunologic impact of IL-I5 administration in vivo during the chronic phase of
the infection was tested in SIV-infected rhesus macaques, in which it was shown to induce
the expansion of both NK and memory T cells, as well as of CD8+ EM T cells and CD4+ EM
T cells with ART, with no effects on viral replication (559). IL-I5 administration during the
acute phase of SIV infection, however, increased viral set point by three logs, and in 30% of
the animals it increased the rate of disease progression (561). Like IL-2, IL-I5 is also being
tested as an immune adjuvant for vaccination and several studies have been conducted in
SIV -infected animals, although the usefulness of IL-I5 treatment seems to be strictly
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dependent on the virus used for the challenge, thus suggesting that its potential utility for
HIV/SN vaccine or immune-based therapies may be very limited (547).
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1.S IL-7
I.S.1 Phenotype and function of CD4+ and CDS+ T cells subsets
T-cell maturation occurs predominantly at the level of the thymus (from here the
term "thymocytes" for T cells), where hematopoietic progenitors derived from
hematopoietic stem cells of the bone marrow colonize and proliferate to generate a large
population of immature thymocytes. The earliest thymocytes in the thymus do not express
CD4 nor CD8, and are therefore called "double negative" (CD4"CD8"), whereas, as they
progress through their development, they become "double-positive" (CD4+CD81 first, and
subsequently "single-positive" (CD4+CD8" or CD4"CD8+) before being released into
peripheral tissues. The thymus provides an inductive environment that allows for the
development and selection of physiologically useful T cells, which occur through the
processes of beta-selection, positive selection, and negative selection. These processes shape
the population ofthymocytes into a peripheral pool ofT cells able to respond to foreign
pathogens and immunologically tolerant towards self antigens. These cells are called
"narve", and are mature T cells that have not encountered their cognate antigen within the
periphery yet.
T-cell maturation was once thought to occur entirely within the thymus, but
nowadays consensus exists about the fact that the youngest peripheral T cells, termed recent
thymic emigrants (RTEs) comprise a distinct population from their more mature, yet still
naive counterparts (562). Indeed, RTEs undergo a process of post-thymic maturation,
involving both phenotype and immune function, that ensures T-cell fitness and self tolerance
(562). RTEs constitute a considerable proportion of the T-cell pool in neonates, infants and
young adults (563), and they also maintain T cell receptor (TCR) repertoire diversity in
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young and middle-aged adults to allow for recovery from lymphopenia (564). Mature naive
T cells, typically expressing L-selectin (CD62L) and lacking the expression of activation
markers (CD25, CD44 or CD69) and of CD45RO (565), constantly recirculate through
peripherallymphoid organs, particularly lymph nodes (they also express CCR7 for lymph-
node homing) (566), where, eventually, they encounter antigen-presenting cells (dendritic
cells and macrophages). In the naive state, T cells are thought to be quiescent and non-
dividing, requiring the common-gamma chain cytokines IL-7 and IL-15 for homeostatic
survival mechanisms. Indeed, they also express functional IL- 7 receptor, consisting of IL- 7
receptor-a, CD127, and common-v chain, CD132.
In peripheral lymphoid organs, narve T cells can respond to novel pathogens that the
immune system has not yet encountered. In the cortex of lymph nodes, T cells that do not
encounter their specific antigen leave the lymph node and return to circulation; by contrast,
T cells that encounter their specific antigen on antigen-presenting cells are activated to
proliferate and differentiate into effector cells (phenotype: CD25+, CD44+, CD62L1ow,
CD69+, CD45RO+). Recognition by a narve T cell clone of its cognate antigen results in the
initiation of an immune response. The proliferation and differentiation of activated T cells
depends upon the production of cytokines, such as IL-2, and its binding to the high affinity
receptor (CD25) expressed on the surface of activated T cells. Armed effector T cells
mediate a variety of functions, including killing of infected cells by CDS+ cytotoxic T cells
and the activation of macro phages by CD4+ THI cells and ofB cells by CD4+ THI and TH2
cells.
THcells translate antigen stimulation to tissues and instruct tissue cells to increase
immune responses and the type of response depends on the properties of the T cells that
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interact with the tissue. In addition to THl and TH2 cells, also THl7 and regulatory T (Treg)
cells are known to play important roles. Each THcell subset secretes a characteristic set of
cytokines. Thus, THI and TH2 typically produce IFN-y and IL-4, whereas IL-17A is
specifically produced by the TH17 subset and coordinates tissue inflammation through
induction of pro inflammatory cytokines and chemokines, such as IL-6, TNF -ct, and IL-8
(567). Consistently, TH17 cells were shown to playa key role in many autoimmune
disorders, such as rheumatoid arthritis, multiple sclerosis, systemic lupus erythematous, and
inflammatory bowel disease (567). Another cytokine that is known to be produced by THl7
cells is IL-22, whose function has not been fully clarified yet. Recent studies have
determined that some T cells express IL-22 independently ofIL-17, and these cells were
named TH22 (568). TH22 are present within the epidermal layer in inflammatory skin
diseases and seem to be involved in epidermal immunity and remodeling (569).
Tregs, sometimes referred to as suppressor T cells, are a subpopulation of T cells that
contribute to the downregulation of the immune system, the maintenance of the tolerance to
self-antigens, and the downregulation of autoimmune diseases. Several types of regulatory
cells do exist, some of which are induced in response to infectious challenge (the so-called
inducible Treg) and some that are considered natural regulators (natural occurring Treg)
(570). Inducible Tregs cells can develop from conventional CD4+ T cells that are exposed to
specific stimulatory conditions such as the blockade of costimulatory signals, deactivating
cytokines or drugs (570). By contrast, natural Treg cells arise during the normal process of
maturation in the thymus and survive in the periphery as Treg cells. Natural Tregs express a
specific set of markers like C025, the T cell inhibitory receptor CTLA-4 and the
glucocorticoid-inducible tumor necrosis factor receptor (GITR). The unique transcription
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factor Foxp3 is required for the generation of natural Treg cells, and this represents their
most specific marker identified so far (571). Natural Treg cells can respond to a large variety
of self antigens, and they may also respond to antigens expressed by microbes, whereas
inducible Treg cells may control various infectious processes (572).
A primary adaptive immune response to an infection serves not only to clear the
primary infection from the body, but also to provide protection against a second reencounter
with the same pathogen, in a process that is called protective immunity. One of the most
important consequences of the adaptive immune response is the immunological memory,
generally defined as the ability of the immune system to respond more rapidly and
effectively to pathogens that have been previously encountered, and reflects the pre-
existence of a clonally expanded population of antigen-specific lymphocytes.
Memory T cells are heterogeneous in terms of both homing capacity and effector
functions and they can be broadly classified in central memory (TCM)and effector memory
(TEM)(573). According to the model proposed by Lanzavecchia and Sallusto, TEMmigrate to
inflamed peripheral tissue and display immediate effector function, whereas TCMhome to
the T-cell areas of secondary lymphoid organs and have little effector function, but
immediately proliferate and differentiate in effector cells in response to antigen stimulation
(574). TCMare CD45RO+ cells that constitutively express CCR7 and CD62L, two receptors
that are also expressed by naive cells, and are necessary for extravasation and migration to
the T-cell areas of secondary lymphoid organs (575, 576). Following TCR triggering they
produce IL-2 and proliferate and differentiate into effector cells which in turns produce high
amounts ofIFN-y and IL-4. TEMcells are memory cells that have lost the expression of
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CCR 7 and are heterogeneous for CD62L. As compared to TCM,they are characterized by a
more rapid effector function, as they produce high amounts ofIFN-y, IL-4 and IL-5 within
hours after stimulation. Some CD8+ TEMexpress CD45RA (TEMRA)and carry the largest
amount of perf orin. The distribution of TCMand rEM in the body varies according to the
CD4+ and CD8+ T-cell compartment and to the tissues: TCMare predominant in CD4+ T cells
and TEMin CD8+ T cells, and TCMare enriched in lymph nodes and tonsils, whereas TEMare
predominant in lung, liver and gut (577). In antigen-primed individuals, antigen-specific T
cells are detected in both TCMand TEMcompartments, although the relative proportion can be
extremely variable according to the condition. For instance, HIV -l-specific T cells are
largely TEM(CD45RA-CCR7") (578).
In the body several subsets of TCMand TEMcells with distinct functional properties
exist, and can be identified according to the expression of surface molecules, being them
costimulatory molecules, such as CD27 and CD28, or chemokine receptors, like CCR4 or
CCR5, which can be expressed at variable levels in CD4+ and CD8+ T cells (Figure 1.11).
For instance, the simultaneous expression of CLA and CCR4 identifies skin-homing T cells
(579), whereas 1l4f37 and CCR9 characterize gut-homing cells (580). As compared to narve T
cells, memory T cells show low-activation threshold and vigorous proliferation, with the
expansion potential progressively decreasing from rCM to TEMand TEMRA(581, 582).
According to the model proposed by Lanzavecchia A. and Sallusto F., it is the
strength of the signal delivered by rCR and cytokine stimulation that determines
proliferation and differentiation of T cells, driving them through hierarchical thresholds of
differentiation, which follows a sequence of proliferation, acquisition of fitness, effector
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function and death (Figure 1.12) (583). T cells receive TCR and cytokine stimulation
through stochastic interactions with dendritic cells at different levels and, therefore, they
reach different levels of differentiation. At low signal levels naive T cells proliferate but do
not acquire effector functions and they retain lymph node-homing capacity. By contrast, at
thigh signal strength and in the presence of costimulatory cytokines that polarize
differentiation, T cells loose lymph node-homing capacity and acquire effector functions and
the capacity to migrate to inflamed peripheral tissues. At even higher signals, T cells
undergo activation induced cell death (AICD). At the end of the antigen stimulation phase,
activated T cells are selected for their capacity to survive in the presence of homeostatic
cytokines: "unfit" cells die by neglect, whereas "fit" cells that home to the appropriate
tissue survive as memory T cells. After the proliferative burst most of the effector cells die,
but a minor fraction persists as long-term memory T cells that continue to divide slowly in
the absence of antigen. Evidences suggest that TCMderive from cells stimulated with sub-
threshold amounts of antigen and they are arrested at an intermediate stage of
differentiation, retaining lymph node-homing capacity and with low effector functions, that
precedes TEM;by contrast, TEMseem to arise directly from effector cells (Figure 1.12).
Very recently, a novel human memory T cell subset with stem cell-like properties has been
identified (584). These stem cell-like memory T cells (TsCM)are long-lived memory T cells
that have an enhanced capacity of self-renewal and a multipotent ability to derive central
memory, effector memory and effector T cells. They were found within the naive T cell
compartment (CD45RO·CCR 7+CD45RA +CD62L+CD27+CD28+IL-7Ra +), but they also
express markers that are typical of memory T cells, like CD95, IL-2R~, CCR3 and LFA-l,
as well as numerous functional attributes distinctive of memory T cells. The hypothesis
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suggested by the authors is that TSCM are a clonally expanded primordial memory subset
arising after antigen stimulation with increased proliferative and reconstitutive capacity.
I.S.2 IL-7 in Physiology
IL- 7 is the only cytokine of the gamma-chain family to be constitutively produced,
instead of being secreted upon stimulation, and low levels ofIL-7 are constantly detectable
in the human serum (585). IL-7, initially identified as a B-cell growth factor (586), was
shortly after recognized as a key factor also for the development and homeostasis of both
thymic and peripheral CD4+ and CD8+ T cells (587), particularly on the naive and memory
compartments. It is produced by stromal tissues, including the bone marrow, as well as by
thymic epithelial and intestinal epithelial cells (588). In the absence of perturbation, the
number of T cells in the peripheral lymphoid compartment is strictly controlled through
several mechanisms, including death, survival and turnover, and IL-7 in this context plays
an essential role, also mediated by a feedback control mechanism by which IL-7 stimulation
downregulates the expression ofIL-7Ra (CD127) (589), to ensure that the cells that have
already responded to the cytokine do not compete with those that have not encountered it
yet. After the first encounter with an antigen, narve T cells become activated and undergo
several rounds of expansion differentiating into effector cells that produce IL-2, which in
turns downregulates IL-7Ra expression (590). This ensures IL-7- independence. At the end
of the immune response, T cells progress to a resting state with upregulation of IL- 7Ra
expression, which promotes the differentiation into memory and their subsequent survival
(591-593) (Figure 1.10). IL-7 also contributes to the maintenance of the CD4+ and CD8+
memory T-cell pools, by supporting their "homeostatic" division in the absence of antigen
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stimulation (592). In lymphopenic hosts IL-7 was shown to support the division of both
CD4+ and CD8+ T cells. It seems that the regulation of the survival and proliferative effects
of IL- 7 is mediated by both IL- 7Ra expression and IL- 7 concentration. IL- 7Ra is expressed
at high levels on resting cells, to ensure that the physiological IL-7 concentration (2.7 pg/ml
in serum (594)) supports the survival of narve and memory T cells but not of effector cells,
which do not express the receptor, or express it at much lower levels (591). The dose ofIL-7
is also crucial for discriminating between proliferation and survival: at low doses receptor-
expressing cells respond inducing a pro-survival signal, whereas when the concentration
increases, the same cells can undergo proliferation and division, probably through the
synergy with TCR stimulation (Figure 1.13) (595). Thus, in lymphopenic conditions CD4+
and CD8+ memory T cells, as well as naive T cells albeit to a lesser extent, expand in an L-
7-dependent manner, probably as an effect of the increased availability of the cytokine,
together with de novo cytokine synthesis (585).
1.5.3 IL-7 in RIV/SIV infection
Several lines of evidence suggest that the IL-7IIL- 7R system is impaired in HIV -1-
infected individuals, as well as in SN -infected macaques. Indeed, virus-induces T-cell
lymphopenia is accompanied by increased levels of plasma IL-7, which correlate inversely
with CD4+ T-cell counts and can be normalized after ART treatment has restored the CD4+
T-cell subpopulation (585, 596-599); moreover, pre-HAART plasma IL-7 levels were
shown to correlate with long-term CD4+ T-cell increase after treatment (600). The
augmented IL-7 levels seem to be mediated by increased production by dendritic-like cells
within the peripheral lymph nodes and by peripheral lymphocyte-depleted lymphoid tissue,
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and was proposed as a compensatory mechanism of the body to try to counteract the virus-
induced lymphopenia (585). A recent longitudinal study, showing that in patients with low
or moderate immunodeficiency CD4+ T-cell counts and IL-7 levels do not evolve in parallel
either in the absence or presence of HAAR T, suggest that factors other than CD4 +T-cell .
count might contribute to the upregulation of plasma IL-7 in HN -I-infected individuals
(601). Other studies documented reduced IL-7Ra expression on all subsets ofCD4+ and
CD8+ T cells from HIV -l-infecting individuals, correlated with disease progression and
restored upon ART treatment, thus suggesting that the increased production of IL- 7 to
promote homeostatic rebalance may be ineffective, in the absence of therapy (602-608).
Indeed, recently, mathematical modeling demonstrated that the normalization of plasma IL-
7levels following ART can be explained by changes in the receptor expression: these data
indicate that T-cell restoration after ARTis driven predominantly by CD 127+ T cells and
that the observed decreases in serum IL-7 levels following ART can be simply due to
improved CD I27-mediated clearance (609). A soluble form ofIL-7Ra (sCDI27), derived
from shedding ofCDI27 from CD8+ T cells (610), was found to be increased in the plasma
of HIV- l-infected individuals as compared to uninfected control subjects, and was recently
proposed as an explanation for the reduced membrane-bound expression ofCDI27 observed
in HN-l-infected individuals, as well as for the lack of effect of IL-7, which would be
sequestered by the soluble receptor, thus limiting its bioavailability (611). However, other
studies reported lower or equal levels of soluble IL-7Ra in the serum of HN-l-infected
patients (612), thus indicating that this field needs a more extensive investigation. An
alternative explanation for lower CD127 expression was recently proposed by Faller et al.,
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showing that soluble HN -1 Tat protein promotes the internalization of CD 127 and
subsequently targets it for degradation via the proteasome (613).
Functional defects of the IL-7R were also reported for T cells from HIV-l-infected
individuals, which may contribute to explain the lack of effect of the IL-7 -mediated
compensatory response. These include decreased IL- 7 binding capability and abnormal
activation of the JAKlSTAT pathway (614), aging of the cells (615), decreased induction of
Bcl-2 and CD25 expression and impaired induction of cellular proliferation (616). Finally, a
recent study showed that IL-7 failed to enhance antigen-mediated cellular proliferation on
CD8+ memory T cells derived from HIV -l-infected individuals, indicating that the effect of
IL- 7 in the secondary immune responses is impaired in memory CD8+ T cells from HN -1-
infected individuals, thus contributing to the loss of CD8+ T-cell function observed inHN-I
infection (617).
1.5.4 Pre-clinical Studies with IL-7
Pre-clinical studies in macaques showed that IL-7 treatment dramatically alters
peripheral T-cell homeostasis, of both naive and non-naive phenotype, in healthy and T-cell
depleted animals (618-620). In these studies narve as well as memory T-cells increased
within days of IL- 7 administration, and the number of recent thymic emigrants, measured by
the TCR recombination excision circle (TREC) values, decreased, suggesting that peripheral
rather than central effects playa major role. In a complementary experiment with
cynomolgus macaques, IL- 7 was also shown to lead to the expansion of all T-cell subsets,
with a subsequent dilution of newly generated T-cells, confirming that homeostatic
proliferation, rather than thymic effects, are responsible for the IL-7 effects (618). The same
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hypothesis was also suggested in another study of IL-7 administration to baboons after
autologous CD34 cell transplantation (621). Nugeyre et al. demonstrated that IL-7 induces
increases in the number ofCD4+ and CD8+ T-cells in both infected and uninfected animals,
persisting over several weeks, and returning to baseline by 11 weeks (620). Importantly, in
this and other studies, IL- 7 did not increase the viral loads during the chronic phase of SIV
infection, even in the absence of ART, and did not seem to promote B-cell expansion nor
tumorigenesis (618, 620, 622). In another study with uninfected macaques, IL-7 induced T-
cell proliferation in a dose-dependent manner, and led to a marked phenotypic conversion of
naive T-cells to memory phenotype and function (619). Remarkably, these T-cells reverted
back to narve phenotype after IL- 7 therapy withdrawal (619), suggesting that transient
treatment did not convert these cells to the memory fate. Recent data suggest that the
proliferative and pro-survival effects of IL-7 strictly depend upon dosing intervals, which
therefore need to be carefully planned during the design of a study according to the desired
effects (623). Recently, IL-7 was also shown to stimulate SIV-specific CD8+ T-cell
responses in SIV -infected rhesus macaques, thus suggesting another possible useful effect of
IL-7 treatment (624).
1.S.SClinical Studies with IL-7
The first five studies ofrhIL-7 in humans evaluated an E. Coli produced, non-
glycosylated rhlL-7 recombinant human IL-7 from Cytheris (France), CYT99007. Two
trials involved oncology subjects, one trial involved a subject following allogeneic
transplantation for nonlymphoid malignancy and two trials involved HIV+ subjects.
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The first two clinical trial involving rhIL-7 were dose escalation studies (3, 10, 30, 60,
and 100 ug/kg) of 8 repeated IL- 7 administrations, covering respectively two and three
weeks, to subjects with refractory malignancies (625, 626). In both studies rhIL-7 was
shown to mediate selective increases in circulating CD4+ and CD8+ lymphocytes, and
decreases in Treg cells. Moreover, rhIL-7 induced in vivo T cell cycling, Bcl-2 up-
regulation and T cell expansion, causing a significant broadening of circulating TCR
repertoire diversity with a preferential expansion of naive T cells, including recent thymic
emigrants (RTEs) (626).
The study of IL-7 administration following allogeneic transplantation has involved so
far one single patient and the results have not been published (627,628).
The first study on Hl'V-l-Infected individuals was ACTO 5214, a multicenter phase 1,
placebo-controlled double-blinded study with a 3: 1 randomization (rhIL-7: placebo) for each
dose level in 2 strata according to plasma HIV-I RNA levels at screening (stratum 1: < 50
copies/ml, stratum 2: 50-50000 copies/ml) (629). Participants, with CD4+ T-cell counts
higher than 100 cells/ul and plasma HIV-I RNA lower than 50000 copies/ml on HAART for
a minimum of 12 months, received a single subcutaneous dose of rhIL-7 or placebo in a
consecutive dose escalation design (3, 10,30,60, and 100 Ilg/kg) on day 0 and were then
monitored for toxicity on days 1,4, 14, and 28 with an additional visit on day 56. Results
have documented beneficial effects of IL-7 treatment, which was tolerated for up to 30
ug/kg, with induction of peripheral T-cell cycling in both CD4+ and CD8+ T cells, as well as
of antigen specific CD8+ T cells, and transient increases in the absolute numbers of
circulating CD4+ and CD8+ T cells, particularly of the memory phenotype. Interestingly,
rhIL-7 administration was associated with only limited or no increase in the levels of virus
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replication. Recent data on sequencing of the viruses detected during episodic blips
following IL-7 administration indicate that these viruses are similar to those found in the
plasma and in PBMC before treatment (630). This suggests that the low level of viremia
induced by IL-7 likely reflects transient induction or release of virus from a preexisting pool
rather than activation of silent quasispecies. The second study of IL-7 administration in
HIV -1 infection was a prospective open-label multicenter phase I1I1atrial, conducted on 14
HIV -l-infected individuals with a CD4 +T cell count of I00-400 cells/ul and plasma HIV-l
RNA levels lower than 50 copies/ml for at least 6 mo while receiving cART for at least 12
months, who received subcutaneous injections of rhIL-7 every other day for a total of 8
doses over 16 days. Visits for safety and immunological efficacy were made at 7, 14,21,28,
and 35 days and 12 weeks. An extended follow-up period lasted until48 weeks (631). Six
patients received a dose of rhIL- 7 of 3 ~g/kg and the remaining 8 patients were treated with
10 ~glkg. Results showed that IL-7 administration was clinically and biologically well
tolerated, and induced significant increases of CD4+ and CD8+ T cells in a dose-dependent
manner, which were sustained for up to 45 weeks after treatment interruption. Phenotypic
analysis ofCD4+ and CD8+ T-cell subsets revealed that narve and central memory T cells
were preferentially increased by IL- 7 treatment in both subsets and that increases were not
associated with increased immune activation but rather with increased T'-cell cycling.
Injection of rhIL-7 also expanded CD4+ and CD8+ T cells following polyclonal and
antigenic stimulation. In the group of patients treated with the higher dose (10 ~glkg),
transient increases were detected in plasma HIV-l RNA, but not in the content of viral DNA
in CD4 +T cells, suggesting that IL- 7 treatment did not directly affect the cellular HIV-l
DNA content. This clinical study, the first of repeated IL-7 administration in chronically
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lymphopenic HIV -l-infected patients, provided evidence that rhIL-7 therapy is better
tolerated as compared to other immunotherapeutic strategies, thus giving good hopes for
further investigation.
A second-generation glycosylated rhIL-7 made by Cytheris is CYTI07, produced via a
recombinant mammalian cell culture system. This new glycosylatedrhIL-7 is currently
being tested in several Phase II clinical trials for the treatment of HIV-I-infected individuals
(INSPIRE, INSPIRE 2 and INSPIRE 3 and EraMune 01), actually ongoing (see Cytheris
website: IL-7 HIV Trials). INSPIRE studies involve patients with variable peripheral CD4+
T-cell counts (two ranging from 101 and 400 cells/mm" and the third above 500 cells/mm')
and suppressed HIV viremia (HIV-l RNA< SOcopies/ml) following HAART. Interim data
released from the INSPIRE study at week 12 of the study were presented at the 49th
Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) held
September 12-15,2009, in San Francisco, CA (Abstract H-I230a) and published in "AIDS
Patient Care and SIDs" in 2009 «632) and Drugs.com News Clinical Trials). INSPIRE is a
Phase I1IIa study randomized placebo controlled, single-blinded multicenter (Europe, United
States, and Canada) dose-escalation study of subcutaneous intermittent injections of
glycosylated rhIL-7 (CYT107) in chronically HIV -l-infected patients with CD4+ T
lymphocyte counts between 101 to 400 cells/mm" and plasma HIV-l RNA<50 copies/ml.
These patients were categorized as immunological low or non responders (INR), meaning
patients who have not optimally restored their immunity despite at least 12 months of
HAART and with complete control of viral replication. Three doses were tested: 10,20, or
30 Jlg/kg/week (8 patients CYT107 versus 2 placebo per dose). Results show a dose
dependent and sustained increase of total CD4+ T cells (>500 cells/mm'), as well as of'narve
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CD4+ T cells, and CD8+ T cells and a trend toward higher thymic output at the dose of 20
ug/kg, with a transient increase of plasma HIV-l RNA in 4 patients. No clinical or
laboratory side effects higher than grade 2 were recorded. These data, although preliminary,
clearly indicate the potential of this cytokine for the treatments of HIV -l-infected
individuals with low CD4+ T-cell counts despite HAART, and justify its further clinical
development.
EraMune 01 is a Phase II international, multicenter, randomized, non-comparative
controlled study of therapeutic intensification plus immunomodulation in HIV -I-infected
patients with long-term viral suppression, designed to test the effect of rhIL-7 together with
ART intensification (cART + raltegravir and maraviroc) on HIV -1 viral reservoirs. This trial .
arises from the observation that in previous studies IL-7 in combination with cART has been
demonstrated to induce a certain extent ofHIV-I replication, and is based on the hypothesis
that by combining the antiretroviral drugs, with an immunomodulating agent capable of
targeting or inducing activation of latently infected cells, the reservoirs of HIV -1 could
possibly be decreased and, in the best case scenario, eradication of the virus may be possible
(Clinical'Irials.gov),
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1.6 Aims of the current study
In the context of innovative therapeutic strategies based on the use of
immunomodulatory agents, as a complement to ART, to try to restore the RIV-I-induced
CD4+ T-cell lymphopenia, the potential effects of IL-7 treatment are currently being
evaluated. As extensively described in paragraph 1.5 of this thesis work, several pre-clinical
and clinical studies have documented a positive effect of in vivo IL- 7 administration to SIV-
infected macaques and RIV-I-infected individuals on the CD4+ and CD8+ T-cell pools.
More in details, sustained increases in the absolute numbers of naive and memory CD4+ and
CD8+ T cells in the peripheral blood have been observed during and following treatment.
The effects ofIL-7 seem to be mediated by both induction of cell cycling and proliferation
and reduction of apoptosis. Although protection from apoptosis could be very useful to
preserve the CD4+ T-cell pool that is severely depleted during the course ofRIV/SIV
infection during both the acute and chronic phases, induction of cellular proliferation,
particularly on CD4+ T cells, is looked at skeptically, as this could on one hand increase the
pool of cells target for viral infection, and on the other hand it could induce the reactivation
of latent proviruses. Therefore, we could postulate that the "safety" and efficacy of IL-7
treatment strictly depends upon a fine modulation of this "dual" effect.
The overall aim of the current study was to investigate the effects of IL- 7 on
spontaneous apoptosis in RIV ISIV infection ex vivo, on T cells freshly isolated from RIV -1-
infected individuals (CHAPTER TWO), and in vivo, during the acute phase of SIV infection
in rhesus macaques, the pathogenic animal model for AIDS (CHAPTER THREE).
Increased spontaneous apoptosis ex vivo have been documented on T cells from RIV-
l-infected individuals as compared to uninfected control subjects, and the levels of apoptosis
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were shown to correlate inversely with the CD4+ T-cell counts of the patient in vivo,
emphasizing the relevance of apoptosis in disease progression. Thus, we designed a study
aimed at evaluating the effects of IL- 7 ex vivo on the survival of T cells derived from HIV -
I-infected individuals and cultured in vitro for several days in the absence of additional pro-
survival stimuli. Specific aims of this part of the study were also to correlate the pro-survival
effect of the cytokine with immunological and virological parameters and to discriminate
between anti-apoptotic and proliferative effects, to eventually find an ideal concentration of
the cytokine at which T cells could be preserved without inducing high levels of cell cycling
and proliferation.
The results of the ex vivo studies are described in CHAPTER TWO and provided a
strong rationale for testing the protective effects of IL-7 in vivo, during the acute phase of
SIV infection in rhesus macaques (described in CHAPTER THREE). Indeed, several studies
had previously evaluated the consequences of IL-7 administration to both SIV -infected
macaques and HIV -l-infected individuals during the chronic phase of the infection,
documenting sustained increases in both CD4+ and CD8+ circulating T cells mediated by the
induction of cellular proliferation and the reduction of apoptosis (outlined in paragraph 1.5
in this thesis work). However, no previous studies have investigated the effects of IL-7
administration during the acute phase of SIV infection. Specific aims for this second study
were to evaluate the effect ofIL-7 on various CD4+ and CD8+ T-cell subpopulations, with a
particular focus on naive and memory CD4 +T cells that are typically depleted within the
very first weeks after infection, on viral replication, on humoral and cellular responses to the
virus and, eventually, on disease progression.
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To summarize, the main objective of this study was to evaluate the immunomodulatory
effects of IL- 7 in RIV /SIV infection, with a particular focus on the pro-survival properties of
this cytokine. An extensive investigation ofIL-7-mediated effects during both the acute and
chronic phases of the infection could lead on one hand to a deeper understanding of the
pathogenesis of the disease and on the other hand to designing new regimens of immune-
based therapeutic strategies.
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1.7 Figures and Figure Legends
......
o data <.1%
Figure 1.1 Globalprevalence of HIV, 2009. Map showing the distribution and frequency of
HIV -1/AIDS in different regions of the globe relative to the total number of HIV-1
infections worldwide for 2009. Source: "UNAIDS REPORT ON THE GLOBAL AIDS
EPIDEMIC 12010".
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Figure 1.2 Current Global Distribution of HI V-I Subtypes and Recombinant Forms. Map
showing the distribution of HIV-I subtypes and Circulating Recombinant Forms (CRFs) at
the global level. (From Taylor et al. N Engl J Med 2008; 358:1590).
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Figure 1.3 Overview of the HIV-llife cycle. The infectious life cycle begins when the HIV-
1 gp120 glycoprotein binds to the CD4 receptor on the surface of helper T cells,
macrophages or dendritic cells. This interaction induces conformational changes in the core
region of gp120, leading to unmasking of the chemokine co-receptor (CCR5 or CXCR4)
binding site. Further interaction with CCR5 (or CXCR4) leads to further conformational
changes, activation of gp41 and
virus fusion with the cell membrane (1.). The viral core is then inserted into the cytoplasm
where it is reverse-transcribed into eDNA (2.) before being transported to the nucleus and
integrated into the human genome, a process that is catalyzed by HIV-l integrase (3.).
Transcription of the integrated proviral DNA leads to the production of multiply, singly and
unspliced mRNAs that are then transported back to the cytoplasm where they are translated
and processed into HIV-l structural and accessory proteins (4.). Env and immature
precursors of the capsid (Gag) and viral polymerase (Pol) are transported to the cell
membrane and assembled into HIV-l virions (5.). Virus infectivity is acquired after Gag and
Gag-Pol cleavage, particle maturation and budding from the cell surface (6.). (Adapted from
Monini et al. Nat Rev Cancer 2004;4:861).
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Figure 1.4 Typical course of HI V-I infection. Schematic representation of the typical
course of HIV -1 infection showing changes in CD4 +and CD8+ T-cell counts in peripheral
blood and plasma viral load. (From Munier et al. Immunol and Cell Biol, 2007; 85: 6-15).
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Figure 1.5Diagrammatic representation of T-cell dynamics in an individual with chronic
HIV-l infection. Resting cells along the bone marrow axis to naive T cells are shown in
yellow, activated T cells in green, resting memory T cells in blue, dying cells in black, HIV-
1-infected cells in red. The red arrows depict negative effects ofHIV-1 on cell production
and survival, including destruction of the lymphoid organs architecture. The green arrows
depict HIV-specific and bystander HIV-1-induced T-cell activation. (From Douek et al.,
Annu Rev Immunol, 2003; 21 :265-304).
92
Figure 1.6 Schematic representation of gut-associated lymphoid tissue (GALT). Peyer's
patches and isolated lymphoid follicles (ILFs) are composed of a specialized follicle-
associated epithelium (FAE) containing M cells, a subepithelial dome (SED) rich in
dendritic cells (DCs), and B-cell follicle(s) that contain germinal centres (GCs), where
follicular B cells efficiently undergo class-switch recombination (CSR) and somatic
hypermutation (SHM). The diffuse tissues of the lamina propria contain a large number of
IgA+plasma cells, T and B cells, macrophages, dendritic cells (DCs) and stromal cells
(SCs). IgA+B cells and plasma cells are shown in red, IgG+ cells in blue and IgM+ cells in
pink. (From Fagarasan S. and Honjo T., Nat Rev Immunol2003 Jan;3(1):63-72).
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Figure 1.7 Mechanistic link between mucosal functionality and systemic levels of immune
activation in HIV/SIVinfection. Right: during pathogenic HIV/SIV infections, CD4+ T-cell
depletion and chronic levels of immune activation (lA) result in a loss of mucosal immune
function and breakdown of the mucosal barrier, thus resulting in microbial translocation.
Microbial products in turns may cause a toll-like receptor-mediated broad immune system
activation, with consequent activation-induced cell death of bystander lymphocytes. Left:
despite similar levels of CD4+T-cell depletion, in the context of normal IA, natural SIV host
preserve mucosal immune functions and show no microbial translocation. (From Paiardini
M. et al. AIDS Rev. 2008;10:36-46).
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Figure 1.8 Overview of extrinsic and intrinsic apoptotic pathways. Arrows indicate
positive effects, whereas block arrows indicate inhibition. Extrinsic apoptotic pathway with
death receptors on the surface of the cell and intracellular mediators of the cascade which
activates the mediator pro-caspase 8 is shown. The intrinsic pathway initiated by
intracellular stress and leading to the release form mitochondria of CytC, which in turns
activates the mediator pro-caspase 9 is also shown. Both pathways converge on the
activation of the effector caspases 3, 6 and 7. (From Cell Signaling Technology website).
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Figure 1.9 Potential synergy between low immune activation and reduced CCR5
expression in preserving CD4+ T cell homeostasis in SIV-infected SMs despite high virus
replication. This figure shows how, in SlY-infected SMs (natural hosts), low immune
activation, expressed as the fraction of CD4+ T cell clones that undergo activation at any
given time, may act in concert with reduced and/or delayed expression of CCR5 in
promoting a steady state where immune system homeostasis is preserved despite high virus
replication. The top row shows how in HIV-infected humans and SlY-infected RMs,
presence of a high fraction of activated CD4+ T cell clones results in the rapid accumulation
of CD4+ T cells expressing CCR5 that are infected and killed by the virus, resulting in the
disruption of the homeostasis of these activated clones. In SlY-infected SMs (bottom row), a
smaller fraction of CD4+ T cells clones are activated, but a delayed and reduced expression
of CCR5 on these cells may allow for their accumulation, resulting in an equally high level
of virus replication when CCR5 is finally expressed. In this case, however, the homeostasis
of fewer CD4+ T cells clones is disrupted at any given time. (From Silvestri G. et al. J Clin
Invest. 2007 Nov;117(11):3148-54).
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Figure 1.10Differential role of y-chain cytokines on T cells. Receptor expression and
cytokine availability dictate the effects of common y-chain cytokines on T cells. Narve CD4
and CD8 T cells express high levels of the IL-7R and low levels of the receptors for IL-2, -4
and -15. On T-cell activation through antigen stimulation of the TCR, IL- 7R expression
reduces, whereas receptor expression for IL- 2, -4 and -15 increases. On clearance of antigen
and the formation of a stable memory population, cytokine receptor expression returns to
that seen on the narve population. (From Bradley, L. M. et al. Trends Immunol. 2005
Mar;26(3): 172-6).
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Figure 1.11 Phenotypic heterogeneity of human memory T cells. Expression of various
cell surface markers on TCMand TEMCD4+ and CD8+ T cells and on TEMRACD8+ T cells.
(From Lanzavecchia, A. and Sallusto F., Annu Rev Immunol. 2004 22:745-763).
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Figure 1.12 Signal strength model for T cell differentiation and memory T cell
generation. The duration and intensity of antigenic stimulation is indicated by the length
and thickness of the solid arrows. Antigen-independent events leading to T-cell proliferation
and differentiation are indicated by the dotted lines. AICD, activation-induced cell death.
(From Lanzavecchia, A. and Sallusto F., Annu Rev Immunol. 2004 22:745-763).
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Figure 1.13 Role ofIL-7 and TCR signaling in regulating T-cell responses. At low doses
ofIL-7, CD4+ T cells are induced to survive but not divide, whereas at higher doses,
division is also induced. Evidence suggests that signals to the TCR synergize in the
induction of division. T-cell division in lymphopenic hosts is likely to be due to higher IL- 7
levels, probably as a result of the deletion ofIL-7R-expressing lymphocytes. (From Bradley,
L. M. et al. Trends Immunol. 2005 Mar;26(3): 172-6).
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3.0 Introduction
Infection with human immunodeficiency virus type 1 (HIV -1) causes a progressive
depletion of CD4+ T cells that ultimately leads to AIDS (1). Several mechanisms have been
implicated in the loss of CD4+ T cells, including direct virus-induced cytolysis, defective T-
cell regeneration, anergy, and apoptosis (2). Both CD4+ and CDS+ T cells derived from
RN -infected individuals show an increased propensity to undergo spontaneous apoptosis
both in vivo (3-5) and after short-term ex vivo culture (6). Remarkably, the vast majority of
the cells that undergo apoptosis are uninfected (5). Similar observations were made in
macaques infected with simian immunodeficiency viruses (SIV) (7, 8). The level of
apoptosis in HIV -1 infected individuals was shown to correlate with the levels of circulating
CD4+ T lymphocytes and stage of disease (9, 10), reinforcing the concept that apoptosis may
be one of the primary mechanisms of CD4 depletion in HIV infection. Various mechanisms
have been invoked to account for the spontaneous apoptosis observed during the course of
RIV -1 infection, including sustained immune activation associated with dysregulated
cytokine production (10, 11), inappropriate signaling mediated by HIV-l envelope binding
to CD4 (12) or coreceptors (13), defective antigen presentation (14), activation of death
receptors (15, 16), and loss of extracellular survival signals (17).
The increase in apoptosis levels seen in RIV -infected individuals implies that therapeutic
interventions aimed at reducing apoptosis may also decrease the rate ofT-cell depletion. For
example, interleukin-2 (IL-2), a cytokine that induces a marked increase in the number of
total and naive CD4+ T cells in RIV-l-infected patients (18), was shown to reduce the levels
ofT-cell apoptosis both in vivo (19) and ex vivo (20); the long-term benefits of this
therapeutic regimen are being determined in clinical trials. Another cytokine that is under
129
evaluation as a potential agent of immune reconstitution in HIV -1 infection is interleukin-7
(IL- 7), a key factor in the generation, activation and homeostasis of the T-cell compartment
of the immune system (21). The pro survival effects ofIL-7 are primarily mediated by
upregulation of Bcl-2 synthesis and inactivation of pro-a pop totic proteins like Bad and Bax
(22). Conflicting evidence has been reported on the anti-apoptotic effects ofIL-7 on T cells
from HIV -I-infected individuals studied after short-term ex vivo culture. Zaunders et al.
found no effects of IL-7 on peripheral blood mononuclear cells (PBMC) from patients with
acute primary HIV-I infection (23), whereas others have reported a limited anti-apoptotic
effect in patients with chronic HIV -1 infection, which was less pronounced than in
uninfected individuals (24, 25). Likewise, a limited, but not statistically significant, effect of
IL-7 was reported on CD4+ and CDS+ T cells from macaques chronically infected with SIV
(S). Another controversial issue is the putative ability ofIL-7 to induce HIV-I replication.
At doses that promote T-cell proliferation, IL- 7 has been reported to induce the transcription
oflatent HIV-I in resting peripheral blood CD4+ T cells derived from infected patients on
anti-retroviral therapy cultured for several weeks ex vivo (26). However, in vivo
administration of IL-7 to SIV -infected macaques did not cause a detectable increase in viral
load both in lymph nodes and in peripheral blood, in spite of a widespread induction of T-
cell proliferation (27, 2S).
In the present study, we investigated the protective effects ofIL-7 against spontaneous
T-cell apoptosis in a cohort of HIV -l-infected subjects at different stages of disease. An
extensive time-course analysis over 7 days of ex vivo culture permitted us to document a
potent anti-apoptotic effect ofIL-7 on both CD4+ and CDS+ T cells from HIV-infected
130
individuals. This effect was not associated with T-cell proliferation or reactivation of latent
provirus.
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3.1 Materials and Methods
2.1.1 Study subjects
Twenty-nine RIV-I-infected individuals and 14 RIV-I-seronegative age-matched
controls were included in this study. The HIV-I-infected individuals were selected among
those attending the National Institute of Allergy and Infectious Diseases (NIAID) Outpatient
Clinic to represent different clinical stages. All patients provided informed consent, in
accordance with the NIAID Institutional Review Board, and were subjected to leukapheresis
according to approved protocols to obtain PBMC
2.1.2 Isolation of PBMC and purification of CD4+ and CDS+ T cells
PBMC were isolated by gradient centrifugation from leukapheresis packs using
Lymphocyte Separation Medium (MP Biomedicals). CD4+ and CDS+ T cells were purified
by negative selection using Dynabeads goat anti-mouse IgG (Dynal) and a cocktail of
purified monoclonal antibodies (mAb) against human CDI4 and CDI9 (Biodesign
International), CDI6 and CD56 (BD Pharmingen) and either CDS (BD Pharmingen) or CD4
(Biodesign International). The purity of the CD4+ and CDS+ populations was consistently
greater than 95%, as determined by cytofluorimetry.
2.1.3 Cell cultures
Isolated PBMC or purified CD4+ and CDS+ T-cell populations were cultured for up
to 21 days at 37°C in 25 cm2 flasks at a density of 106 cells/ml in complete culture medium
[RPMI 1640 with L-glutamine (Gibco) supplemented with Penicillin-Streptomycin at 10000
Vlml each (Gibco) and 10% fetal bovine serum (FBS) (HyClone)]. Recombinant human IL-
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7 (peprotech) at different concentrations (0.04-50 ng/ml) or IL-2 (Roche) at 100 Vlml were
added at the beginning of the culture.
2.1.4 Measurement of apoptosis
Analysis of apoptosis was performed every day over the first 7 days of culture by the
detection of Annexin V binding (Figure 2.1) and caspase 3 activation. Annexin V binding
was measured using the Annexin V-PE Apoptosis Detection Kit I (BD Pharmingen).
Briefly, at each time point, 5 x 105 cells were stained with mAbs anti-CD3-APC, anti-CD4-
FITC and anti-CD8-PerCP (BD Pharmingen), and in selected experiments anti-CD45RA-
FITC or anti-CD45RO-FITC (BD Pharmingen), and then washed and incubated with 2J.lIof
Annexin V-PE or 5J.lIofpropidium iodide (PI). Cells were then immediately analyzed using
a FACScalibur Flow Cytometer (Beckton Dickinson). Both live and apoptotic cells were
included in the analysis, while cellular debris was excluded. Apoptosis was demonstrated by
transition from a single-positive (Annexin- V+ Pl') towards a double-positive phenotype.
Reduction of apoptosis by IL-7 or IL-2 was calculated by subtracting the percent Annexin
V+cells in cytokine-treated cultures from the percent Annexin v+ cells in untreated controls.
In selected experiments, apoptosis was confirmed by evaluating the activation of caspase 3.
After surface staining as described above, the cells were fixed using BD FACS Lysing
Solution, permeabilized using BD FACS Permeabilizing Solution 2 and incubated with a
PE-conjugated rabbit mAb against the active form of caspase 3 (BD Pharmingen). The cells
were then analyzed by flow cytometry. All the flow data were analyzed using the Flowjo
software (Tree Star).
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1.1.5 Analysis of cellular proliferation
Cellular proliferation was evaluated using intranuclear expression ofKi67, dilution
of the vital dye CFSE, and absolute cell counting. Ki67 was assessed using a PE-conjugated
anti-Ki67 mAb (BD Phanningen) after fixation and permeabilization of the cells. Labeling
with CFSE was performed using the CellTrace™ CFSE Cell Proliferation Kit (Invitrogen),
following the provided protocol. Labeled cells were then cultured in complete medium for
up to 7 days with or without rhIL-7 or rhIL-2, as described above and analyzed by flow
cytometry. Absolute cell counting was obtained by flow cytometry analysis of a fixed
volume of cell culture at high flow pressure for 30 seconds. To calculate the absolute
number of cells in each sample, the number of events acquired was multiplied by the flow
rate.
1.1.6 Measurement ofHIV-l replication
HIV -1 replication was evaluated by measuring the levels of HIV -1 p24 antigen
released into the culture supernatants using an HIV -1 p24 Antigen capture EIA (Beckman
Coulter). To maximize sensitivity, the samples were analyzed undiluted. The plates were
read according to a kinetic protocol using a microplate spectrophotometer (Bio-Rad
Instruments).
1.1.7 Statistical analysis
Statistical analysis was conducted using the softwares SAS (version 9.1 for Windows),
S-Plus (version 6.2 for Windows), and StatView (version 5.0.1). Paired t-tests were used to
compare differences in apoptosis between IL-7-treated and untreated cells on each day and
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averaged over all 7 days. Regression analysis was used to compare the effect of IL-7,
averaged across the first 6 days of culture, to other covariates. Non-parametric Mann
Whitney tests were used for comparisons between different groups of patients. Mixed model
methodology was used in analyses comparing slopes relating the IL-7 effect and days.
Pitman's test was used to compare pairs of days with respect to the variability oflL-7
effects.
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3.2 Results
2.2.1 Anti-apoptotic effect ofIL-7 on spontaneous apoptosis in PBMC from HIV-l-
infected subjects
The effects ofIL-7 were initially evaluated in unfractionated PBMC from a cohort of
HIV-I-infected subjects (n = 24) at different stages of disease as reflected by levels of
peripheral CD4+ T-cell counts and HIV-I plasma viremia (nos. 1-24, Table 2.1). The cells
were cultured ex vivo in the presence or absence of recombinant human IL- 7; IL-2 was
tested in parallel as a positive control for the reduction of apoptosis. Apoptosis was
evaluated on freshly isolated cells (baseline), and then every day for 7 days by using two
unrelated techniques: Annexin V binding (Figure 2.1) and caspase 3 activation. To
determine most accurately the effect of IL-7 on apoptosis over the 7-day period, we
calculated the mean of all daily apoptosis measurements for each patient and then from
those data we determined the mean value for the 24 patients.
The proportion of Annexin V-binding cells at baseline was similar in HIV -l-infected
patients and controls (p = 0.61); however, it significantly increased upon ex vivo culture in
HIV -l-infected subjects (p < 0.0001), while the increase was only marginal in seronegative
controls (p = 0.52) (Figure 1.1 A). The addition of exogenous IL-7 (5 ng/ml) induced a
dramatic reduction in the levels of spontaneous apoptosis in cells from all the HIV -1-
infected patients tested. The mean level of Annexin V binding over the 7 days of culture was
significantly lower in cells treated with IL-7 than in untreated homologous cells (p<0.0001)
(Figure 1.1 A). As expected, treatment with IL-2 (lOOU/ml) also significantly reduced the
levels of Annexin V binding (p = 0.002) in PBMC from HIV -l-infected individuals (Figure
2.2 A). At each time point between day 1 and 6, Annexin V binding was significantly,
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reduced in IL-7-treated cells compared to controls; the difference was no longer significant
at day 7 (Figure 2.2 B). In PBMC from selected patients, IL-7 was titrated over a wide dose
range (0.04-50 ng/ml). Reduction of apoptosis was consistently seen at doses higher than 0.5
ng/ml (Figure 2.10 A).
The anti-apoptotic effect oflL-7 was also investigated by measuring the activation of
caspase 3. Overall, the mean levels of caspase 3 activation during the 7 days of culture were
significantly lower in IL-7-treated than in untreated cells (n = 7; P = 0.01). The levels of
caspase 3 activation paralleled those of Annexin V binding in the presence and absence of
IL-7 (Figure 2.2 C). In line with previous observations (29), the reduction of apoptosis
mediated by IL-7 was associated with an increase in intracellular levels ofBcl-2 (Figure
2.3).
Despite the consistency of the anti-apoptotic effect of IL-7, its kinetics and
magnitude showed a marked variability among patients. The peak reduction in the
proportion of apoptotic cells in different patients ranged from 5.1% to 28.4% (mean,
14.1±5.7%), and occurred at different time points during ex vivo culture (range, 1-6 days;
mean, 3.9±1.5). In some patients the effect oflL-7 increased over time (positive slope),
while in others it remained constant or even decreased (negative slope). Z-score values
comparing each patient's slope to the overall slope confirmed that such differences were real
(p < 0.0001). The fact that patients had relatively similar baseline values but different
trajectories over time explains the increased variability in the last days of culture (Figure 2.2
B; also confirmed by Pitman's test for paired variances).
As stated above, exposure ofPBMC from HIV-1-infected individuals to IL-2 (100
V/ml) effectively reduced the levels of spontaneous apoptosis (Figure 2.2 A) with peak
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reductions ranging from -0.9% to 31.0% (mean, 16.6±7.1 %); the peak effect ofIL-2 tended ,
to occur slightly earlier than that ofIL-7 (range, 1-4 days; mean, 2.3±1.1).
2.2.2 Limited antl-apeptetic effects ofIL-7 on PBMC from HIV-I-seronegative
individuals
Treatment with IL-7 had limited effects in PBMC from a group of age-matched HIV-
uninfected subjects (n = 14). The mean levels of spontaneous apoptosis during the 7-day
culture period were not significantly different in IL-7 -treated and untreated cultures (Figure
2.2 A), and comparisons at each time point showed a significant apoptosis reduction only at
day 2 (p = 0.002) (data not shown). Thus, the mean effect of IL-7 over 7 days of culture was
significantly different in cells from HIV -l-infected and uninfected subjects (mean:
8.2±S.4% vs. 0.6±3.3%; p = <0.0001) (Figure 2.2 A); a similar difference was seen
considering the peak levels ofapoptosis reduction (mean: 14.1±S.7% vs. S.3±4.1; p
<0.0001). Analogous results were obtained in IL-2-treated cells with regard to both the mean
(7.6±8.9% vs. -2.0±S.2%; p = 0.002) (Figure 2.2 A) and peak (16.6±7.1 % vs. 6.S±8.9%; p =
0.01) levels of reduction ofapoptosis.
2.2.3 Correlation between the sensitivity to the anti-apoptotic effect of IL-' ex vivo and
the CD4+ T-cell count in vivo
The propensity to undergo spontaneous apoptosis in HIV-l-infected subjects was
previously shown to correlate directly with the plasma viral load and inversely with the
levels of circulating CD4+ T cells (30, 31). Thus, we evaluated the potential correlations
between the sensitivity to the anti-apoptotic effects ofIL-7 and several demographic, clinical
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and immunologic parameters at the time of sampling (see Tables 2.1 and 2.2). No
significant correlations were observed between the mean levels of apoptosis reduction by
IL- 7 over the first 6 days in culture and the plasma HIV -1 load, CD8 count and age (Figure
2.4 A, left panel), as well as with the expression of CD8+ T-cell narve/memory markers,
CD8+ T-cell activation markers (HLA-DR+, CD38+, CD38~LA-DR+, CD25+), selected
CD4+ T-cell activation markers (HLA-DR+, CD38+HLA-DR+, CD25+)(Figure 2.S A), and
treatment status (Figure 2.S B). In contrast, a significant inverse correlation was observed
with the circulating CD4+ T-cell count (R2 = 0.266, P = 0.0099) (Figure 2.4, left panel). For
selected parameters, these findings were confirmed by comparing the levels of reduction of
apoptosis between different groups of patients defined by specific cut-off values (Figure
2.4, right panel). Moreover, the mean levels of reduction of apoptosis by IL-7 over the first 6
days in culture were inversely correlated with the absolute number of memory CD4+ T cells
(R2 = 0.229, p = 0.018), as well as with the proportion ofCD4+ T cells expressing the
activation marker CD38 (R2 = 0.221, P = 0.020) (Figure 2.S A).
Interestingly, within patients with low CD4 counts « 350 cells/ul), no significant
differences were observed in the mean levels of apoptosis reduction between patients that
were naive to treatment and patients that were on therapy at the time of testing or had been
treated in the past, as well as between patients with different plasma viremia (two cut-off
values were used: 50 and 30000 copies/ml), irrespective to their treatment status (Figure 2.S
C).
The CD4+ T-cell counts were also predictive of the slopes ofIL-7-mediated
reduction of apoptosis over time, with a greater increase in IL-7 effectiveness over time in
patients with lower CD4 counts (Figure 2.6).
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2.2.4 Anti-apoptotic effect ofIL-7 on both CD4+ and CDS+ T cells from HIV-l-infected'
subjects
As a preliminary approach to elucidate whether IL-7 can protect from apoptosis both
CD4+ and CD8+ T cells derived from Hl'V-l-infected individuals, we analyzed separately
the two subpopulations by multiple color flow cytometry within unfractionated PBMC
cultures. The results indicated that IL-7 treatment reduced the level of Annexin V binding in
both CD3+CD4+ and CD3+CD8+ gated cells (Figure 2.7 A). To address this issue more
formally, we enriched CD4+ and CD8+ T-cell subpopulations by negative selection from
PBMC of 5 HIV -l-infected individuals, and then cultured the cells for 6 days in the
presence or absence ofIL-7 (5 ng/ml), IL-7 had strong anti-apoptotic effects on both CD4+
and CD8+ purified T cells from all the HIV -l-infected individuals analyzed (Figure 2.7 B):
the peak levels of reduction of apoptosis measured by Annexin V binding ranged from
10.2% to 40.5% for CD4+ T cells (mean, 20.8:t13.1 %; p=0.02 for the comparison between
IL-7-treated and untreated cells) and from 15.5% to 52.8% for CD8+ T cells (mean,
27.2:t16.2%; p=0.02); likewise, there was a marked reduction in the mean levels of
apoptosis over the first 6 days of culture in both CD4+ T cells (11.7:t6.6%; p=0.02) and
CD8+ T cells (14.6:t9.1 %; p=0.02). Similar data were obtained when caspase 3 activation
was used as an indicator of apoptosis: representative time courses of Annexin V binding and
caspase 3 activation in purified CD4 + and CD8+ T cells in the presence or absence of IL- 7
are presented in Figure 2.8.
When naive and memory CD4+ and CDS+ T cells were separately analyzed either on
unfractionated PBMC cultures by multiple color flow cytometry or on purified CD4+ and
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CDS+ T cells, IL- 7 was shown to reduce apoptosis in both the narve and memory subsets
(Figure 2.9). As expected, treatment with IL-2, used as a positive control, reduced the levels
of spontaneous apoptosis in both naive and memory CD4+ and CDS+ T cells from HIV-l-
infected individuals (Figure 2.9).
2.2.5 Uncoupling of the antl-apoptotlc effects of IL-7 from the induction of cellular
proliferation
Since IL-7 exerts concentration-dependent proliferative effects on CD4+ and CDS+ T
cells (32), we measured the fraction of cells undergoing cycle progression and proliferation
in IL-7-treated cells from 10 selected patients using three different methods: expression of
the nuclear antigen Ki67, dilution of the vital dye CFSE and absolute cell counting (Figure
2.10). Although IL-7 at 5 ng/ml induced cellular proliferation in PBMC from all the patients
analyzed, we consistently observed a temporal dissociation with the anti-apoptotic effect. As
illustrated in Figure 2.10 A, IL-7 induced an anti-apoptotic effect from the earliest days of
culture; in contrast, Ki67 expression appeared later (day 5) and was seen in a high
proportion of cells only at 5 nglml ofIL-7 (Figure 2.10 B). At lower IL-7 concentrations,
Ki67 was expressed in less than 10% of the cells, with negligible levels in cells treated with
0.6 nglml. Analogous results were obtained by analysis of absolute cell counting and CFSE
dilution over time (Figure 2.10 C and D). Unlike IL-7, IL-2 at a concentration of 100 Ulml
induced an early proliferative effect that was first detectable at day 3 of culture and peaked
at day 6 (Figure 2.10 C). However, even with IL-2 we observed a temporal dissociation
between reduction in apoptosis and Ki67 expression, since its anti-apoptotic effect was
already evident at day 1 of culture and peaked at day 2 (Figure 2.10 A).
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2.2.6 Lack of effect ofIL-7 on the induction ofHIV-I replication in purified CD4+ T
cells from HIV-I-infected individuals
Ex vivo treatment of purified resting CD4+ T cells from a fraction ofRIV-l-infected
patients with high doses of IL- 7 has been reported to induce the activation of latent provirus
after several weeks in culture (26, 33). Thus, we measured the levels of endogenous HIV-l
replication over time in purified CD4+ T cells derived from 7 HIV-l-infected individuals,
cultured in the presence or absence of IL-7 at 5 ng/ml or IL-2 at 100 U/m!. RIV-l
replication was evaluated by measuring secretion of HIVI p24 in the tissue culture media.
No quantification of cell- or media-associated HIV-l RNAIDNA was performed.
Table 2.3 shows that supernatants from 5 out of7 CD4+ T-cell cultures treated with
IL- 7 remained negative for HIV -1 p24 throughout the culture period, while the remaining
two showed only minimal levels ofp24 release (0.01 nglml). Of note, similar levels ofp24
were also seen in IL-7-untreated cultures approximately at the same time points, suggesting
that HIV -1 replication was unlikely a result of IL-7 treatment and actually represented
spontaneous release of virus. Likewise, treatment with IL-2 at 100 U/ml resulted in the
appearance of low levels ofp24 (0.01-0.142 ng/ml) in CD4+ T-cell cultures from 4 of the 7
patients, including one (no. 29) in which IL-7 did not induce any detectable viral replication;
IL-2 treatment yielded the highest levels ofp24 release. Analogous data (not shown) were
obtained using unfractionated PBMC followed for up to 21 days after establishment in
culture.
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2.3 Discussion
Although the introduction of effective antiretroviral therapy (ART) has resulted in a
dramatic decline in the morbidity and mortality among HIV -l-infected individuals,
phenotypic and functional immunologic abnormalities may persist even in patients with
sustained suppression of viremia for several years (34). Thence, innovative approaches
aimed at improving immune reconstitution have been proposed as a complement to ART. In
particular, cytokines that play an essential role in T'-cell homeostasis and proliferation, such
as IL-2 and IL-7, are currently under clinical investigation (18). In this study, we
demonstrated that IL-7 exerts protective effects against spontaneous apoptosis on both CD4+
and CD8+ T cells derived from mv-l-infected individuals. In agreement with previous
reports (6, 9, 35), we found that the level of spontaneous apoptosis was significantly higher
in RIV -l-infected subjects than in seronegative controls and that, among the former, it
correlated with the degree of CD4+ T-cell depletion in vivo, reinforcing the concept that
apoptosis is a key mechanism of T-cell destruction during HIV -1 infection. Thus, the anti-
apoptotic activity of IL-7 provides an additional rationale for consideration of this cytokine
as a potential immunotherapeutic agent in the treatment of HIV-I-infected individuals.
An unexpected finding emerging from our study is that the reduction of apoptosis mediated
by IL-7 in HIV -l-infected individuals was inversely correlated with the level of circulating
CD4+ T cells. Thus, in spite of a more severe immune dysfunction, patients with lower CD4+
T-cell counts showed a higher sensitivity to IL-7, while those with higher CD4+ T-cell
counts, whose levels of spontaneous apoptosis are generally lower, exhibited a lesser
sensitivity. In line with this trend, the effect of IL-7 on spontaneous apoptosis was even
lower, failing to reach statistical significance, on cells derived from HIV-I-seronegative
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individuals. These findings suggest that under physiological conditions, there is a basal level
of spontaneous apoptosis that is largely insensitive to IL-7. With the progression of HIV-I:
disease, the proportion of cells that are prone to spontaneous apoptosis increases, and a large
fraction of these cells is sensitive to the anti-apoptotic effects of IL-7. The ex vivo effects of
IL-7 in chronically HIV -l-infected individuals have been previously investigated in only
two studies, which reported a limited, if any, reduction of spontaneous apoptosis, while a
more pronounced effect was seen with cells derived from HIV-seronegative individuals (24,
25). However, these studies evaluated apoptosis only at a single time point after several days
(6 or 7) of ex vivo culture. By contrast, the present study was designed to provide a detailed
longitudinal representation of apoptosis levels, with daily measurements for 7 days of ex
vivo culture in the presence or absence of IL- 7. This extensive time-course analysis
permitted to document variable kinetics ofIL-7-mediated reduction of apoptosis in different
patients, with some patients showing an increasing effect over time, and others manifesting
an effect that remained constant or even decreased over time. Thus, there was an increasing
variability of the IL- 7 effect at the late time points of culture, as attested by a reduced
statistical significance at days 5 and 6, and a loss of significance at day 7. These
observations suggest that a single determination is unlikely to accurately represent the
effects of IL-7 on spontaneous apoptosis. The role played by IL-7 in vivo in the course of
HIV -1 infection is still poorly understood. Increased plasma levels of IL-7 were documented
in HIV -l-infected individuals and inversely correlated with CD4 counts (30, 31, 36). In
parallel, the expression of the a-chain of the IL-7 receptor (CDI27), was shown to be
downmodulated (24, 36, 37). Since the levels oflL-7 decreased when the CD4+ T cell
counts were restored during therapy, the increases in IL-7 levels have been interpreted as a
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homeostatic response to lymphopenia (31). However, the fact that in the absence of ART the
number of circulating CD4+ T cells remains low suggests that IL-7 per se is unable to
reconstitute the loss ofCD4+ T cells resulting from the effects ofHIV viremia. Different
mechanisms may account for this inability. The rate ofCD4+ T-cell destruction in patients
with advanced HIV -1 disease may exceed the regenerative capacity of IL-7 or the pool of
progenitor T cells may be irreversibly damaged or depleted. Alternatively, the IL-7IIL-7
receptor axis may be impaired (37). The marked sensitivity to the effects of IL-7 that we
documented in patients with low CD4+ T cell counts indicates that circulating T cells from
these patients did express a functional IL-7 receptor. Interestingly, however, kinetic analysis
demonstrated that the ex vivo effect of IL-7 in these patients was delayed, suggesting that
their T cells might be in a state of IL-7 refractoriness in vivo. Responsiveness to IL- 7 would
then be gradually restored upon ex vivo culturing, presumably due to the removal of putative
inhibitory factor(s).
Studies of IL-7 administration to uninfected and SIV-infected macaques have
demonstrated a proliferative effect on CD4+ and CD8+ T cells expressing both memory and
naive phenotypes (27, 28,38). Analogous results were more recently obtained in human
cancer patients (39), as well as in HIV-l-infected individuals (40). In the present study, we
observed that IL- 7 given ex vivo at concentrations higher than 2.5 ng/ml consistently
induced cellular proliferation. However, this effect became detectable only after several days
in culture and was temporally dissociated from the effect of IL-7 on apoptosis. Moreover, at
concentrations below 1 ng/ml, IL- 7 was still effective in reducing apoptosis, but failed to
induce cellular proliferation. The evidence that the different activities of IL-7 can be
dissociated is encouraging with regard to the potential therapeutic use of this cytokine in
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HIV -I-infected subjects, since it mitigates concerns related to the putative risk of enhancing
the level of immune activation and viral replication. Previous studies have shown that ex
vivo treatment with IL-7 increases the levels of HIV -1 replication in naturally infected COS-
depleted mononuclear cells (33), and may lead to reactivation oflatent provirus in purified
resting C04+ T lymphocytes isolated from HIV-I-infected subjects receiving ART with
undetectable plasma viremia (26). At variance with these observations, however, we
detected only minimal levels, if any, of HIV-I replication in purified C04+ T cells treated ex
vivo with IL-7. Our results are in agreement with the findings in SIV-infected macaques
treated in vivo with IL-7, which showed no increase in viral load both in the presence (27)
and in the absence (2S) of concomitant ART.
In conclusion, results of the present study provide a further rationale for
consideration of IL-7 as a potential adjuvant therapy in HIV -infected individuals in
association with ART. Studies are under way to elucidate the precise molecular mechanisms
underlying the increased propensity to spontaneous apoptosis in HIV -l-infected individuals,
as well as the anti-apoptotic action of IL-7. Further experimental studies in nonhuman
primates and clinical studies in HIV -l-infected individuals should allow elucidation as to
whether IL-7 administration effectively leads to a reduction in the levels of spontaneous
apoptosis in vivo, and whether this effect is associated with a stable immune reconstitution
in patients with sustained suppression of viremia.
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2.4 Tables
Table 2.1 Demographic, immunologic and clinical characteristics of the HIV-1-
infected patients included in the study.
Viral load CD4 CDS Anti-
Patient (plasma count count retroviral Age
copies/mIl (cells/mI) (cells/mI) therapy (years)
1 308,702 230 440 Naive 58
2 <50 665 437 On 42
3 122,947 323 1,466 Off 56
4 119,086 263 627 Off 38
5 125 217 926 On 49
6 <50 247 945 On 53
7 1,936 536 739 Naive 34
8 2,942 582 699 Naive 37
9 120,291 445 1,674 Off 5010 160,954 444 2,331 Naive 39
11 34,759 381 748 Naive 4712 57,180 513 591 Naive 4713 68,832 897 1,569 Off 3214 252 631 1,860 On 4815 156 485 719 On 5516 2,212 417 1,132 Naive 42
17 6,639 437 647 Naive n.a.18 <50 258 1,210 Naive n.a.19 112,697 318 1,021 Naive 3320 32,602 337 411 Naive 4221 8,944 314 286 Naive 4522 <50 79 459 On 3023 6,111 464 824 Naive 3824 461 336 814 On 4725 1,964 415 1,319 Narve 3626 <50 308 517 On 2927 <50 230 1,026 On 2428 12,473 422 991 Naive 2029 <50 596 611 On 41
n.a. = not available
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Table 2.2 Immunologic characteristics of the HIV-1-infectedpatients included in the study. '
Pat. CD4+ T cells CDS+ T cells
1 230 48 182 41 90 55 175 440 255 392 255 18 48 396 '
2 655 92 210 33 360 85 570 437 135 162 61 57 92 345
3 323 162 216 103 94 48 275 1466 1261 1363 1143 15 205 1261
4 237 59 187 43 123 69 166 624 337 574 331 62 156 468
5 217 33 152 26 104 41 176 926 389 611 361 74 83 852
6 247 37 188 35 91 37 207 945 425 869 454 28 38 907
7 536 75 445 64 107 155 381 739 355 606 347 0 118 621
8 582 64 343 47 210 146 437 699 343 419 252 14 182 517
9 445 89 289 49 89 125 320 1674 988 1172 787 17 184 1490
10 444 209 315 182 147 49 395 2331 1795 2238 1888 70 70 2261
11 381 156 236 99 99 65 316 748 576 621 509 15 75 673
12 513 56 328 31 174 159 359 591 230 313 148 24 136 455
13 897 72 368 27 395 179 727 1569 424 533 235 31 314 1255
14 631 82 448 57 240 177 454 1860 1004 1451 930 74 298 1562
15 485 78 383 58 63 189 291 719 360 546 324 14 230 489
16 417 50 209 33 209 58 359 1132 702 634 509 34 181 951
17 437 57 310 39 122 205 236 647 336 518 ·298 13 188 459
18 258 72 183 44 46 85 173 1210 738 774 472 12 109 1101
19 318 105 251 102 95 99 223 1021 868 970 888 10 51 970
20 337 74 283 61 118 155 182 411 148 378 152 8 115 296
21 314 44 170 22 157 66 248 286 189 146 117 11 77 209
22 79 24 30 8 21 8 71 459 225 ··197 101 14 50 409
23 464 84 380 65 111 190 274 824 494 692 470 16 181 643
24 336 77 138 44 151 17 319 814 293 399 220 114 147 667
25 415 71 261 58 178 108 311 1319 831 976 739 40 383 936
26 308 55 145 22 188 43 265 517 222 253 119 26 181 336
27 230 101 145 60 76 5 225 1026 380 852 339 41 41 985
28 422 46 321 42 127 186 236 991 704 892 684 30 139 862
29 596 36 387 30 256 191 405 611 238 360 196 24 202 409
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Table 2.3 HIV-I replication in purified CD4+ T cells derived from selected HIV-l-infected
subjects, cultured ex vivo for 6 days in the absence of additional stimuli (rCM = tissue culture
medium) and in the presence of IL-7 (5 ng/ml) or IL-2 (100 U/ml). Reduction of apoptosis at
the same time point is shown in parenthesis.
Days in HIV-l ~24 (ng/ml)
Patient Culture TCM IL-' IL-2
5 2 0 0(7.1) 0(7.5)
3 0 0(9.2) 0(9.3)
4 0 0(9.7) 0(9.2)
5 0 0(11.6) 0(7.5)
6 0 0(9.3) 0(2.9)
10 2
3 0 0(-) 0(-)
4
5
6 0 0(9.8) 0(9.2)
25 2 0 0(0.2) 0(-4.2)
3 0 0(2.1) 0(3.1)
4 0 0(14.5) 0(8.5)
5 0 0(19.7) 0.05 (-)
6 0 0(27.9) 0(19.0)
26 2 0 0(1.9) 0.04 (1.0)
3 0 0(11.0) 0.04 (7.6)
4 0 0(804) 0(6.9)
5 0 0(9.8) 0(7.9)
6 0 0(13.9) 0(15.5)
27 2 0 0(18.3) 0(7.3)
3 0 0(19.1) 0(31.5)
4 0 0(29.9) 0(39.7)
5 0.01 0.01 (23.9) 0(31.0)
6 0.01 0(40.5) 0(49.7)
28 2 0 0.01 (9.2) 0.01 (6.3)
3 0.01 0.01 (10.2) 0.01 (10.8)
4 0.01 0.01 (6.3) 0.01 (5.9)
5 0 0.01 (8.1) 0.01 (10.3)
6 0.01 0.01 (8.5) 0.01 (11.4)
29 2 0 0(2.5) 0(-0041)
3
4 0 0(-) 0(-)
5
6 0 0(0) 0.142 (7.7)
- = not tested
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2.S Figure Legends
Figure 2.1 Schematic representation of the Annexin V assay. (A) Annexin V is a
molecule that binds in a calcium-dependent manner to phosphatidylserine (PS), a component
of the cellular membrane. On a viable cell PS in mainly in the cytoplasmic face of the
membrane, and therefore Annexin V binding does not occur in the absence of
permeabilzation. By contrast, when a cell undergoes apoptosis, structural changes occur at
the membrane level, leading to the externalization of PS on the extracellular surface, thus
allowing for Annexin V binding. If Annexin V is conjugated with a fluorochrome this
binding can be measure by FACS analysis. (B) Discrimination between apoptotic and
necrotic cells by double staining with propidium iodide (PI) and Annexin V: double negative
cells are viable cells; double positive cells are dead cells (by necrosis or apoptosis); cells that
are positive for Annexin V and negative for PI are apoptotic cells.
Figure 2.2 Protective effects of IL-7 against spontaneous apoptosls in ex vivo-
cultured PBMC from HIV-I-Infected patients and uninfected controls. (A) Mean
levels of Annexin V binding at baseline (day 0) and over 7 days of ex vivo culture in the
presence or absence of IL-7 at 5 ng/ml or IL-2 (100 U/ml). C = untreated controls. (B)
Time-course analysis of IL- 7-mediated reduction of Annexin V binding over 7 days of ex
vivo culture in PBMC from HIV -l-infected patients. Reduction of apoptosis by IL-7 was
calculated by subtraction of the percent Annexin v: cells in IL-7 -treated cultures from the
percent Annexin v: cells in untreated controls. '"= p<O.OOOIfor the comparison between
IL-7-treated and -untreated cultures; t = p<O.OOS;~ = not significant. The comparisons
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were performed by paired Student's t-test. (C) Time-course analysis of Annexin V binding
and caspase 3 activation in PBMC from a HIV -l-infected patient, representative of 7 HIY-
l-infected patients (n=7), cultured in the presence or absence of IL-7 at 5 ng/ml.
Figure 2.3 Up regulation of Bcl-2 expression by IL-7. (A)Mean fluorescence
intensity (MFI) ofBcl-2 expression by FACS analysis in unfractionated PBMC from a
HIV-1-infected individual, #14 representative of5 Hl'V-l-Infected individuals (n = 5) on
freshly isolated cells (Day 0) and after 5 days of culture in the absence or presence of
various concentration ofIL-7 (5.0-2.5-1.2-0.6 ng/ml) or IL-2 (100 Vlml). numbers in red
indicate the MFI for Bcl-2 expression in each condition. (B) Histogram overlay of Bcl-2
expression at Day 5 in PBMC cultured in the absence or presence of various concentration
ofIL-7 (5.0-2.5-1.2-0.6 ng/ml) or IL-2 (100 Vlml).
Figure 2.4 Correlation between the mean levels of IL-7-mediated reduction of
apoptosis in PBMC from 24 HIY-I-infected patients over the tlrst 6 days in culture
and various demographic, clinical and immunologic parameters. The left panel shows
scatterplots with regression lines relating differences in apoptosis to covariates. Also
shown are R-squared values (squares of the Pearson's correlation coefficients) and p
values. The right panel shows the comparisons between different groups of patients
defined by specific cut-off values for each parameter. Apoptosis was measured by
Annexin V binding.
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Figure 2.S Correlation between the mean levels of IL-' -medlated reduction of
apoptosis in PBMC from 24 HIV-l-infected patients over the first 6 days in culture
and various demographic, clinical and immunologic parameters. (A) Scatterplots with
regression lines relating differences in apoptosis to covariates. Also shown are R-squared
values (squares of the Pearson's correlation coefficients) and p values. Apoptosis was
measured by Annexin V binding. (B) Comparison of the mean levels of Annexin V
binding in patients with different treatment status (on-therapy, off-therapy, narve to
treatment). (C) Statistical analysis restricted to patients with CD4 counts < 350 cells/ul (n
== 11): comparison of the mean levels of Annexin V binding between patients naive to
treatment and patients on/off therapy at the time of testing, and between patients divided
according to their level of viremia (two different cut-off values were used, 50 and 30000
copies/ml). Non-parametric Mann Whitney test was used for statistical comparisons
between different groups of patients.
Figure 2.6 Correlation between the slope of IL-'-mediated reduction of
apoptosis and the CD4+ T-cell counts. The figure shows the scatterplots with the
regression line relating the slope of IL-7 -mediated reduction in Annexin V-binding over 7
days of culture in PBMC from 24 RIV -l-infected patients and the number of circulating
CD4+ T cells. The upper panel shows the analysis performed on cells from a1l24 RIV-l-
infected patients; the lower panel shows the same analysis after removal of a single outlier
(patient no. 13). Also shown are the R-squared values and p values calculated by Pearson's
correlation test.
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Figure 2.7 Protective effects of IL-7 against spontaneous apoptosis in CD4+
and CD8+ T cells from HIV-I-infected patients. (A) Mean levels of Annexin V binding
over 6 days of culture in CD4+ or CDS+T cells identified by multicolor flow cytometry in
unfractionated PBMC cultured in the presence or absence of IL-7 (5 ng/ml), (B) Mean
levels of Annexin V binding over 6 days of culture in CD4+ or CDS+ T-cell populations
cultured separately as purified subpopulations in the absence or presence of IL- 7 (5
ng/ml).
Figure 2.8 Protective effects ofIL-7 against spontaneous apoptosis in ex vivo-
cultured purified populations of CD4+ and CD8+ T cells from one representative
RIV-I-infected patient. The figure shows time-course analyses of the levels of Annexin
V binding and caspase 3 activation over 6 days of culture in the presence or absence of IL-
7 (5 ng/ml) in purified CD4+ (A) or CDS+ (B) T-cell populations from a HIV-1-infected
patient, # 25 representative of 5 HIV -l-infected individuals (n = 5).
Figure 2.9 Protective effects of IL-7 against spontaneous apoptosis in ex vivo-
cultured naive and memory CD4+ and CD8+ T cells from 7 HIV-I-infected patients.
Mean levels of Annexin V binding over 6 days of culture in the presence or absence of IL-
7 (5 ng/ml) or IL-2 (100 V/ml) are shown. Naive and memory T cells were identified by
multiple color staining with antibodies to CD45RA and CD45RO, respectively, and
Annexin V. In 5 patients, the cultures were established with unfractionated PBMC, and the
CD4+ and CDS+ T-cell subsets were separately analyzed by gating. In 2 patients (# 5 and #
153
27, indicated by an asterisk), the CD4+and CD8+T-cell populations were purified by
negative selection before culturing.
Figure 2.10 Temporal dissociation between the anti-apoptotic and
proliferative effects ofIL-7 and IL-2 from a representative HIV-l-infected individual
(# 14 of 4 patients). Time-course analysis of Annexin V-binding reduction (A) and Ki67
expression (B) in PBMC from a representative RIV-I-infected patient (# 14) cultured for 6
days in the presence or absence ofIL-7 (0.6, 1.2, 2.5 and 5 ng/ml) or IL-2 (100 U/ml). (C)
and (D) Proliferative effects ofIL-7 and IL-2 in PBMC from a representative RIV-I-
infected patient (# 14), analyzed by absolute cell counting by flow cytometry (C) and
CFSE dye dilution (D), in PBMC cultured in the absence or presence of IL-7 (0.6, 1.2, 2.5
and 5 ng/ml) or IL-2 (100 U/m!).
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CHAPTER THREE
In vivo
Effects of Treatment with IL-7 during the Acute Phase of SIV Infection
in Rhesus Macaques
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3.0 Introduction
Although HN -1 establishes a chronic active infection that evolves toward
clinical immunodeficiency over a span of several years, accumulating evidence indicates
that critical pathogenic events take place during the acute phase of infection, leading to a
massive and seemingly irreversible depletion of memory CD4+ T cells (1,2). The extent
of such depletion is not accurately mirrored by circulating CD4+ T-cell counts, as
peripheral blood contains only a minor fraction of the total T cells in the body (3). Gut-
associated lymphoid tissue (GALT), a compartment that harbors the largest fraction of
the T-cell pool (3), has been identified as a primary anatomical site for CD4+ T-cell
depletion in both HIV -I-infected patients (4-6) and SN -infected nonhuman primates
(1,2,7,8). Yet, the loss of memory CD4+ T cells within the early phase of infection
appears to be a systemic phenomenon that involves all secondary lymphoid organs (1,9).
Taken together, these observations suggest that interventions aimed at preventing or
reducing the long-term immunologic damage caused by HN -1 would be most effective
if implemented during the earliest stages of infection, before the pool of memory CD4+
T cells becomes irreversibly depleted.
In spite of extensive research over the past three decades, the mechanism of
CD4+ T-cell depletion during the course of HIV-I infection is still debated. Studies in
SN -infected macaques have highlighted a major role of cytopathic effects due to direct
virus infection during the course of acute primary infection (1,9). However, indirect
mechanisms, including bystander apoptosis, may also be important, as suggested by the
detection of increased levels of apoptosis in the blood and lymphoid organs of macaques
acutely infected with pathogenic SN strains (2,10-14), as well as in ex vivo-cultured T
169
cells from individuals with acute HIV -1 infection (15-17). Thus, the use of anti-
apoptotic agents during primary HIV -1 infection may have beneficial effects for
preserving the integrity of the CD4- T-cell pool. We previously demonstrated that
interleukin-7 (IL-7), a nonredundant cytokine that plays a critical role in the
development and homeostasis of the T-lymphoid compartment of the immune system
(18-20), effectively reduces the levels of spontaneous apoptosis in both CD4+ and CD8+
T cells from HIV-l-infected individuals (21). In hosts who are lymphopenic from a
variety of causes, the levels of endogenous IL- 7 increase, causing transient proliferation
of naive and central memory (CM) CD4+ and CD8+ T cells, leading to the reconstitution
of the physiological T-Iymphocyte pool (18-20). Owing to these unique biological
properties, IL- 7 is currently under clinical investigation as an immune reconstitution
agent in various forms of natural and iatrogenic immunodeficiencies, including those
associated with AIDS and cancer (22,23).
Pre-clinical studies in macaques chronically infected with SIV (24-27), as well as
clinical studies in patients chronically infected with HIV -lor treated with
immunosuppressive anti-neoplastic drugs (28-31), have documented beneficial effects of
short-term courses of IL-7 treatment, resulting in proliferation and expansion of naive and
CM T cells in peripheral blood and secondary lymphoid organs. However, the effects of IL-
7 treatment in acute HIV -1 (or SIV) infection have never hitherto been investigated, and the
anti-apoptotic action of IL-7 was never evaluated in vivo. In the present study, we
administered fully glycosylated recombinant macaque IL- 7 to rhesus macaques during the
acute phase of infection with a pathogenic SIV strain (mac251). We deliberately avoided the
concomitant use of ART in order to exclude the confounding effects of ART -induced
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suppression of virus replication on T-Iymphocyte pathogenesis as well as to verify the
effects of IL-7 on SIV replication. We demonstrated that treatment with IL-7 is safe and
prevents the early depletion of naive and CM CD4+ T cells without increasing the levels of
SIV replication. These results provide a scientific basis for consideration of IL-7 as an
adjuvant therapy during the acute phase of HIV -1 infection.
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3.3 Materials and Methods
3.1.1 Animals and study design
The study protocol enrolled 12 colony-bred juvenile Rhesus macaques, which were
housed at Bioqual Inc. (Rockville, MD) and handled in accordance to the standards of the
American Association for the Accreditation of Laboratory Animal Care. The animals were
quarantined and tested to exclude infections with SlY, STLV and herpes B virus. The study
included two groups of animals: untreated controls (group 1) and IL-7 treatment (group 2).
Blood samples were obtained three times during the first week of IL-7 treatment, then twice
weekly for the entire treatment period and then once per week; terminal ileum biopsies were
obtained on day 14-16 post-infection; lymph node biopsies were obtained on day 25-27
post-SIV infection. Since one animal in the control group (H744) was lost on day 14 post-
infection during the procedure to obtain intestinal biopsies, all the data for time points
subsequent to day 14 refer to 11 animals (5 untreated and 6 IL-7-treated).
3.1.2 IL-7 treatment and SIV infection
Recombinant glycosylated simian IL-7 (Cytheris, France) was employed in this
study since it has a considerably longer half-life and greater plasmatic stability (M. Morre et
al., unpublished results) than the non-glycosylated form that had been employed in several
previous studies (32, 33). A schematic diagram of the design of the study is provided in
Figure 3.1. IL- 7 was administered subcutaneously to the 6 monkeys included in group 2 at a
concentration of SOug/kg of body weight once per week for a total of 7 consecutive
administrations. To allow for the achievement of steady-state plasmatic levels of the
cytokine prior to SIV infection, treatment was initiated 1 week before SIV inoculation (day -
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7). All 12 monkeys were inoculated intravenously with 100 macaque infectious doses of the
pathogenic strain SlY mac2S1, kindly provided by Dr. R. Desrosier. Multiple clinical,
immunological and virological parameters were monitored throughout the acute phase of the
infection, as well as for a follow-up period of 6 months post-infection.
3.1.3 Measurement of plasma fL-7 concentrations
The concentration of IL-7 in serial plasma samples was measured using a high-
sensitivity commercial ELISA (Quantikine HS, R&D Systems, Minneapolis, MN).
3.1.4 Peripheral blood cell counts and cytofluorimetric analysis
Peripheral blood was collected under sterile conditions in vacutainer tubes with
EDTA as anticoagulant. A complete blood cell count (CBC) with differential was performed
by a commercial laboratory (Antech Diagnostics, Rockville, MD). Plasma was separated by
spinning whole blood at 500xg for 20 min at 4°C without brake and stored at -SO°C. PBMC
were isolated by gradient centrifugation using Lymphocyte Separation Medium (LSM; MP
Biomedicals). Blood was diluted in Phosphate Buffered Saline (PBS), stratified over LSM
and centrifuged at 500xg for 25 min at 4°C without brake. The mononuclear cell ring was
collected and the PBMC were washed twice with PBS, counted and used for
cytofluorimetric analyses. The following monoclonal antibodies (mAbs) were used for
surface staining: CD2S-FITC (clone CD2S.2), CD4-PerCpCy5.5 (clone L200), CD95-APC
or-PE (clone DX2), CDS-PECy7 (clone SKI), CD3-APCCy7 (clone SP34-2), all from BD
Biosciences. The naive (CD2S+CD95"), memory (CD2S+CD95+) and effector (CD2S"CD95+)
T-cell subsets were identified as previously described (34). At selected time points, a more
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detailed characterization of the memory T-cell compartment was performed by using a
combination of the following mAbs: CD4SRA-FITC (clone SH9), CD28-PECy7, CCR7-
APC (clone 3DI2), CD9S-Biotin (followed by Streptavidin-PerCpCyS.S), CD3-V4S0, CD4-
APCH7 (all from BD Biosciences), and CDS-eFLOUR 60SNC (clone RPA-TS;
eBioScience). Additional mAbs were used to measure expression levels of other cell-surface
markers, including IL-7 receptor-a/CDI27-PE (clone hIL-7R-M21), CCRS-PE (clone 3A9),
CXCR4-PE (clone 120S) and the activation markers HLA-DR-PE (clone L243/046-6) and
CD2S-PE (clone M-A2S1) (all from BD Biosciences). Apoptosis was assessed by measuring
the levels of Annexin V binding, using Annexin V-APC conjugated (BD Biosciences), as
follows: after surface staining, the cells were washed with Annexin V-binding buffer,
incubated for IS min at room temperature with Annexin V-APC, and analyzed immediately.
Bcl-2 expression levels and cellular proliferation were assessed by intracellular staining
using mAbs anti-Bcl-2-PE (clone Bcl-2/100) and anti-Ki67-PE (clone BS6) (BD
Biosciences). Briefly, after surface staining, the cells were fixed and permeabilized using
BD CytofixiCytoperm solution (BD Biosciences) and incubated with the appropriate
antibody for 20 min at 4°C. Stained cells were analyzed by flow cytometry using a BD
FACSCanto collecting a minimum of 100,000 events per sample. Flow data were analyzed
using the Flowjo software (Tree Star) or FCS Express (DeNovo Software).
3.1.5 Measurement of SIV plasma viremia, proviral DNA and antigenemia
Plasma levels ofSIV RNA were measured using a quantitative real-time RT-PCR
assay. Viral RNA was purified from 280 ml of cell-free plasma using the QIAamp Viral
RNA kit (Qiagen, USA), and stored at -80°C. The number of SIV RNA genome equivalents
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(ge) was determined using a real-time RT-RCR assay based on the AgPath-IDTM One-Step
RT-PCR Kit (Applied Biosystems, USA). Briefly, reverse transcription and polymerase
chain reaction phases were carried out in a single tube, under the following amplification
conditions: 10 min at 45°C (RT), 10 min at 95°C and 40 cycles of 15 sec at 95°C and 45 sec
at 60°C (PCR). Primers and probe used for reverse transcription and amplification were
specifically designed within the SIV gag gene, in order to amplify a fragment of91 bp.
Forward primer: 5'-GCAGAGGAGGAAATTACCCAGT-3'; reverse primer: 5'-
ATTTTACCCAGGCATTTAATGTTC-3' (used for the RT phase); TaqMan MGB probe,
FAM-Iabelled: 5'-ACAAATAGGTGGTAACTATG-3'. Primers and probe were used at a
concentration of 300 nm and 200 nm respectively. The copy number was determined by
interpolation on a standard curve of a DNA plasmid carrying a fragment of the SIV gag gene
containing the RT-PCR amplicon (seriall0-fold dilutions from 10° copies/reaction to 106
copies/reaction). Forward cloning primer: 5'-GCAGAGACACCTAGTGATGGAAAC-3';
reverse cloning primer: 5'- TCTCCCACACAA TTTAACATCTG-3' .
The SIV proviral DNA load was measured by real-time PCR using the same primers
and probe as in the plasma SIV viremia assay. Normalization for cell number was performed
by quantification of a non-polymorphic single-copy gene, CCR5, and the copy number per
million ofCD4+ T cells was obtained by normalizing for the percentage ofCD4+ T cells in
the corresponding sample, as determined by flow cytometry. Additional details about the
method have been reported (35).
SIV p27 Gag antigenemia was measured by using the SIV Core Antigen Assay
(Coulter Corporation, Miami, USA) according to the manufacturer's instructions. All
samples were initially tested undiluted and retested at 1:10 dilution if the p27 Gag content was
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higher than the highest point of the standard curve. Plates were read using an end-point
protocol with a microplate spectrophotometer (Bio-Rad Instruments).
3.1.6 Terminal ileum and lymph node biopsies
Ileum biopsies were performed by retrograde ileoscopy on day 14-16 post-infection
(Figure 3.1). A pediatric colonoscope was passed through the large intestine and the ileo-
cecal valve. At least 6-8 punch biopsies were obtained with cold forceps from the terminal
ileum of each animal, immediately placed in cold RPMI medium and then processed within
3 hours of excision. During the first procedure, one animal (H744) suffered an intestinal
perforation and was lost. Ileum biopsies were digested in Iscove's media supplemented with
2 mglml Type II collagenase (Sigma-Aldrich) and 1 U/ml DNase I (Sigma-Aldrich) for 30
min at 37°C. After digestion, the samples were passed through a 70llm strainer, and the
suspended cells were washed twice with RPMI media supplemented with 10% heat-
inactivated FBS.
Lymph node excisional biopsies were performed on day 25-27 post-infection
(Figure 3.1) on axillary lymph nodes from all animals using sterile instruments and aseptic
technique. Lymph nodes were cut longitudinally in two halves, one of which was stored at-
80°C for subsequent analysis. The remaining half was finely minced using sterile scalpels
and mechanically smashed to release lymphoid cells into the media. Cells were then washed,
passed through a 70llm strainer and stained for surface and intracellular markers as
described above.
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3.1. 7 Analysis of SIV -speciflc T-cell responses
SIV -specific CD4+ and CD8+ T-cell responses were analyzed by measuring
intracellular cytokine production after antigen stimulation as follows. Frozen samples of
unfractionated PBMC collected during the acute phase of SIV infection and during the
follow-up period were thawed in complete RPMI medium supplemented with 10% FBS and
rested at 37°C for at least 5 hrs. Cells were then plated at a concentration of 5xl 05 cells/well
in a 96-well round-bottom plate in RPMI 10% FBS in the presence of purified anti-CD28
and anti-CD49d mAbs both at a final concentration of 1 ng/ml. Two pools of SIV -gag
peptides and one pool of SIV:-tat peptides (from NIBSC, EVA Centre for AIDS reagents) at
a final concentration of 1 ug/ml (each peptide) and Staphylococcus aureus Enterotoxin B
(SEB, Sigma) as positive control at a final concentration of2 ug/ml were added to the
samples and the volume was adjusted to 200fll with RPMI 10% FBS. A negative control
with no stimulation was also included. After lhr incubation at 37°C, 5% CO2, lul of
Brefeldin A (BD GolgiPlug, BD Biosciences) was added to each well, and the plates were
then incubated for an additional IIhrs. At the end of the incubation period the cells were
transferred to 96-well V-bottom plates and washed twice with PBS before surface
intracellular staining. Cells were stained first with LIVEIDEAD® Fixable Dead Cell Stain
reagent (Invitrogen by Life Technologies) at a concentration of Ifll/I 06 cells for 20 min at
4°C and then with the mAbs to lineage antigens (CD3-V450 and CD4-APCH7, BD
Biosciences), before fixation and permeabilization with BD Cytofix/Cytoperm Buffer (BD
Biosciences). After two washing steps with BD PermWash Buffer (BD Biosciences), the
cells were then incubated for 20 min at 4°C in the presence ofanti-MIP-ll3-PE (clone 021-
1351), anti-IFN-y-PECy7 (clone P2GI0) and anti-IL-2-APC (clone MQI-I7HI2; all from
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BD Biosciences), washed twice with PBS and analyzed on a BD FACSCanto instrument. T-
cell responses were then quantified and analyzed qualitatively using the Flowjo (Tree Star):
and Spice softwares.
3.1.8 Statistical analysis
Statistical analysis was conducted using the softwares SAS (version 9.1 for
Windows), S-Plus (version 6.2 for Windows), StatView (version 5.0.1 for Macintosh) and
GraphPad Prism (version 4.0b for Macintosh). Paired Student's t-tests were used for the
comparison between different time points within the same animal group (untreated or IL-7-
treated). Non-parametric Wilcoxon rank sum tests were used to analyze differences between
IL-7-treated and untreated animals.
To compare untreated and IL-7-treated animals with respect to changes from baseline to
multiple time points simultaneously the 0'Brien test was used: it is a natural extension of
the Wilcoxon rank sum test to accommodate multiple time points per subject. The analysis
was used to compare simultaneously the changes from baseline to each time point during the
treatment period (day 7, 14,21,28, and 35). First, changes from baseline to each of the time
points were ranked separately, and then the ranks for each animal were averaged across the
time points. To assess statistical significance, a permutation test was used. Under the null
hypothesis of no effect of IL-7 treatment, one should not be able to distinguish treated
monkeys from controls; the control monkeys could have been any group of 5 selected from
the 11 total (excluding monkey #744 for which several time points were missing).
Considering that there are 462 ways to select 5 subjects from 11, for each of these
relabelings, the difference between the average for animals labeled as "IL- 7-treated" and the
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average for animals labeled as ''untreated'' was computed. Afterwards, we computed the
proportion of relabeled datasets that produced a mean difference at least as extreme as the
actual trial data.
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3.2 Results
3.2.1 MBC screening and study groups
A critical issue in the study design was the assignment of the 12 animals to the two
study groups (i.e., treatment and control) in order to avoid potential biases in SIV-disease
susceptibility. Since previous work had identified MHC class-I alleles that confer disease-
protective (Mamu-AOl, Mamu-A08) or disease-enhancing (Mamu-BOl) effects (36-39), we
pre-screened the animals for defined Mamu haplotypes and attributed a positive score (+ 1)
to the presence ofMamu-AOI or Mamu-A08 and a negative score (-1) to the presence of
Mamu-BOI (Table 3.1). The final study groups (no treatment and IL-7 treatment) were
balanced considering both the MHC scores and the baseline circulating CD3+ and CD4+ T-
lymphocyte counts (Table 3.1). Indeed, not significant p values for the comparison of CD3+
and CD4+ T-lymphocyte counts between the two groups of animals were obtained even after
the exclusion of the single outlier animal (# 749) in the untreated group.
3.2.2 Safety and pharmacokinetics of glycosylated macaque IL-7
None of the animals treated with IL-7 exhibited adverse clinical side effects such as
fever, weight loss or neurological signs, or specific hematological and biochemical
alterations. After the first IL-7 injection (day -7 relative to SIV infection), plasma IL-7
levels peaked on day -S to return to baseline after 7 days (Figure 3.2 A). The two
subsequent injections (day 0 and 7) induced higher peak levels and a greater area under the
curve (AVC), resulting in markedly elevated trough levels before each of the following
injections. This pattern likely reflects the initial distribution of the cytokine to a high-affinity
compartment that became saturated at subsequent injections. A significant increase in
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plasma IL-7 levels was also observed in untreated animals, albeit to a considerably lesser
extent than in IL-7-treated animals, starting on day 28 in parallel with the most pronounced
reductions in circulating lymphocyte counts (Figure 3.2 A). No significant correlations were
found between plasma IL-7 levels and several immunological or virological parameters
(data not shown). In agreement with previous studies (24-31), IL-7 treatment initially caused
a significant downmodulation of the IL-7 receptor (CDI27) in both naive and memory T
cells (Figure 3.2 B).
3.2.3 IL-' treatment during the acute phase of SIV infection does not increase the
levels of SIV replication and proviral SIV DNA load
The effects of IL-7 administration on SIV replication were evaluated by measuring
the levels of SIV viremia and antigenemia on sequential plasma samples. Treatment with IL-
7 did not increase the mean levels of SIV plasma viremia (Figure 3.3 A) at any time during
the acute phase of infection, including the peak, viral set point and AUC, with the only
exception of the earliest point analyzed (day 4 post-infection). Likewise, there were no
differences between treated and untreated animals in the levels of SIV antigenemia (Figure
3.3 B) and proviral SIV DNA load measured in blood mononuclear cells on days 14 and 77,
as well as in the GALT (ileum) on days 14-16 and in axillary lymph nodes on days 25-27
post-infection (Figure 3.3 C and D). All animals developed SIV-specific IgG antibodies,
which became detectable between days 11 and 21 after infection (data not shown).
3.2.4 IL-' treatment during the acute phase of SIV infection prevents the depletion of
naive and memory CD4+ T cells
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While all the animals in the untreated group experienced a marked and sustained
depletion of circulating CD4+ T lymphocytes starting at the time of peak SIV replication
(day 14 post-infection), IL-7-treated animals showed no depletion ofCD4+ T cells over
the entire treatment period, with even a significant increase in CD4+ T-cell counts,
relative to baseline, on day 41 (Figure 3.4 A). When the two groups of animals were
compared, IL-7 -treated macaques showed higher absolute numbers of peripheral CD4 +
and CD8+ T cells at multiple time points, including day 14 post-infection.
To better characterize the effects of IL-7 on the different CD4+ T-cell populations,
the naive, memory and effector subpopulations were separately analyzed. In the absence of
IL-7 treatment, SIV infection resulted in significant decreases in the absolute numbers of
naive and memory CD4+ T cells, compared to pre-infection levels, throughout the acute
phase of the infection (Figure 3.4 A). In contrast, IL-7 caused an initial increase in
+ .
memory CD4 .T cells (day 7) and subsequently prevented the depletion of naive and
memory CD4+ T cells throughout the treatment period; effector CD4+ T cells were
increased at several time points (Figure 3.4 A). When the absolute numbers of circulating
naive, memory and effector CD4+ T cells in the two groups of animals were compared,
significant differences were detected at several time points (Figure 3.4 A). A detailed
subset analysis of the memory CD4+ T-cell population was performed at selected time
points: while in untreated animals all memory CD4+ T-cell subsets (CM, transitional
memory [TM] and effector memory [EM]) were depleted during the acute phase of the
infection, no depletion was observed in any subset in animals receiving IL-7 (Figure 3.4
B). However, the protective effects of IL-7 on CD4+ T cells were not sustained after
treatment interruption. In fact, both naive CD4+ T cells and all subsets of memory CD4+ T
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cells became significantly depleted, compared to baseline values, on day 62 post-infection,
4 weeks after the last injection ofIL-7 (Figure 3.4 A and B).
3.2.5 IL-' treatment expands all subsets of CDS+T cells
IL-7 -treated animals experienced sustained increases in all subsets of CDS+ T cells
throughout the acute phase of infection (Figure 3.4 A), associated with increased expression
of T-cell activation markers (Figure 3.5). In contrast, untreated animals experienced a
transient depletion of narve and memory CDS+ T cells (Figure 3.4 A). When the two groups
of animals were compared, IL-7 -treated monkeys showed higher absolute numbers of
peripheral CDS+ T cells at multiple time points (Figure 3.4 A). Subset analysis of memory
CD8+ T cells revealed no major changes in untreated animals, whereas IL-7 induced
significant increases at several time points in all memory CDS+ T-cell subsets (Figure 3.4
B), with significant differences in comparison to untreated animals (Figure 3.4 B).
However, on the last determination (day 62 post-infection), CM CD8+ T cells returned to
baseline values, while TM and EM CDS+ T cells became significantly depleted in both IL- 7-
treated and untreated animals (Figure 3.4 A and B).
3.2.6 Changes in T-cell subpopulations mediated by IL-' in acutely SIV-infected
macaques
Further analysis was conducted using the 0 'Brien permutation test to simultaneously
compare the changes in narve, memory and effector CD3+, CD4+ and CD8+ T cells from
baseline to all the time points during the treatment period (day 7-35 post-infection) in IL-7-
treated versus untreated animals. As shown in Figure 3.6 A, this analysis demonstrated that
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the changes were significantly different in IL-7-treated and untreated macaques. Likewise,
significant differences between IL-7-treated and untreated animals were also observed for;
naive, memory and effector CD4+ and CD8+ T cells, as well as for naive and effector CD3+
T cells, but not for memory CD3+ T cells (Figure 3.6 B). When the analysis of changes was
restricted to day 14 post-infection, the differences between IL-7-treated and untreated
animals were significant for all T-cell subpopulations (not shown).
3.2.7 Repeated administrations of IL-7 induce only transient T-cell proliferation but
persistent reduction of apoptosis
To investigate to what extent the effects ofIL-7 on CD4+ and CD8+ T cells were
due to cellular proliferation or rather to prolonged survival of the pre-existing cellular
pools, the levels of in vivo proliferation and apoptosis were longitudinally monitored in
freshly isolated peripheral blood T cells. As shown in Figure 3.7, IL-7 treatment
induced only a transient increase in the proportion of Ki67-expressing CD4+ T cells
during the first week of treatment (day -5 and -3 prior to SIV infection), which returned
to baseline at the time of SIV inoculation (day 0) (Figure 3.7 A); remarkably, there were
no further changes in Ki67 expression in circulating CD4+ T cells after each of the
subsequent IL-7 injections (Figure 3.7 B). In contrast, CD8+ T cells showed elevated
Ki67 expression both before SIV inoculation and at two time points (day 4 and 11) after
infection, although the proportion of cycling cells returned to baseline thereafter
«Figure 3.7 A and B). Analysis of apoptosis in peripheral blood did not show
significant elevations of Annexin- V-binding cells in both untreated and IL- 7-treated
animals throughout the acute phase of SIV infection (Figure 3.7 C); however, IL-7 ~
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treated animals exhibited significant and sustained increases in the intracellular levels of
the anti-apoptotic protein Bc1-2 in both CD4+ and CDS+ T cells during the first three
weeks of treatment (Figure 3.7 D). These results suggest that the lack of depletion of
CD4 +T cells in IL-7 -treated animals was primarily due to a decrease in apoptosis rather
than to the induction of cellular proliferation, whereas both phenomena likely
contributed to the sustained increases in circulating CDS+ T cells.
Terminal ileum biopsies were obtained on days 14-16 post-infection. In both
groups of animals, the yield of CD3+ T cells from intestinal biopsies was highly variable
(range = 1.25-15% of the total cell population), underscoring the inherent difficulties in
obtaining specimens with comparable representation of the GALT via retrograde
ileoscopy. Regardless of these limitations, no significant differences were detected in the
relative proportions of total, naive, memory and effector CD4+ T cells in IL-7-treated vs.
untreated macaques (Figure 3.8 A, upper panels); likewise, the proportion of Annexin-
V-positive CD4+ T cells was similar in the two groups (Figure 3.8 A, lower panels). In
contrast, the proportion of Annexin-Vvpositive CDS+ T cells was lower in IL-7-treated
animals (p = 0.041), primarily due to reduced apoptosis among memory CDS+ T cells (p
= O.04S), associated with a lower proportion of apoptosis-prone naive CDS+ T cells (p =
0.024) (Figure 3.8 A). Both the proportion of effector CDS+ T cells (Figure 3.8 A) and
the CDS/CD4 ratio (not shown) tended to be higher in the intestine ofIL-7-treated
animals, but the differences did not reach statistical significance.
Lymph node biopsies were collected on days 25-27 post-infection. The relative
proportions of total, naive, memory and effector CD4+ and CD8+ T cells were not
significantly different between IL-7-treated and untreated macaques (Figure 3.8 D,
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upper panels), and the level of T-cell proliferation, as measured by Ki67 expression, was
very low in both groups of animals (data not shown). Analysis ofT-cell apoptosis by
Annexin-V binding (Figure 3.8 B, lower panels) and intracellular Bc1-2 expression did
not show significant differences between the two groups of animals despite a trend
toward reduced apoptosis in memory CD4+ T cells, memory CD8+ T cells and effector
CD8+ T cells in IL-7-treated macaques.
3.2.8 Rapid disease progression in 4 SIV -infected macaques: re-analysis of
virological and immunological data after exclusion of rapid progressors
During follow-up, two monkeys in each group (H745, H749 untreated; H751,
H752 IL-7-treated) developed early signs ofSIV-disease progression and were euthanized
for humanitarian reasons after a mean of 143.5 ± 2004 days (range, 115-163). Albeit
infrequently, SIV-infected macaques have been shown to undergo a rapid disease course
characterized by high-level virus replication in cells of the mononuclear phagocytic
lineage rather than in CD4+ T cells (40). In agreement with these previous observations,
our rapid progressors (RP) showed persistently higher levels of SIV plasma viremia
(Figure 3.9 A) and antigenemia (Figure 3.9 B), compared to conventional progressors
(CP), as well as overall higher numbers of circulating CD4+ T cells, even though the
difference reached statistical significance only on day 62 post-infection (Figure 3.9 C).
Although it is impossible, without extending the study to a larger group of animals, to
establish if the RP course was affected by IL-7 treatment, the fact that two animals in each
group progressed rapidly suggests that IL-7 did not influence this unique form of SIV-
disease evolution.
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Since the rapid disease course has been associated with an unusual pathogenesis
(40), which is likely influenced by genetic factors and insensitive to IL-7 treatment, we
reasoned that the inclusion ofRP animals could be a confounding factor in our study,
and therefore all the immunological and virological data were re-analyzed after
exclusion of these 4 animals. This re-analysis showed no major changes in the statistical
comparisons between treated and untreated animals regarding SIV viremia and
antigenemia (Figure 3.10 A), CD4+, CD8+, narve, memory and effector T cells in
peripheral blood (Figure 3.10 B), ileum and lymph nodes. However, the exclusion ofRP
animals had important effects on the analysis of T-cell apoptosis in lymph nodes. Unlike
in the GALT (Figure 3.11, upper panels), re-analysis of Annexin-V binding in lymph
nodes demonstrated lower levels of apoptosis in memory CD4+ T cells, memory CD8+ T
cells and effector CD8+ T cells in spite of the smaller sample size (Figure 3.11, lower
panels). Likewise, when the analysis was restricted to CP animals, CD4+ T cells in
lymph nodes exhibited higher levels of intracellular Bcl-2 (not shown).
3.2.9 IL-7 treatment elicits earlier and stronger SIV-speciftc CD4+ and CDS+ T-cell
responses
SIV -specific T-cell responses were evaluated at multiple time points during and
after the IL- 7 treatment period by measuring the intracellular production of IFN -y, IL-2
and MIP-l j3 in CD4+ and CDS+ T cells stimulated with peptide pools derived from SIV
Gag and Tat proteins. Vigorous SIV-specific responses were detected at multiple time
points starting from the first time point analyzed (day 21 post-infection). In contrast, we
were unable to document the induction of SIV-neutralizing antibodies at any time during
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acute primary infection inboth untreated and IL-7-treated macaques. The total number
of Tat-specific CD8+ T cells on day 21 was significantly higher in IL-7-treated than in
untreated animals (p = 0.017), whereas the difference in Tat-specific CD4+ T-cell
responses did not reach statistical significance (p = 0.051) (Figure 3.12). IL-7 treated
animals also displayed overall higher numbers of Gag-responding T cells, particularly
CD4+ T cells on day 35 post-infection; however, the difference did not reach statistical
significance (Figure 3.12).
Qualitative analysis of SIV -specific T-cell responses revealed that initially most
Tat-specific (Figure 3.13 A) and Gag-specific (Figure 3.14 A) CD4+ and CD8+ T cells
were monofunctional in both groups of animals, producing a single cytokine (single-
producing, SP). When SP cells were analyzed separately from double- and triple-
producing cells (OP and TP), the difference between IL-7-treated and untreated animals
was significant for both CD4+ and CD8+ Tat-specific T cells (p = 0.030 and o.oi 7,
respectively; Figure 3.13 B). The quality of the T-cell responses evolved over time, with
both Tat-specific (Figure 3.13 B) and Gag-specific (Figure 3.14 B) cells acquiring some
degree of poly functionality over time. This phenomenon was more prominent in IL-7-
treated animals, as shown by a significant difference in the proportion of the various
functional subpopulations of Tat-specific CD8+ T cells in the two groups of animals on
day 62 post-infection (Figure 3.13 C). These results indicate that IL-7 treatment led to
the early elicitation of vigorous Tat-specific CD4+ and CD8+ T-cell responses following
the peak of viral replication, which was not observed in the absence of treatment.
188
3.3 Discussion
While the progressive refinement of multi-drug ART protocols has led to
extraordinary advances in the treatment of chronic HIV -1 infection, the clinical
management of acute primary HIV -1 infection remains a challenge. A critical hurdle is
the inherent difficulty in identifying and treating patients at the earliest possible stage in
order to reduce the peak of HIV -1 replication and its deleterious effects on the immune
system. This issue is particularly relevant considering that a profound depletion of the
CD4+ T-cell pool occurs within the first few weeks of infection (1,2), marking a critical
and seemingly irreversible event in the pathogenesis of HIV -1 disease. Although a
beneficial effect of early ART treatment on the induction and maintenance ofHIV-
specific cellular immune responses has been reported (41-43), additional studies in
patients (44) and macaques (45) have shown limited effects of ART alone on Tvcell
preservation in the intestinal lamina propria, underscoring the importance of devising
effective adjunctive therapies aimed at preventing the immunologic damage that occurs
during the acute disease. A potential candidate in this respect is the homeostatic cytokine
lL-7, which is currently under investigation as an immune reconstitution agent in chronic
HIV -1 infection and other immunodeficiencies (28-31), but whose effects during acute
primary HIV -1 (or SlY) infection have not been evaluated. We found that treatment of
macaques with lL- 7 during the acute phase of SIV infection prevented the depletion of
narve and CM CD4+ T cells that occurred, as expected, in untreated animals, without
significantly increasing the levels of virus replication. In striking contrast, treatment of
acutely SlY-infected macaques with another common-v-chain cytokine, lL-15, was
recently shown to induce a 3-log increase in the viral set-point associated with increased
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CD4+ T-cell activation, leading to accelerated disease progression (46). We have to point
out, however, that the analysis of the SIV DNA load in CD4+ T cells performed in the
blood as well as in peripheral lymphoid tissues (GALT and lymph nodes) of infected
monkeys revealed no significant differences between IL-7-treated and untreated animals,
thus suggesting that the CD4+ T cells preserved by IL-7 might actually harbor the virus,
or, alternatively, that IL-7 does not preferentially protect uninfected cells.
To elucidate the mechanisms responsible for the CD4-protective effects of IL-7
in our macaques, we examined the kinetics of CD4+ T-cell proliferation and apoptosis,
as well as the induction of SIV -specific cellular immune responses during IL- 7
treatment. We documented only low and transient levels ofCD4+ T-cell proliferation,
suggesting that repeated injections of glycosylated IL-7 may in fact induce
tachyphylaxis, at least concerning the proliferative effects of the cytokine. Conversely,
in agreement with our ex vivo findings (21), several observations pointed to reduction of
apoptosis as a major mechanism for the preservation of CD4+ T cells in IL-7-treated
macaques. First, IL-7 induced a sustained increase in the expression of the anti-apoptotic
protein Bcl-2 in both CD4+ and CDS+ T cells. Second, analysis oflymphoid tissues
demonstrated reduced levels of apoptosis in various CD4 + and CD8+ T-cell populations
in IL-7-treated macaques, even though for CD4+ T cells in lymph nodes statistical
significance was only achieved when the analysis was restricted to animals with a
conventional disease course. In contrast, analysis of the GALT at the time of peak SIV
replication demonstrated that lL-7 reduced apoptosis in CDS+ T cells, but not in CD4+ T
cells. An important caveat that must be considered in this setting is the inconsistent
quality of ileum specimens obtained by retrograde ileoscopy, which have a high
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probability of sampling error due to a highly variable yield of lymphoid cells.
Nevertheless, the fact that we did not observe reduced apoptosis among GALT CD4+ T
cells most likely reflects the fact that IL-7 was inactive against the direct cytopathic
effects of the virus (1,9). IL-7 does not per se exert antiviral effects, and indeed similar
levels ofSIV proviral DNA were measured in the GALT of untreated and IL-7-treated
animals. However, we demonstrated that IL-7 treatment elicited early and vigorous Tat-
specific CD4+ and CD8+ T-cell responses associated with the expansion, activation and
proliferation of all CD8+ T-cell subpopulations, which may help explain the lack of
increase in SIV replication in the blood and lymphoid tissues ofIL-7-treated animals,
despite the preservation ofSIV-harboring CD4+ T cells. Since Tat is a regulatory protein
expressed early in the viral life cycle, Tat-specific T-cell responses presumably were
able to halt the infection before the completion of a full replicative cycle. Moreover,
CD8+ Tat-responding cells in IL-7-treated animals were shown to be more
polyfunctional as compared to untreated animals, a profile that has been proposed as a
correlate of protective antiviral immunity in HIV -1- and other chronic viral infections
(47). Of note, a particularly pronounced numerical increase was detected in EM CD8+ T
cells, a functionally competent subset that was recently associated with effective
vaccine-elicited protection in macaques (48). An interesting correlate of our findings
was illustrated in a recent study in mice acutely infected with LCMV, in which early
treatment with IL-7 augmented the number and functionality of specific effector T cells,
thereby reducing organ pathology and promoting viral clearance (49). Thus, altogether,
our data suggest that IL- 7 treatment prevented the depletion of naive and CM CD4 +T
cells during the acute phase ofSIV infection by inducing an early expansion of the CD4+
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T-cell pool due to initial proliferation combined with preservation ofCD4+ T cells via
sustained reduction of bystander apoptosis and induction of vigorous virus-specific
cellular immune responses.
The results of our study may have implications for devising new treatment
strategies for the acute phase of HIV-I infection. Even if ART is promptly initiated
during primary infection, its effects may not be sufficient for fully preventing the
immunologic damage caused by HIV -1 due to dishomogeneous drug biodistribution or
inactivation by P-glycoproteins present within the intestinal mucosa; moreover,
complete suppression of viral replication could take several weeks, and indirect
mechanisms of cell destruction, such as bystander apoptosis, may remain active for some
time after the virus has ceased to replicate. Our results provide a scientific rationale for
the initiation of clinical trials involving the use of IL-7 as an adjunct therapy, in
combination with ART, in acute primary HIV-l infection.
, .
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3.4 Tables
Table 3.1 HLA haplotype and baseline peripheral blood CD3+ and CD4+ T-
lymphocyte counts in untreated and IL-7-treated macaques.
MHC MHC CD3+ CD4+
haplotype score* (cellsl JlJ) (cells/Jll)
Untreated:
H743 AOI-A08 +2 1831 925
H744 B01 -1 2471 1774
H745 A08 +1 2878 1879
H747 A08-BOI 0 2097 1317
H749 n.d."'''' 0 6771 3656
H753 n.d."'''' 0 3194 1996
Mean (::f:SD): +2 3207::f:1815 1925::f:938
IL-7-treated:
H746 none 0 2604 1338
H748 A01 +1 3167 2211
H750 A08 +1 3972 2367
H751 BOI -1 3223 2269
H752 none 0 2767 1486
H154 A02 0 2233 1351
Mean (::f:SD): +1 2994::f:603 1845::f:483
* The MHC score was calculated by attributing a positive score (+1) to alleles associated
with protection from SIV disease and a negative score (-1) to alleles associated with
accelerated disease progression; no score was attributed to alleles with no known effects on
SlY disease progression.
** Animals for which none of the MHC alleles tested (AOlt A02t A08t Al l, BOlt B03t B04tB 17) were detected.
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3.5 Figure Legends
Figure 3.1 Schematic diagram of the study design. IL-7 -treatment period of
six weeks is shown in grey with black arrows indicating the 7 weekly injections. SIV
inoculation, blood draws, intestinal and lymph node biopsies are also shown.
Figure 3.2 IL-7 pharmacokinetics and CD127 expression in circulating T
cells in IL-7-treated and untreated animals. (A) Plasma IL-7 concentrations in IL-7-
treated and untreated macaques. IL-7-treated animals received 7 weekly injections of 50
ug/kg of body weight of a recombinant, fully glycosylated form of simian IL-7 (the grey
shaded area indicates the IL-7-treatment period). The asterisks denote significant
differences with baseline values (p < 0.05 by paired Student's t test). (B) CDI27
expression on total, narve, memory and effector CD3+ T cells from untreated (blue) and
IL-7-treated (red) animals. Average values of mean fluorescence intensity (MFI) ±
standard error of the mean (SEM) from each group of macaques are shown. Blue and red
asterisks denote significant differences with baseline values (day -7) in untreated and
treated animals, respectively (...p < 0.05, ......P < 0.01, by paired Student's t test).
Figure 3.3 Effect oflL-7 treatment on SIV replication. Mean levels (± SEM)
ofSIV plasma viremia (A) and p27Gagantigenemia (B) in untreated (blue) and IL-7-
treated (red) animals. No significant differences were observed between the two groups
of animals, with the only exception of SIV plasma viremia on day 4 post-infection, when
IL-7-treated animals showed higher levels compared to untreated controls (indicated by
the asterisk; p < 0.05, by Wilcoxon rank sum test). The grey-shaded area indicates the
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IL-7-treatment period. (C) Mean number of genome equivalent copies (± SEM) of SIV
proviral DNA in mononuclear cells from peripheral blood (days 14 and 77 post-
infection) and lymphoid tissues (GALT, days 14-16; axillary lymph nodes, days 25-27
post-infection). SIV DNA genome equivalents normalized for million of CD4+ T cells
are shown.
Figure 3.4 Effect ofIL-7-treatment on peripheral blood T-Iymphocyte
kinetics. (A) Mean absolute numbers (± SEM) of circulating total, naive, memory and
effector CD4+ and CD8+ T cells in untreated (blue) and IL-7-treated (red) animals. Naive
(CD28+95"), memory (CD28+95+) and effector (CD28"95+) T-cell subsets were identified
using a combination ofmAbs against CD28 and CD95. (B) Subset analysis of memory
CD4+ and CD8+ T cells in untreated (blue) and IL-7-treated (red) animals. The various
memory T-cell subsets (central memory, CM; transitional memory, TM; and effector
memory, EM) were identified using a combination of CD28, CD95, CD62L and
CD 197ICCR7. Absolute counts for each T-lymphocyte subpopulation were calculated
by multiplying the percent values obtained by flow cytometry by the total lymphocyte
counts obtained from the complete blood counts (CBC). The grey shaded area indicates
the IL- 7-treatment period; blue and red asterisks denote significant differences versus
baseline values in untreated and IL-7-treated animals, respectively (* p < 0.05, ** p <
0.01, by paired Student's t test).
Figure 3.5 Effect ofIL-7-treatment on peripheral blood CD8+ T-Iymphocyte
activadon. Relative proportion of activated (HLA-DRlCD25 double expressing) cells
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among circulating CDS+ T-cells in untreated (blue bars) and IL-7-treated (red bars) monkeys
at multiple time points throughout the IL-7-treatment period. Relative significant p values
obtained by unpaired t tests are shown.
Figure 3.6 Comparison of changes in peripheral blood T-cell subpopulations
between IL-7-treated and untreated macaques during the acute phase of SIV Infection.
Simultaneous comparisons of changes from baseline to all the time points during acute SIV
infection as analyzed by the O'Brien permutation tests. (A) Analyses for total CD3+, CD4+
and CDS+ T cells. (B) Analyses for the narve, memory and effector T-cell subsets. The
histograms represent the distribution of all possible values of the difference between IL-7-
treated and untreated animals considering all the possible relabelings of the animals in the
two groups (by permutation test); dots indicate the values of the differences between IL-7-
treated and untreated animals for the actual trial assignments with the relative p values.
Significant differences were observed in all T-cell subsets, except in memory CD3+ T cells.
Figure 3.7 Effect ofIL-7-treatment on cellular proliferation, apoptosis and
Bcl-l expression In peripheral blood T cells. (A) Mean levels of cellular proliferation,
as measured by expression of the cell-cycling marker Ki67, in CD4+ and CDS+ T cells
freshly isolated from untreated (blue) and IL-7 -treated (red) animals during the first two
weeks ofIL-7-treatment. IL-7 injections and SlY inoculation are indicated by arrows.
(B) Mean levels (± SEM) of Ki67 expression in CD4+ and CDS+ T cells freshly isolated
from untreated (blue) and IL-7-treated (red) animals throughout the entire study period.
(C) Mean levels (± SEM) of spontaneous apoptosis, as measured by Annexin- V binding,
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in circulating CD4+ and CD8+ T cells from untreated (blue) and IL-7-treated (red)
animals. (D) Average MFI levels (± SEM) ofBc1-2 expression in circulating CD4+ and
CD8+ T cells from untreated (blue) and IL-7-treated (red) animals. The grey shaded area
indicates the IL-7-treatment period. The asterisks denote significant differences between
untreated and IL-7-treated animals (* p < 0.05, ** P < 0.01, by Wilcoxon rank sum test).
Figure 3.S Frequency of CD4+ and CDS+ T-cell subsets and analysis of
spontaneous apoptosis in terminal ileum and lymph node biopsies from untreated
and IL-7-treated macaques. (A) Intestinal biopsies were obtained from all animals on
days 14-16 post-infection. Upper panels: Relative proportion of total, naive, memory and
effector CD4+ and CD8+ T cells in terminal ileum biopsies from untreated (blue) and IL-
7-treated (red) animals. Lower panels: Mean levels of spontaneous apoptosis, as
measured by Annexin-V binding, in total, naive, memory and effector CD4+ and CD8+ T
cells isolated from terminal ileum biopsies from untreated (blue) and IL-7-treated (red)
animals. The differences between untreated and IL-7-treated animals were analyzed by
unpaired t-test (similar results were obtained by Wilcoxon rank sum tests). (B) Lymph
node biopsies were obtained from all animals on day 25-27 post-infection. Upper panels:
Relative proportion of total, naive, memory and effector CD4+ and CD8+ T cells in
lymph node biopsies from untreated (blue) and IL-7 -treated (red) animals. Lower panels:
Mean levels of spontaneous apoptosis, as measured by Annexin- V binding, on total,
naive, memory and effector CD4+ and CD8+ T cells freshly isolated from lymph node
biopsies from untreated (blue) and IL-7-treated (red) animals. The differences between
untreated and IL-7-treated animals were analyzed by unpaired t-test.
197
Figure 3.9 Levels of SlY replication and CD4+ T cells In conventional
progressor (CP) versus rapid progressor (RP) SlY-Infected macaques. Mean levels (±
SEM) of SN plasma viremia (A) and p27Gagantigenemia (B) in CP (orange) and RP
(green). RP animals showed higher levels of both SIV viremia and antigenemia compared to
CP at several time points, starting on day 18 post-infection, as indicated by the asterisks (*p
< 0.05, *'" P < 0.01, by Wilcoxon rank sum test). (C) Mean absolute numbers (± SEM) of
circulating CD4+ T cells in CP (orange) and RP (green). A significant difference was
observed on day 62 post-infection, when RP had higher mean levels of circulating CD4+ T
cells compared to CP, as indicated by the asterisk (p < 0.042, by Wilcoxon rank sum test).
Figure 3.10 Reanalysis of virological and Immunological parameters in IL-7-
treated and untreated macaques after exclusion of macaques with rapidly progressive
(RP) disease course. (A) Mean levels (± SEM) of SN plasma viremia and p27 Gag
antigenemia in untreated (blue) and IL-7-treated (red) animals. (B) Mean absolute numbers
(± SEM) of circulating total, naive, memory and effector CD4+ and CD8+ T cells in
untreated (blue) and IL-7-treated (red) animals. The grey shaded area indicates the IL-7-
treatment period; blue and red asterisks denote significant differences with baseline values
in untreated and IL-7-treatedanimals, respectively (*p < 0.05, ** P < 0.01, by paired
Student's t test).
Figure 3.11 Reanalysis of apoptosis in Intestinal and lymph node biopsies from
IL-7-treated and untreated macaques after exclusion of animals with rapidly
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progressive (RP) disease course. Mean levels of spontaneous apoptosis, as measured by
Annexin-V binding, in total, naive, memory and effector CD4+ and CD8+ T cells freshly
isolated from terminal ileum (A) and lymph node biopsies (B) from untreated (blue) and IL-
7-treated (red) animals. The differences between untreated and IL-7-treated animals were
analyzed by unpaired t-test.
Figure 3.12 SIV-specific T-cell responses in untreated and IL-7-treated
macaques. Mean absolute numbers (± SEM) of total CD4+ and CD8+ T cells responding
to overlapping peptides derived from the Tat (A) and Gag (B) proteins of SIV in
untreated (blue) and IL-7-treated (red) animals. The asterisk indicates a significant
difference between total responses in IL-7-treated vs, untreated macaques. The numbers
above each line point indicate the fraction of monkeys that gave a measurable response
over background in each group at the corresponding time point.
Figure 3.13 QuaHtative analysis of SIV-specffle T-cell responses in
untreated and IL-7-treated macaques. (A)Mean absolute numbers (± SEM) ofCD4+
and CD8+ T cells producing one cytokine (single-producing, SP), two cytokines (double-
producing, DP) or all three cytokines (triple-producing, TP) in response to SIV Tat
peptide stimulation in untreated (shades of blue) and IL-7 -treated (shades of red)
animals. The asterisks indicate significant differences between SP T cells in untreated
vs. IL-7-treated animals, as analyzed by Wilcoxon rank sum test. (B). Mean absolute
numbers ofSIV Tat-responding CD4+ and CD8+ T cells in untreated (U) and IL-7-
treated (IL-7) animals. The bars indicate the mean numbers of total responding cells; the
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colors indicate the mean numbers ofIFN-y, IL-2, or MIP-l~ SP cells (shades of blue),
IFN-yIIL-2, IFN-yIMIP-l~ or IL-2IMIP-l~ OP cells (shades of green), and IFN-yIIL-
2IMIP-l ~ TP cells (purple). The numbers above each bar indicate the fraction of
monkeys that gave a measurable response over background to SIV Tat peptides at the
corresponding time point. The grey shaded areas indicate the IL-7-treatment period. (C)
Qualitative analysis of SIV Tat-specific COS+ T-cell responses in IL-7 -treated and
untreated macaques on day 62 post-infection. The pie charts indicate the average
contribution of the various functional subpopulations of Tat-responding COS+ T cells
(single-, double- and triple-producing, SP, OP, TP, respectively) to the total number of
Tat-responding cells in untreated and IL-7-treated animals at day 62 post-infection. The
p value was calculated by permutation analysis using the Spice software.
Figure 3.14 SIV Gag-specific T-cell responses in IL-7-treated and untreated
macaques. (A) Mean absolute numbers (± SEM) ofC04+ and COS+ T cells producing one
cytokine (single-producing, SP), two cytokines (double-producing, OP) or all three
cytokines (triple-producing, TP) in response to SIV Gag peptide stimulation in untreated
(shades of blue) and IL-7-treated (shades of red) animals. (B) Mean absolute numbers of
SIV Gag-responding C04+ and COS+ T cells in untreated controls (c) and IL-7-treated
animals (IL-7). The bars indicate the mean numbers of total responding cells; the colors
indicate the mean numbers ofIFN-y, IL-2, or MIP-l~ single-producing cells (shades of
blue), IFN-yIIL-2, IFN-yIMIP-l~ or IL-2IMIP-l~ double-producing cells (shades of green),
and IFN-yIIL-21MIP-1~ triple-producing cells (purple). The numbers above each bar
indicate the fraction of monkeys that gave a measurable response over background to SIV
200
Gag peptides at the corresponding time point. The grey-shaded areas indicate the IL-7-
treatment period.
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CHAPTER FOUR
Concluding Remarks
4.0 Main Findings
CHAPTER TWO: Primary cells in vitro
Effect of IL-7 on Spontaneous Apoptosis of CD4+ and CDS+T cells
- IL-7 exerts strong anti-apoptotic effects on PBMC from HIV -l-infected
individuals
- IL-7 exerts anti-apoptotic effects on both CD4+ and CD8+ T-cell subsets
- The anti-apoptotic effect oflL-7 ex vivo inversely correlates with the CD4+ T-cell
count in vivo
- The anti-apoptotic effect ofIL-7 can be uncoupled from the induction of cellular
proliferation
- IL- 7 does not induce HIV -1 replication ex vivo in purified CD4 +T cells from HIV-
l-infected individuals
CHAPTER THREE: In vivo
Effects of Treatment with IL-7 during the Acute Phase of SIV Infection in
Rhesus Macaques
- IL-7 treatment in rhesus macaques is safe and well-tolerated
- IL- 7 treatment during the acute phase of SIV infection does not increase the levels
of SIV replication and proviral SIV DNA load
- IL- 7 treatment prevents the depletion of naive and memory CD4 +T cells
- IL-7 treatment expands all subsets of CD8+ T cells
- Repeated IL-7 administrations induce only transient T-cell proliferation but
persistent reduction of apoptosis
- IL-7 treatment does not impact rapid disease progression in SIV-infected macaques
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- IL-7 treatment elicits earlier and stronger SIV-specific CD4+ and CDS+ T-cell
responses
4.1 Discussion
Although the progressive refinement of drug-combination therapeutic regimens for
HIV-l infection, since their first introduction in the late 90's, has determined major
improvements in the quality of life and disease outcome of HIV-I-infected individuals, the
achievement of complete immunological restoration remains a challenge. Indeed, the
majority of the patients treated with ART experience a sustained increase in peripheral
CD4+ T-cell counts associated with a sustained control of viral replication; yet, CD4+ T-
cell counts often fail to return to normal levels, suggesting a persistent immunologic
damage that may reduce the individual's ability to mount effective immune responses
against infectious agents (1). This constitutes an important drawback considering that
RIV -1 cannot be eradicated from the host, and therefore ART must be administered for the
entire lifetime (2). As outlined in the Introduction, adjuvant therapeutic approaches based
on the use of cytokines of the y-chain family, whose immunomodulatory activities are well
established, are currently under investigation in an attempt to restore the full immunologic
function in ART-treated HIV-l-infected individuals (3). Indeed, considering that key
features of SIV/RIV infection are the rapid depletion of mucosal memory T cells, gradual
depletion of peripheral blood T cells and high levels of immune activation, it has been
hypothesized that these immunomodulatory cytokines could have several beneficial
effects, including enhancement of immunological memory, de novo narve T-cell
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production and increased survival and proliferation of the SNIHIV depleted T-cell
subsets.
The first cytokine of this family used in phase I/phase II clinical trials was IL-2. Its
beneficial effects, mainly an increase in the absolute number of circulating CD4+ T cells,
particularly with a narve phenotype, have been well documented and confirmed by several
studies in Hl'V-l-infected individuals concomitantly receiving ART, including two recent
large-scale phase II studies (SILCAA T and ESPRIT) (4, 5). Nevertheless, the observed
immunological improvements failed to result in a significant clinical improvement, to the
point that the idea of using IL-2 as an immunomodulatory adjuvant for the treatment of
chronic RN-I- infected individuals was brought into question. Moreover, IL-2 treatment
was shown to have adverse side effects, in some case relatively severe, including a flu-like
syndrome, mild capillary leak syndromes, gastrointestinal disturbance, and dermatological
problems including injection site reactions, rashes and dry skin. Another relatively
common adverse effect was endocrine disturbance in the form of chemical hypothyroidism
(5). These adverse effects were shown to be usually short-lived after the end of a dosing
cycle, but nevertheless they represented a further challenge to the clinical use of this
cytokine. After the failure of the SILCAAT and ESPRIT clinical trials (4), the use ofIL-2
as a support "immonorestorative" therapy to ART is slowly being abandoned, and
alternative settings for its use in RN -l-infected individuals are currently under
investigation. Potential benefits of treatment with IL-2 that are being explored in ongoing
clinical trials include its potential role in delaying the start of continued combination ART
during the natural course of the infection and in prolonging the intervals in between
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consecutive ART cycles. Moreover, IL-2 is under evaluation also as an adjuvant to
therapeutic vaccination.
Another cytokine that has been tested in pre-clinical trials is IL-15, which was
shown to have positive effects on several cellular compartments of the immune system,
like NK cells, CD8+ and CD4+ T cells, in SIV-infected macaques receiving ART, as well
as in SIV challenged animals in vaccine-based trials (6-9). To date, IL-15 has never been
tested in HIV-l-infected humans. However, one of the major concerns related to the use of
y-chain cytokines like IL-2 and IL-15, which have strong proliferative effects, is the risk of
augmenting viral replication both directly, by inducing re-activation of latent provirus, and
indirectly, by increasing the pool of CD4+ T cells that would provide new targets for viral
infection. Indeed, in several trials IL-2 administration was associated with transient
increases in plasma viral load, and this occurred even with the concomitant use of ART
(10-12). Albeit initially considered as an unwanted side effect, this IL-2-mediated increase
of viral replication was afterwards looked at as a potential strategy to induce re-activation
of silent provirus from latently-infected cells in an attempt to break latency and eradicate
the virus, resurfaced from its hiding sanctuaries, using aggressive treatment strategies.
Viral eradication may be the only possible strategy to definitively cure HIV -1 infection
and studies to test the effect ofIL-2 administration in this regard are currently under way.
In contrast with the results obtained with IL-2, administration ofIL-15 to rhesus
macaques during the chronic phase of SIV infection did not result in any change in plasma
SIV viremia (6, 7). However, IL-15 administration during the acute phase ofSIV infection
was shown to increase the viral set point by several logs, and in some animals to accelerate
the disease progression (13). This result suggests that the mechanisms of pathogenesis and
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T-cell killing may be very different during the acute and chronic phases of HIV ISIV
infection, as different may be the level of integrity and functionality of the immune
system. Indeed, during the very early phase of infection, T cells may still be functional and
able to respond properly to physiological stimuli, including cytokines like IL-15, entering
the cell cycle and proliferating, thus becoming more susceptible to productive HIV/SIV
infection. Therefore, treatment with IL-15 during the acute phase of the infection may be
even more risky than treatment with IL-2. Of course, the same data provide a rationale for
the use ofIL-15, as discussed above for IL-2, in experiments aimed at re-activating the
replication of latent provirus.
For what concerns the effects of IL- 7 on viral replication, conflicting results can be
found in the literature. On one hand, IL-7 was documented to be, ex vivo, "a potent and
proviral strain-specific inducer of latent HIV -1 cellular reservoirs of infected individuals
on virally suppressive HAART" by the group of Pomerantz (14), and to induce transient
"blips" of viral replication in individuals chronically infected with HIV-l treated with IL-7
(15). However, recent sequencing data of the viruses emerged during these "blips" indicate
that they are very close to those found in plasma and PBMC before treatment (16), thus
inferring that the low level of viremia induced by IL- 7 likely reflects transient induction or
release of virus from the replicating pool rather than reactivation of a latent archival
quasispecies. Moreover, studies of IL-7 administration to SIV -infected macaques failed to
reveal any significant inductive effect of the cytokine on viral replication, even in the
absence of ART (17-19).
The results presented in the present thesis work, showing that IL-7 treatment does
not boost viral replication from CD4+ T cells derived from HIV-l-infected individuals ex
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vivo (CHAPTER TWO) and that IL-7 administration in vivo to SIV-infected macaques
does not induce significant increases in plasma SN viral load (CHAPTER THREE), are in
line with the latter observations. Taken together, these findings suggest that treatment with
IL- 7 may be "safer" in a strictly "therapeutic" design as compared to the other v-chain
cytokines (IL-2 and IL-I5) explored so far. The difference may be related to the
homeostatic properties of the cytokine and/or to the intrinsic features of the IL-7IIL-7R
system, which is tightly and finely tuned both at the level of plasmatic concentration of the
cytokine and expression of the specific chain of the receptor (IL-7Ra, CDI27). In fact, as
described in the Introduction section, the pro-survival and proliferative effects of IL-7 are
strictly dependent upon the IL-7 concentration: at homeostatic, physiological
concentrations, IL-7 is mainly causing a pro-survival response; at supra-homeostatic
concentrations, those typical of lymphopenic conditions, IL-7 induces vigorous
proliferation aimed at reconstituting the original T-cell pool. In CHAPTERS TWO and
THREE of the present thesis, we show that CD4+ and CD8+ T cells derived from both
HfVvl-infected individuals (ex vivo) and SIV-infected macaques (in vivo) respond to IL-7
stimulation with very limited, and in any case dose-dependent (ex vivo), levels of cell
cycling and proliferation but with significant reduction of apoptosis, as documented by the
low induction ofki67 expression and higher induction ofBcl-2 expression, indicating that
the two effects ofIL-7 can be "uncoupled" by finely regulating its concentration. The
effects of IL-7 seem to be mainly anti-apoptotic even at later stages of the disease, at least
ex vivo, and even stronger than at earlier stages, as indicated by the negative correlation
between the extent ofIL-7-mediated apoptosis reduction ex vivo and the CD4+ T-cell
counts of the patient in vivo. These findings led to suggest that IL-7-treatment in vivo may
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be useful even at a more advanced disease stage (CHAPTER THREE). This is apparently
in contrast with the observation that plasma IL-7 levels increase as the disease progresses
both in HIV -l-Infected individuals and in SIV -infected macaques (20-25), but such
increase is not paralleled by the restoration of the CD4+ T-cell pool, implying a low
induction of cellular proliferation or an insufficient compensation for the accelerated loss
of CD4+ T cells. At supra-homeostatic concentrations IL-7 should in fact be primarily
proliferative, whereas our data ex vivo suggest mainly an anti-apoptotic effect. A possible
explanation could be that, at an advanced disease stage, the T-cell pool may be severely
and irreversibly compromised in both number and function, and therefore these cells
would be unable to respond in a "physiological" way. In line with this concept, several
reports have documented impairments in the IL- 71IL-7R system in HIV /SIV infection (26-
32) that could explain the reduced or in any case the non-physiological signaling response
to IL-7. Studies aimed at investigating the intracellular signaling pathways involved in
spontaneous apoptosis in HIV /SIV infection and the mechanisms of IL- 7-mediated
apoptosis reduction are currently under way, although the results obtained so far are very
preliminary and were not included in the present work.
CHAPTER THREE of this work describes the results of a study of IL-7
administration in vivo to SIV-infected macaques, and it shows that IL-7 administration
during the acute phase the infection, when high levels of viral replication and a severe
CD4+ T-cell depletion typically occur, protects the narve and memory CD4+ T cell pools
without inducing any increase in viral replication, in the absence of ART. To our
knowledge, this is the first study documenting positive effects of IL-7 (or other y-chain
cytokines) during the acute phase of the infection, and is in sharp contrast with the study
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conducted by the group of Mueller et al. in which IL-15 administration during the acute
phase of SIV infection was shown to dramatically increase the viral load and to accelerate
disease progression (13).
Although there is still debate regarding the exact mechanisms of CD4+ T-cell
depletion during acute HIV -1 infection, apoptosis has been proposed to playa role, and
our observation that the lack of depletion of'narve and central memory CD4+ T cells in IL-
7-treated macaques was associated with decreased levels of apoptosis seems to add
support to the concept that apoptosis plays a key role in the depletion of CD4+ T cells
during the early phase of HIV -1 infection. Indeed, if the prevalent view that the dice in
HIV /SIV pathogenesis are cast within the very first weeks of the infection is correct, the
results presented herein provide a strong rationale for further pursuing the possibility of an
early IL-7-based immunomodulatory therapy, maybe in association with ART to try to
preserve the CD4+ T-cell pool and therefore the immune system. Indeed, the early acute
phase of infection is when the most severe CD4+ T-cell depletion is believed to occur,
together with high levels of viral replication, leading to a dramatic and seemingly
irreversible damage to the immune system, to the point that its recovery is very difficult to
achieve.
Of course, a critical factor related to this strategy would the inherent difficulty in
identifying and treating patients at an early stage during the acute phase of the infection, in
order to reduce the peak phase of HIV -1 replication. Some studies have documented the
potential benefit of early ART on the induction of HIV -specific cellular immune responses
(33,34). Our data showing that IL-7 treatment in the absence of ART during the acute
phase ofSIV infection increases SIV-specific CD4+ and CDS+ T-cell responses, including
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the effector-memory subset that is fully competent for effector functions and has recently
been associated with effective vaccine-elicited protection in macaques (35), point towards
the same direction and suggest that ART and IL-7 might even have a synergistic effect on
T-cell responses. However, other reports in patients (36) and macaques (37) have
demonstrated a limited effect of ART alone on the preservation of lamina propria T
lymphocytes and other immunologic functions, underscoring the importance of designing
salvage immune-based therapies aimed at preventing or at least reducing the immunologic
damage associated with the acute disease. In this work, IL- 7 treatment was shown to
preserve both the naive and memory CD4+ T-cell pools in peripheral blood, and to reduce
the level of apoptosis in CD8+ T cells in the gut and in CD4+ and CD8+ T cells in the
lymph nodes of SIV -infected animals. Even if these data are not conclusive and a more
extensive analysis aimed specifically at investigating the effect of IL- 7 on gut-associated T
cells, particularly CD4+ T cells, and on tissue-associated viral load is needed, they
nevertheless point to IL-7 as a good candidate for immune-salvage therapies. Of course,
additional studies exploring the combined effects of ART and IL- 7 during the acute phase
of SIV infection are required before moving into clinical trials, which are anyway
challenging due to the difficulties in recruiting subjects immediately after acquisition of
HIV -1 infection.
An interesting correlate of the results presented in CHAPTER THREE is the
observation that in natural SIV infection in sooty mangabeys, which do not progress to
AIDS, there is an early increase in IL-7levels within the very first weeks after infection (1
through 5), that is not observed in disease-prone macaques, in which the levels of IL-7
increase only during the late stages of the disease (38). In the present study, however, no
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differences were observed in terms of disease progression between rhesus macaques
infected with a pathogenic strain of SIV treated with IL-7 for 7 weeks during the acute
phase and untreated infected animals, suggesting that the increase in IL-7 observed in non-
pathogenic infections may not be sufficient to confer protection against AIDS progression,
and confirming the hypothesis that additional factors, including host-related factors may
be crucial, as suggested elsewhere (39, 40).
We also found that IL-7 treatment did not have any effect on rapid progression
(RP), a disease that shows distinct features compared to classical AIDS, which was
documented in a certain percentage of SIV -infected macaques but does not seem to occur
in HIV -l-infected individuals (41). Indeed, four animals developed signs of RP within the
first six months after infection, irrespective of IL-7 treatment (two animals in each
groups).
Of course, we have to point out that IL- 7 was only administered for a relatively
short time (7 weeks) and therefore we do not know what would have happened if IL-7
treatment was continued after the resolution of the acute phase of the infection. We could
speculate that the effects of the cytokine on the peripheral blood lymphocyte kinetics
would have been sustained and that maybe this would have contributed to confer a bigger
advantage to treated animals and towards the progression of the infection, but this is just
pure speculation.
Itmust be emphasized that the CD4 +T cell-protective effects of IL- 7 in our
animals were transient and rapidly reversed after treatment interruption, at a time when the
number of CDS+ T cells in the circulation was still significantly augmented. However,
considering its favorable safety profile, IL- 7 treatment could be continued for a longer
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period than in the present study, and the concomitant use of ART could greatly reduce the
ability of HIV -1 to cause severe immunologic damage after the acute phase.
In summary, the results of this work provide new insights for a deeper
understanding of the mechanisms of HIV -I-induced pathogenesis during both the acute
and chronic phases of the infection, with a particular focus on the role played by
spontaneous and induced apoptosis. Moreover, they provide further rationale for designing
new immune-based treatment strategies aimed at preserving or replenishing the damaged
CD4+ T-cell pool at different stages of the disease.
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